nct_id,brief_title,classification,is_rare
NCT06161974,Study of Olutasidenib and Temozolomide in HGG,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on high-grade glioma (HGG), which includes diffuse intrinsic pontine glioma (DIPG), a rare and aggressive type of brain tumor. According to the information provided, HGG and DIPG are considered rare diseases based on the accepted criteria:

- In the US, HGG and DIPG are estimated to affect fewer than 200,000 people.
- The conditions listed, such as astrocytoma, oligodendroglioma, and diffuse midline glioma, are generally characterized by low prevalence, chronicity, and often genetic origin, which are typical characteristics of rare diseases.

## Confidence Level
High

## Rare Disease Indicators
- Affected population is less than 200,000 people in the US
- Conditions are characterized by low prevalence, chronicity, and genetic origin
- Specific rare brain tumor types are the focus of the clinical trial, such as DIPG",True
NCT06844786,SCORE! ACTIVE Trial,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial information provided indicates that the target conditions are chronic disease and childhood obesity, which are not considered rare diseases based on the given criteria. Chronic diseases and childhood obesity are relatively common conditions that affect a large number of people, well above the thresholds for rare diseases in the US (fewer than 200,000 people) and Europe (affecting no more than 1 in 2,000 people). The trial is also focused on a specific population of newcomer families in Hamilton, which suggests a broader target population rather than a rare disease.

## Confidence Level
High

## Rare Disease Indicators
There are no clear indicators in the provided information that this is a clinical trial for a rare disease.",False
NCT06476132,Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is Chronic Lung Allograft Dysfunction (CLAD), which occurs in lung transplant recipients. While lung transplantation is a relatively uncommon procedure, CLAD is not considered a rare disease. The information provided indicates that this trial is focused on a specific subgroup of lung transplant recipients who are at high risk of developing CLAD, but does not suggest that CLAD itself is a rare condition.

## Confidence Level
High

## Rare Disease Indicators
None. The trial does not meet the criteria for a rare disease, which is typically defined as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.",False
NCT06809049,Music Intervention for Brain-Heart Disease in Myotonic Dystrophy Type 1 (DM1),"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The clinical trial is for Myotonic Dystrophy Type 1 (DM1), which is a rare genetic disorder. According to the information provided, DM1 is characterized as a rare disease based on the accepted criteria:

1. In the US, DM1 affects fewer than 200,000 people.
2. DM1 is a chronic, genetic condition, which are typical characteristics of rare diseases.

## Confidence Level
High

## Rare Disease Indicators
- Affects fewer than 200,000 people in the US
- Chronic, genetic condition",True
NCT06832293,My MS and My Menstrual Cycle,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
Multiple sclerosis (MS) is a chronic, autoimmune disease that affects the central nervous system. It is not considered a rare disease, as it is estimated to affect around 1 in 1,000 people in the United States and around 1 in 2,500 people in Europe. The condition is generally characterized by a relapsing-remitting course, with periods of new or worsening symptoms followed by periods of remission. While the exact causes of MS are not fully understood, it is known to have a complex, multifactorial etiology, including genetic and environmental factors.

## Confidence Level
High

## Rare Disease Indicators
There are no specific indicators in the provided information that suggest this is a rare disease trial. The condition being studied, multiple sclerosis, does not meet the criteria for a rare disease in either the US or Europe.",False
NCT06612268,A Research Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
According to the information provided, sickle cell disease is a chronic, genetic condition that affects fewer than 200,000 people in the United States, which meets the criteria for a rare disease in the US. The brief summary also indicates that this is a study of a new medicine, etavopivat, for the treatment of sickle cell disease, which further supports the classification as a rare disease trial.

## Confidence Level
High

## Rare Disease Indicators
- Affects fewer than 200,000 people in the US (rare disease criteria)
- Chronic and genetic in origin (characteristics of rare diseases)",True
NCT06319430,Technology in Play for Children With Physical Disabilities: the Dice Model of Play,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The information provided in the clinical trial details indicates that the study is focused on children with physical and mental disabilities, which are not considered rare diseases. Rare diseases are typically characterized by low prevalence, affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe. The conditions mentioned in the trial, such as physical and mental disabilities, are relatively more common and do not meet the criteria for a rare disease.

## Confidence Level
High

## Rare Disease Indicators
None applicable in this case, as the trial is not related to a rare disease.",False
NCT04627766,Validation of Continuous Monitoring of Vital Signs in Children with a Connected Patch,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial described does not appear to be for a rare disease based on the accepted criteria. The condition being studied is ""Vital Signs"", which is a common condition and not a rare disease. The trial is focused on validating a continuous monitoring device for children in the pediatric intensive care unit, which is a broader population and not limited to a rare disease.

## Confidence Level
High

## Rare Disease Indicators
None. The trial does not mention any specific rare disease indicators such as low prevalence, chronicity, or genetic origin.",False
NCT06296992,"Type 1 Diabetes, Exercise and Mentoring Trial","## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
Type 1 diabetes is a relatively common chronic condition, with an estimated prevalence of 1.25 million people in the United States and about 1 in 2,000 people in Europe. It does not meet the criteria for a rare disease, which is typically defined as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
None present. The information provided indicates that this clinical trial is focused on a common chronic condition, type 1 diabetes, rather than a rare disease.",False
NCT05894005,The Use of Immersive 360-degree Video in Improving Spatial Orientation,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial information provided does not mention any rare disease. Instead, it focuses on evaluating the effectiveness of immersive 360-degree video in improving spatial orientation among medical students, which is not a rare disease. The condition being studied, ""Virtual Reality"", is not a rare disease. Additionally, the study population consists of pre-clerkship medical students, which is a common and non-rare population.

## Confidence Level
High

## Rare Disease Indicators
There are no rare disease indicators present in the provided information.",False
NCT06763081,Pharmacogenomics of Selective Serotonin Reuptake Inhibitor (SSRI)-Induced Behavioural Activation,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The information provided in the clinical trial description indicates that the conditions being studied, such as major depressive disorder, anxiety disorders, and obsessive-compulsive disorder, are relatively common mental health disorders in children and adolescents. The brief summary mentions that these are ""among the most common mental health disorders in children and adolescents"", which suggests that they do not meet the criteria for a rare disease.

## Confidence Level
High

## Rare Disease Indicators
None of the information provided in the clinical trial description suggests that this is a rare disease. The conditions being studied are not characterized as rare, and the target population (children and adolescents) is not specifically indicated as a rare disease population.",False
NCT06548360,A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is nonsegmental vitiligo, which is a type of vitiligo that affects the entire body. While vitiligo itself is considered a rare disease, affecting less than 1% of the population globally, the nonsegmental form is more common than the segmental form. The brief summary indicates that the purpose of the study is to evaluate the safety and efficacy of ruxolitinib cream in pediatric participants with nonsegmental vitiligo, which suggests that the condition is not considered a rare disease.

## Confidence Level
High

## Rare Disease Indicators
None provided in the given information. The prevalence of nonsegmental vitiligo is not explicitly stated, but the context suggests it is not a rare disease.",False
NCT06619717,Optimal Number of Hyperbaric Oxygen Treatments for Carbon Monoxide Poisoning,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
Based on the information provided, the clinical trial is for the treatment of carbon monoxide poisoning, which is not considered a rare disease. The brief summary indicates that the Misericordia hospital's hyperbaric oxygen (HBO) unit treats an average of 49 patients per year for carbon monoxide poisoning, which is significantly higher than the criteria for a rare disease in the United States (affecting fewer than 200,000 people) or Europe (affecting no more than 1 in 2,000 people).

## Confidence Level
High

## Rare Disease Indicators
There are no clear indicators that this is a rare disease trial based on the information provided. The condition of carbon monoxide poisoning does not meet the criteria for a rare disease.",False
NCT06585774,A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is chronic graft-versus-host disease (cGVHD), which is a rare, serious, and potentially life-threatening complication that can occur after a stem cell or bone marrow transplant. According to the information provided, cGVHD is generally characterized by low prevalence, chronicity, and often genetic origin, which are consistent with the accepted criteria for a rare disease.

## Confidence Level
High

## Rare Disease Indicators
- The condition being studied, chronic graft-versus-host disease (cGVHD), is a rare disease affecting a small population.
- The condition is described as ""rare, serious, and potentially life-threatening"", which aligns with the characteristics of a rare disease.",True
NCT06325280,Exercise MRI to Evaluate Cardiorespiratory Fitness in Children With Heart Disease,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is targeting pediatric patients with acquired heart disease (heart transplant recipients) and congenital heart disease, which are not considered rare diseases. Rare diseases are typically defined as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe. The information provided does not indicate that the conditions being studied (pediatric ALL, congenital heart disease, and heart transplantation) meet these criteria for rarity.

## Confidence Level
High

## Rare Disease Indicators
None provided. The conditions mentioned in the trial do not meet the accepted criteria for rare diseases.",False
NCT06208735,CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial information provided indicates that the study is focused on treating a variety of B-cell malignancies, including B-cell leukemia, non-Hodgkin's lymphoma, B-cell acute lymphoblastic leukemia, diffuse large B-cell lymphoma, high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, mantle cell lymphoma, and B-cell lymphoma. These conditions, while potentially serious, are not considered rare diseases based on the accepted criteria of affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
The information provided does not indicate that the target conditions for this clinical trial meet the criteria for a rare disease.",False
NCT06828861,Oral ARD-101 for Treatment of PWS: The Hunger Elimination or Reduction Objective Trial,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
Prader-Willi syndrome (PWS) is a rare genetic disorder that affects approximately 1 in 15,000 to 1 in 30,000 people worldwide, which falls within the accepted criteria for a rare disease in both the US (affecting fewer than 200,000 people) and Europe (affecting no more than 1 in 2,000 people). The clinical trial is specifically targeting hyperphagia (excessive appetite) in patients with Prader-Willi syndrome, which is a key characteristic of this rare genetic condition.

## Confidence Level
High

## Rare Disease Indicators
- Prader-Willi syndrome affects approximately 1 in 15,000 to 1 in 30,000 people worldwide, which is below the threshold for a rare disease.
- Prader-Willi syndrome is a genetic disorder, which is generally characterized as a rare disease.",True
NCT06500702,"A Study to Evaluate the Efficacy and Safety of Frexalimab, SAR442970, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease","## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The two conditions being studied in this clinical trial, primary focal segmental glomerulosclerosis (FSGS) and primary minimal change disease (MCD), are both rare kidney disorders. According to the provided definition, a rare disease is typically characterized by low prevalence, often genetic origin, and affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
- The conditions being studied, FSGS and MCD, are both rare kidney disorders.
- The low prevalence of the target conditions meets the criteria for a rare disease in both the US and Europe.
- The genetic origins of FSGS and MCD align with the characteristic of rare diseases having a genetic basis.",True
NCT06588855,A Study to Assess the Efficacy and Safety of Induction Therapy With RO7790121 in Participants With Moderately to Severely Active Ulcerative Colitis,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
Based on the information provided, the condition being studied in this clinical trial is moderately to severely active ulcerative colitis (UC). Ulcerative colitis is a chronic inflammatory bowel disease that affects the large intestine and is not considered a rare disease. According to the criteria provided, a rare disease is typically defined as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe. The prevalence of ulcerative colitis is estimated to be much higher than these thresholds.

## Confidence Level
High

## Rare Disease Indicators
None. The condition being studied, ulcerative colitis, is a common chronic inflammatory bowel disease and does not meet the criteria for a rare disease.",False
NCT06667453,A Clinical Study of PGN-EDODM1 in People with Myotonic Dystrophy Type 1,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
Myotonic dystrophy type 1 (DM1) is a rare genetic disorder that affects approximately 1 in 8,000 people worldwide, which falls within the accepted criteria for a rare disease in both the US (fewer than 200,000 people) and Europe (affecting no more than 1 in 2,000 people). Additionally, DM1 is generally characterized by low prevalence, chronicity, and genetic origin, which are also common features of rare diseases.

## Confidence Level
High

## Rare Disease Indicators
- Condition: Myotonic Dystrophy 1, a genetic disorder
- Prevalence: Estimated to affect approximately 1 in 8,000 people worldwide, which is within the accepted criteria for a rare disease",True
NCT06089616,A Study to Document and to Further Describe Long-term Safety and Effectiveness of Palovarotene in Participants With Fibrodysplasia Ossificans Progressiva (FOP),"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on fibrodysplasia ossificans progressiva (FOP), which is described as an ""ultra-rare, severely disabling disease"". This aligns with the criteria for a rare disease, as it affects fewer than 200,000 people in the United States and no more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
- Extremely low prevalence (described as ""ultra-rare"")
- Severely disabling
- Chronic condition
- Genetic origin",True
NCT06422793,The Impact of Nasogastric Tube Gastric Decompression on Postoperative Nausea and Vomiting in Orthognathic Surgery,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is postoperative nausea and vomiting (PONV) in patients undergoing orthognathic (corrective jaw) surgery. PONV is a common side effect of various surgical procedures, affecting up to 60% of patients after orthognathic surgery. This indicates that the condition is not considered a rare disease, as it affects a significant portion of the population undergoing this type of surgery.

## Confidence Level
High

## Rare Disease Indicators
None. The information provided does not indicate that this trial is targeting a rare disease condition.",False
NCT06617429,Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects with AS,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
Angelman syndrome is a rare genetic disorder that affects approximately 1 in 15,000 to 1 in 20,000 people worldwide, which falls within the accepted criteria for a rare disease (affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe). The brief summary and the condition being studied (Angelman Syndrome) indicate that this is a trial for a rare disease.

## Confidence Level
High

## Rare Disease Indicators
- Angelman Syndrome is a rare genetic disorder.
- The condition affects approximately 1 in 15,000 to 1 in 20,000 people worldwide, which is within the accepted criteria for a rare disease.",True
NCT06654752,Streamlined Treatment of Pulmonary Exacerbations in Pediatrics,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
Cystic fibrosis, the condition being studied in this clinical trial, is a rare genetic disorder that affects fewer than 200,000 people in the United States, which is the accepted criteria for a rare disease in the US. Additionally, cystic fibrosis is characterized by low prevalence, chronicity, and genetic origin, which are also general indicators of a rare disease.

## Confidence Level
High

## Rare Disease Indicators
- Cystic fibrosis affects fewer than 200,000 people in the US, which is the accepted threshold for a rare disease in the US.
- Cystic fibrosis is a chronic, genetic condition, which are general characteristics of rare diseases.",True
NCT06672562,Narrative Enhancement and Cognitive Therapy for Self-Stigma in Youth,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The information provided in the clinical trial details indicates that the target conditions for this study are bipolar disorder and multiple mental health conditions, which are not considered rare diseases. Rare diseases are typically defined as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe. The prevalence of bipolar disorder and multiple mental health conditions, while still significant, does not meet the criteria for a rare disease.

## Confidence Level
High

## Rare Disease Indicators
There are no clear indicators that this is a rare disease trial based on the information provided.",False
NCT06341712,Effects of Maintenance Cabozantinib+BSC Versus BSC in Children and AYA With Osteosarcoma,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on osteosarcoma, which is a type of bone cancer that is considered a rare disease. The brief summary states that ""Osteosarcoma is very rare, but it is the most common type of bone cancer in children and teens."" This aligns with the definition of a rare disease, which is affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
- Osteosarcoma is described as a ""very rare"" condition.
- The trial is specifically targeting children, adolescents, and young adults with osteosarcoma, which is more common in this age group.
- The low prevalence and genetic origin of osteosarcoma are indicators of a rare disease.",True
NCT06498128,"Registry to Collect Information on Pregnancy, Neonatal, and Infant Outcomes in Pregnant Women Exposed to QUVIVIQ®","## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is insomnia, which is not considered a rare disease. Insomnia is a common sleep disorder that affects a large number of people, and it does not meet the criteria for a rare disease as defined in the United States (affecting fewer than 200,000 people) or in Europe (affecting no more than 1 in 2,000 people).

## Confidence Level
High

## Rare Disease Indicators
None",False
NCT06719141,A Study to Investigate LP352 in Children and Adults with Developmental and Epileptic Encephalopathies (DEE),"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The clinical trial is investigating the treatment of Developmental and Epileptic Encephalopathies (DEE), which are a group of rare and severe neurological disorders. According to the provided information, DEE is characterized as a condition, and the trial is specifically targeting individuals with this disorder. 

## Confidence Level
High

## Rare Disease Indicators
- The condition being studied, Developmental and Epileptic Encephalopathies (DEE), is generally considered a rare disease, as it is a group of severe and chronic neurological disorders.
- The trial is targeting a specific patient population, children and adults with DEE, which suggests a low prevalence.
- The trial is being conducted across multiple centers, further indicating the rare nature of the condition.",True
NCT06636383,Glycogen Storage Disease Type Ia (GSDIa) Disease Monitoring Program,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on Glycogen Storage Disease Type Ia (GSDIa), which is a rare genetic disorder. According to the information provided, GSDIa is a rare disease as it is characterized by low prevalence, chronicity, and genetic origin. Additionally, the detailed description indicates that this is an observational study to follow up participants with GSDIa, further suggesting that it is a rare disease.

## Confidence Level
High

## Rare Disease Indicators
- Condition: Glycogen Storage Disease Type Ia (GSDIa)
- Characterized by low prevalence, chronicity, and genetic origin
- Observational study to follow up participants with the rare disease",True
NCT06358495,Improving Sleep to Prevent Depression & Anxiety in Adolescents at High Risk,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The information provided about the clinical trial indicates that it is targeting insomnia, depression, and anxiety symptoms in high-risk adolescents. These conditions are not considered rare diseases based on the provided criteria:

- Insomnia, depression, and anxiety are common mental health conditions that affect a significant portion of the population, not just a small subset.
- The trial is targeting adolescents, a larger population segment, rather than a small, specialized group.
- The trial aims to prevent the onset of these conditions, rather than treating a rare, chronic, or genetically-based disorder.

## Confidence Level
High

## Rare Disease Indicators
There are no clear indicators that this is a rare disease trial based on the information provided.",False
NCT06396325,A Registry Based Randomized-Controlled Trial of an Upper Limb Exergaming Intervention for Children and Adolescents with Spinal Muscular Atrophy,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on the condition of Spinal Muscular Atrophy (SMA), which is generally considered a rare disease. According to the information provided, SMA affects fewer than 200,000 people in the US, which meets the criteria for a rare disease in the US. Additionally, SMA is a chronic, genetic condition, which are also characteristics of rare diseases.

## Confidence Level
High

## Rare Disease Indicators
- Affects fewer than 200,000 people in the US
- Chronic, genetic condition",True
NCT06457503,A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is nasopharyngeal cancer, which is not considered a rare disease. According to the provided information, nasopharyngeal cancer is a recurrent and metastatic form of the disease, but it does not meet the criteria for a rare disease. Nasopharyngeal cancer is more prevalent in certain regions, such as Southeast Asia, but it is not generally considered a rare disease globally.

## Confidence Level
High

## Rare Disease Indicators
None. The information provided does not indicate that nasopharyngeal cancer meets the criteria for a rare disease, either in the United States (affecting fewer than 200,000 people) or in Europe (affecting no more than 1 in 2,000 people).",False
NCT06538090,Early Movers Pilot Intervention,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The information provided indicates that the clinical trial is focused on a general population of first-time parents and their infants, with the goal of promoting healthy movement behaviors. There is no mention of the trial targeting a specific rare disease or condition that affects fewer than 200,000 people in the US or 1 in 2,000 people in Europe. The conditions listed, such as child development, activity, and motor skills, are not considered rare diseases based on the provided criteria.

## Confidence Level
High

## Rare Disease Indicators
There are no rare disease indicators present in the given information.",False
NCT06532500,I-CARE: A Pilot Study of Cognitive Behavioural Therapy(CBT) for Mood and Anxiety Disorders,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on mood and anxiety disorders, which are not considered rare diseases. The conditions mentioned in the trial (mood disorders and anxiety disorders) are relatively common and affect a large number of people. The trial is not targeting a disease that affects fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe, which are the accepted criteria for a rare disease.

## Confidence Level
High

## Rare Disease Indicators
There are no clear indicators that this is a rare disease trial based on the information provided.",False
NCT06559176,A Study of the Safety and Efficacy of Prime Editing (PM359) in Participants with P47phox Autosomal Recessive Chronic Granulomatous Disease (CGD ),"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The information provided indicates that Chronic Granulomatous Disease (CGD) is a rare genetic disease affecting the white blood cells, with approximately 20-25% of people with CGD inheriting a mutation in the NCF1 gene. This aligns with the definition of a rare disease in the US, affecting fewer than 200,000 people, and in Europe, affecting no more than 1 in 2,000 people.

## Confidence Level
High

## Rare Disease Indicators
- Low prevalence of the condition (CGD affects only 20-25% of people with the disease)
- Genetic origin of the condition
- Chronic and debilitating nature of the disease",True
NCT06553768,Evaluation of Maralixibat in Pruritus Associated with General Cholestatic Liver Disease (EXPAND),"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The information provided indicates that this trial is targeting cholestatic liver disease, which is a group of rare liver disorders characterized by the build-up of bile in the liver. According to the brief summary, the trial is specifically excluding participants with certain well-known rare cholestatic liver diseases such as Alagille syndrome (ALGS), Progressive familial intrahepatic cholestasis (PFIC), Primary biliary cholangitis (PBC), and Primary sclerosing cholangitis (PSC). This suggests that the target population for this trial is a subset of cholestatic liver disease patients, which is likely to have a low prevalence.

## Confidence Level
High

## Rare Disease Indicators
- The target condition, cholestatic liver disease (excluding ALGS, PFIC, PBC, and PSC), is likely to have a low prevalence.
- The trial is being conducted at multiple sites across North America, Europe, Middle East, and South America, which is a common approach for rare disease trials to reach a sufficient number of eligible participants.",True
NCT06388564,A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
Chronic graft-versus-host disease (cGVHD) is a rare condition that affects individuals who have undergone hematopoietic stem cell transplantation. According to the information provided, cGVHD is the condition being studied in this clinical trial. The prevalence of cGVHD is estimated to be around 5-15% of allogeneic hematopoietic stem cell transplant recipients, which falls within the definition of a rare disease in both the US (affecting fewer than 200,000 people) and Europe (affecting no more than 1 in 2,000 people).

## Confidence Level
High

## Rare Disease Indicators
- Chronic graft-versus-host disease (cGVHD) is the condition being studied, which is a rare disease.
- The brief summary indicates that this is a Phase 2 study, which is typically conducted for rare diseases to evaluate the efficacy and safety of the investigational treatment.",True
NCT06640387,"Viral Dynamics and Transmission of Influenza, RSV and SARS-CoV-2 in Children","## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The conditions described in the clinical trial, namely SARS-CoV-2 infection, RSV infection, and influenza, are not considered rare diseases. These are common viral respiratory tract infections that affect a large number of children, as indicated in the brief summary. The prevalence of these conditions does not meet the criteria for a rare disease, which is typically defined as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
None of the indicators for a rare disease are present in the provided information. The conditions being studied are common and do not have a low prevalence, chronic nature, or genetic origin that are typically associated with rare diseases.",False
NCT05910840,Support-t Online Training in Youth Living With Type 1 Diabetes Transitioning to Adult Care,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial information provided indicates that the condition being studied is Type 1 Diabetes (T1D), which is not considered a rare disease. The brief summary and detailed description mention that the trial will enroll adolescents with T1D, which is a common chronic condition affecting an estimated 1.6 million people in the United States. This number exceeds the threshold of 200,000 people or fewer that is typically used to define a rare disease in the US.

## Confidence Level
High

## Rare Disease Indicators
This trial does not meet the criteria for a rare disease, as T1D is a common chronic condition that affects more than 200,000 people in the United States.",False
NCT06660394,"A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults with Dravet Syndrome (DS)","## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The clinical trial is investigating the treatment of Dravet Syndrome, which is a rare and severe form of epilepsy. Dravet Syndrome is characterized by early-onset, treatment-resistant seizures and is generally considered a rare disease. According to the information provided, Dravet Syndrome affects fewer than 200,000 people in the US, which meets the criteria for a rare disease in the US.

## Confidence Level
High

## Rare Disease Indicators
- Dravet Syndrome is a rare and severe form of epilepsy.
- It affects fewer than 200,000 people in the US, meeting the criteria for a rare disease.
- The clinical trial is specifically targeting Dravet Syndrome, a rare condition.",True
NCT06256744,Resistance Exercise-induced Anabolism in Youths and Adults,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial information provided does not indicate that the condition or disease being studied is a rare disease. The trial is examining the effects of resistance exercise on muscle protein synthesis in children, adolescents, and adults, which is a common condition not considered a rare disease. The trial is not targeting a specific disease or condition that affects fewer than 200,000 people in the United States or no more than 1 in 2,000 people in Europe, which are the accepted criteria for a rare disease.

## Confidence Level
High

## Rare Disease Indicators
None present in the provided information.",False
NCT06473779,Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on patients with severe asthma, which is not considered a rare disease. Severe asthma affects a significant portion of the population, and the study aims to enroll approximately 65 sites in 10 countries, suggesting a larger patient population.

## Confidence Level
High

## Rare Disease Indicators
There are no clear indicators in the provided information that this is a rare disease trial. The condition being studied, severe asthma, is a common chronic respiratory disorder that affects millions of people worldwide.",False
NCT06641687,Be Sweet to Babies During Nasolaryngoscopy,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial information provided does not indicate that the condition being studied (infant conditions) is a rare disease. Infants and infant conditions are generally common and not considered rare based on the accepted criteria. The brief summary and detailed description suggest that the study is focused on pain management during a common medical procedure (flexible nasolaryngoscopy) in infants, which is not indicative of a rare disease.

## Confidence Level
High

## Rare Disease Indicators
None present in the provided information.",False
NCT06504342,Clocks in Sync - Circadian Rhythm and Bipolar Mania,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on bipolar disorder, which is not considered a rare disease. Bipolar disorder is estimated to affect around 2.8% of adults in the United States, which is significantly higher than the 0.05% (1 in 2,000) threshold for a rare disease in Europe or the 200,000 people threshold in the United States.

## Confidence Level
High

## Rare Disease Indicators
This clinical trial does not meet the criteria for a rare disease, as bipolar disorder has a relatively high prevalence.",False
NCT06571383,STEP TEENS Weight Maintenance: A Research Study on How Well Semaglutide Helps Teenagers With Excess Body Weight to Lose Weight and Maintain Weight Loss,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this trial is obesity, which is a common disease affecting a large population. According to the information provided, obesity is the target condition, and the trial is testing a treatment (semaglutide) for weight maintenance in adolescents with excess body weight. Obesity is not considered a rare disease, as it affects a much larger population than the criteria for rare diseases, which are typically defined as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
None. The condition of obesity does not meet the criteria for a rare disease.",False
NCT06589986,A Study to Assess the Efficacy and Safety of RO7790121 for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The information provided indicates that the condition being studied is moderately to severely active ulcerative colitis, which is a form of inflammatory bowel disease. Ulcerative colitis is a relatively common condition, affecting an estimated 2-12 per 100,000 people in the United States. This is significantly higher than the threshold of 200,000 people or less that defines a rare disease in the US. Similarly, the condition affects more than 1 in 2,000 people, which is the threshold for rare disease in Europe.

## Confidence Level
High

## Rare Disease Indicators
None",False
NCT06081348,Sertraline Vs. Placebo in the Treatment of Anxiety in Children and AdoLescents with NeurodevelopMental Disorders,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The clinical trial is investigating the use of sertraline for the treatment of anxiety in children and adolescents with various neurodevelopmental disorders, including both common and rare conditions. The rare conditions mentioned in the trial conditions include Fragile X Syndrome, Tuberous Sclerosis, and 22Q11 Deletion Syndrome. These are considered rare diseases as they affect fewer than 200,000 people in the United States, which is the accepted criteria for a rare disease.

## Confidence Level
High

## Rare Disease Indicators
- Fragile X Syndrome
- Tuberous Sclerosis
- 22Q11 Deletion Syndrome",True
NCT06232304,Transforming Care for Individuals with Childhood-onset Systemic Lupus Erythematosus,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
Systemic Lupus Erythematosus of Childhood (cSLE) is a rare disease that meets the accepted criteria. According to the information provided, cSLE disproportionately impacts females of color and is associated with a 20-fold increased risk of mortality compared to adult-onset SLE. Additionally, the brief summary mentions that cSLE is a ""chronic, multisystem, autoimmune disease"" that is generally characterized by low prevalence, chronicity, and genetic origin, which are all indicators of a rare disease.

## Confidence Level
High

## Rare Disease Indicators
- Affects a small number of individuals (disproportionately impacts females of color)
- Associated with a significantly increased risk of mortality compared to the adult-onset form
- Chronic, multisystem, autoimmune disease with genetic origins",True
NCT06529380,Deep Brain Stimulation for Severe Self-Injurious Behaviour in Children,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is autism spectrum disorder (ASD), which is not considered a rare disease. According to the information provided, ASD affects a significant number of people, with an estimated prevalence of 1 in 54 children in the United States as of 2016. This is well above the criteria for a rare disease in the US (affecting fewer than 200,000 people) and Europe (affecting no more than 1 in 2,000 people).

## Confidence Level
High

## Rare Disease Indicators
None. The prevalence of autism spectrum disorder does not meet the criteria for a rare disease.",False
NCT06121375,"Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Obeticholic Acid (OCA) Compared to Placebo in Pediatric Participants With Biliary Atresia, Post-hepatoportoenterostomy","## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
Biliary atresia is a rare congenital condition that affects the bile ducts, with an estimated incidence of 1 in 10,000 to 1 in 15,000 live births in the United States. This falls within the accepted criteria for a rare disease, which is defined as affecting fewer than 200,000 people in the US. Additionally, biliary atresia is generally characterized as a chronic condition with a genetic origin, which aligns with the general characteristics of a rare disease.

## Confidence Level
High

## Rare Disease Indicators
- Condition affects fewer than 200,000 people in the US
- Condition is chronic and often has a genetic origin",True
NCT06098716,All in the Family: Promoting Family Function Through Physical Activity,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial information provided does not indicate that the condition being studied (physical activity and family functioning) is a rare disease. The brief summary and detailed description suggest that this trial is focused on increasing physical activity and improving family functioning, which are not characteristics of rare diseases. Additionally, the conditions listed (physical activity and family functioning) are not typically considered rare diseases.

## Confidence Level
High

## Rare Disease Indicators
There are no clear indicators in the provided information that this is a clinical trial for a rare disease.",False
NCT06572228,Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial information provided does not indicate that the condition being studied, asthma, is a rare disease. Asthma is a common chronic respiratory condition that affects a large number of people. The brief summary states that the study is focused on patients with ""uncontrolled asthma,"" which suggests that the overall prevalence of asthma is higher than the criteria for a rare disease.

## Confidence Level
High

## Rare Disease Indicators
None provided. The information given does not suggest that asthma, the condition being studied, meets the criteria for a rare disease.",False
NCT06586905,"A Cross-sectional Investigational Study to Evaluate the Sensitivity, Specificity, and Utility of the MedMira Inc. Multiplo® Complete Syphilis (TP/nTP) Antibody Test (POCT) to Diagnose Infectious Syphilis in Participants Attending the Sexual Health Clinic in Ottawa, Ontario.","## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is syphilis, which is not considered a rare disease. Syphilis is a sexually transmitted infection that affects a significant number of people, and it is not characterized by low prevalence, chronicity, or genetic origin, which are the general characteristics of rare diseases.

## Confidence Level
High

## Rare Disease Indicators
None",False
NCT05785533,A Mobile Recovery Guidance App for Children and Young Adults With Acute Ankle Inversion Injuries,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The information provided indicates that ankle sprains, particularly ankle inversion injuries, are a very common condition, with over 2 million emergency department visits annually in Canada and the United States. The trial is specifically targeting children and young adults, which are the groups with the highest incidence of ankle sprains. The prevalence of this condition does not meet the criteria for a rare disease, which is typically defined as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
There are no indicators that this condition would be considered a rare disease based on the information provided.",False
NCT05843253,Study of Ribociclib and Everolimus in HGG and DIPG,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The clinical trial is studying high-grade gliomas (HGG), including diffuse intrinsic pontine glioma (DIPG), which are rare and aggressive brain tumors. According to the information provided:

- HGG and DIPG are generally characterized as rare, with low prevalence, chronic nature, and often genetic origin.
- The trial is specifically targeting pediatric, adolescent, and young adult patients with these conditions, which further indicates the rarity of the target population.

## Confidence Level
High

## Rare Disease Indicators
- The trial is targeting HGG and DIPG, which are rare brain tumors.
- The trial is focused on pediatric, adolescent, and young adult patients, a population with low prevalence for these types of brain tumors.
- The trial is international, suggesting the need to recruit from a wider geographic area to find enough eligible patients, another indicator of rarity.",True
NCT06461897,A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is for the treatment of atopic dermatitis, which is a common skin condition. According to the information provided, approximately 675 participants aged 2 to less than 12 years will be enrolled in this study at around 150 sites worldwide. This indicates that the target population for the trial is not considered a rare disease, as it affects more than 200,000 people in the United States and more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
None. Atopic dermatitis is not considered a rare disease.",False
NCT06556329,Canada-UK AI Study,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The information provided indicates that the clinical trial is focused on using an AI-enhanced social robot to reduce pain and distress in children during intravenous insertions. This condition, while potentially causing significant discomfort and anxiety in children, is not considered a rare disease based on the accepted criteria. The brief summary and detailed description do not mention any rare or genetic condition that the trial is targeting. Additionally, the prevalence of children requiring intravenous insertions is likely much higher than the thresholds defined for rare diseases in the US (fewer than 200,000 people) and Europe (affecting no more than 1 in 2,000 people).

## Confidence Level
High

## Rare Disease Indicators
There are no clear indicators in the provided information that this is a clinical trial for a rare disease.",False
NCT06677424,NeuroCatch Reference Interval Database,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The information provided in the clinical trial details indicates that the study is being conducted on healthy controls and individuals with ""brain function"" as the target conditions. There is no mention of a rare disease being the focus of the study. Additionally, the study aims to develop a reference database for a medical device (NeuroCatch Platform 2) and quantify the expected distribution of brain responses across sex and age, which is not typical of a rare disease clinical trial.

## Confidence Level
High

## Rare Disease Indicators
There are no clear indicators of this being a rare disease clinical trial based on the information provided.",False
NCT05839379,Targeted Pediatric High-Grade Glioma Therapy,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The clinical trial is targeting high-grade gliomas, including diffuse intrinsic pontine glioma (DIPG), in children, adolescents, and young adults. High-grade gliomas, specifically DIPG, are considered rare diseases based on the accepted criteria:

1. In the US, high-grade gliomas, including DIPG, affect fewer than 200,000 people.
2. DIPG, a specific type of high-grade glioma, is a very rare disease, affecting only 300-400 children in the US each year.
3. High-grade gliomas, including DIPG, are generally characterized by low prevalence, chronicity, and often genetic origin.

## Confidence Level
High

## Rare Disease Indicators
- Targeting a condition that affects fewer than 200,000 people in the US (high-grade gliomas)
- Specifically including a rare subtype of high-grade glioma (DIPG)
- Describing the condition as having low prevalence, chronicity, and genetic origin",True
NCT06528938,Comparing the Efficacy of Accelerated Vs. Standard FMRI-guided ITBS in Treating Adolescents Depression,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is major depressive disorder (MDD), which is a common mental health condition. According to the National Institute of Mental Health, major depression is one of the most common mental disorders in the United States, affecting over 21 million adults in 2020. Therefore, this condition does not meet the criteria for a rare disease, which is typically defined as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
None. The condition being studied, major depressive disorder, is a common mental health condition and does not meet the criteria for a rare disease.",False
NCT06208657,Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The trial is focused on childhood and adolescent cancers, which are generally considered rare diseases. The detailed description mentions that the trial is targeting the ""pediatric population"", which aligns with the criteria for a rare disease affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
- The trial is focused on childhood and adolescent cancers, which are rare diseases.
- The target population is the ""pediatric population"", which is a characteristic of rare diseases.",True
NCT06392009,"Astroscape: a Study of Radiprodil on Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms in Patients with TSC or FCD Type II","## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The clinical trial is targeting Tuberous Sclerosis Complex (TSC) and Focal Cortical Dysplasia (FCD) type II, which are both considered rare diseases. According to the information provided:

- TSC is a genetic disorder that affects approximately 1 in 6,000 people, which is less than the 1 in 2,000 people threshold for a rare disease in Europe.
- FCD type II is a rare neurological condition with an estimated prevalence of 1 in 10,000 to 1 in 100,000 people.

The trial is also expected to enroll a relatively small number of participants, with approximately 20 participants with TSC and 10 participants with FCD type II.

## Confidence Level
High

## Rare Disease Indicators
- Tuberous Sclerosis Complex (TSC) affecting fewer than 1 in 6,000 people
- Focal Cortical Dysplasia (FCD) type II affecting 1 in 10,000 to 1 in 100,000 people
- Small anticipated enrollment of approximately 30 participants",True
NCT06100744,"A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab","## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is juvenile psoriatic arthritis (jPsA), which is a form of psoriatic arthritis that begins before the patient's 16th birthday. Psoriatic arthritis is not considered a rare disease, as it affects approximately 30% of people with psoriasis, which is a relatively common condition. The brief summary indicates that approximately 40 juvenile participants with jPsA will be enrolled at approximately 30 sites worldwide, suggesting that the condition is not considered rare.

## Confidence Level
High

## Rare Disease Indicators
There are no clear indicators that this is a rare disease trial based on the provided information. The prevalence and target enrollment do not meet the criteria for a rare disease as defined in the question.",False
NCT06470828,A Study of TAK-861 for the Treatment of Narcolepsy Type 1,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
Narcolepsy type 1 (NT1), the condition being studied in this trial, is considered a rare disease. According to the information provided, NT1 is characterized by excessive daytime sleepiness and cataplexy (sudden attacks of muscle weakness while conscious). The trial is targeting a condition that is generally characterized by low prevalence, chronicity, and often genetic origin, which aligns with the accepted criteria for rare diseases.

## Confidence Level
High

## Rare Disease Indicators
- Condition: Narcolepsy Type 1
- Brief Summary: Mentions the main aims are to evaluate the efficacy and safety of the investigational drug TAK-861 in improving excessive daytime sleepiness and reducing cataplexy in people with narcolepsy type 1.
- Detailed Description: Indicates that the study will enroll approximately 152 patients, which is consistent with the rare disease criteria of affecting fewer than 200,000 people in the US.",True
NCT06468228,A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
Hidradenitis suppurativa (HS), the condition being studied in this clinical trial, is not considered a rare disease based on the provided criteria. The brief summary indicates that ""around 1280 adult and adolescent participants with moderate to severe HS will be enrolled in the study at approximately 275 sites world wide,"" which suggests a larger patient population than the criteria for a rare disease in the US (fewer than 200,000 people) or Europe (affecting no more than 1 in 2,000 people).

## Confidence Level
High

## Rare Disease Indicators
None. The information provided does not indicate that HS meets the criteria for a rare disease.",False
NCT06303518,End Tidal Carbon Dioxide Concentration and Depth of Anesthesia in Children,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial described is investigating the effects of end-tidal carbon dioxide concentration on depth of anesthesia in children undergoing total intravenous anesthesia. This is a common condition and procedure, not a rare disease. The trial does not mention any specific rare disease or condition affecting fewer than 200,000 people in the US or 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
This clinical trial does not have any indicators of a rare disease. The conditions and procedures mentioned are common and widely practiced in pediatric anesthesia.",False
NCT06425549,A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is moderate to severe plaque psoriasis, which is not considered a rare disease. Psoriasis is a relatively common skin condition that affects approximately 2-3% of the population in the United States, which is significantly higher than the threshold of 200,000 people or less that defines a rare disease in the US.

## Confidence Level
High

## Rare Disease Indicators
None",False
NCT06467084,"Open-Label Safety, PK, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) With HAE Type I or II","## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is Hereditary Angioedema (HAE), which is considered a rare disease. According to the provided criteria, a rare disease is typically defined as affecting fewer than 200,000 people in the US or affecting no more than 1 in 2,000 people in Europe. Hereditary Angioedema is a rare, genetic disorder that causes episodes of severe swelling, and it is estimated to affect around 1 in 50,000 people worldwide.

## Confidence Level
High

## Rare Disease Indicators
- The condition being studied, Hereditary Angioedema, is generally characterized as a rare disease with low prevalence, chronicity, and genetic origin.
- The trial is specifically targeting pediatric patients aged 2 to 11 years old with HAE Type I or II, which further indicates the rare nature of the condition.",True
NCT06102499,Comparison of Pulse Oximetry (SpO2) With Different Oximeters and Arterial Saturation (SaO2): Oxygap2 Study,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The information provided in the clinical trial description does not indicate that the trial is targeting a rare disease. The conditions mentioned, which include respiratory failure, hypoxemia, and hyperoxemia, are relatively common and affect more than 200,000 people in the United States. The study aims to compare the performance of different pulse oximeters, which are widely used in the management of these common respiratory conditions, rather than focusing on a rare disease.

## Confidence Level
High

## Rare Disease Indicators
None provided. The clinical trial description does not mention any of the typical characteristics of rare diseases, such as low prevalence, chronicity, or genetic origin.",False
NCT06388200,A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on the treatment of retinitis pigmentosa, which is a rare genetic disorder. According to the information provided, retinitis pigmentosa affects fewer than 200,000 people in the United States, which meets the accepted criteria for a rare disease. Additionally, the condition is generally characterized by low prevalence, chronicity, and genetic origin, further supporting the classification as a rare disease.

## Confidence Level
High

## Rare Disease Indicators
- Affects fewer than 200,000 people in the US
- Genetic origin
- Chronic condition",True
NCT06232733,HELP (HEalthy Lifestyles Project) for Youth With Mental Distress,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on investigating an e-health intervention for youth with mental health issues, which is a relatively common condition. The detailed description does not mention the prevalence or incidence of the target condition, but mental health issues in youth are generally not considered rare diseases. The trial aims to assess the impact of the intervention on emotional health and lifestyle behaviors, which are relevant to a broader population of youth with mental distress, rather than a small, specific subset of the population.

## Confidence Level
High

## Rare Disease Indicators
None provided in the given information. The condition being studied (mental health issues in youth) does not meet the criteria for a rare disease, which typically affect fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.",False
NCT06311682,A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is atopic dermatitis, which is a common skin condition. According to the information provided, atopic dermatitis is a ""moderate-to-severe"" condition, which suggests that it affects a significant number of individuals. The trial is being conducted in children and infants, but there is no indication that the prevalence of atopic dermatitis in this population would meet the criteria for a rare disease.

## Confidence Level
High

## Rare Disease Indicators
None provided. The clinical trial information does not indicate that this study is targeting a rare disease.",False
NCT06473506,Group a Streptococcus Saliva Study,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
Group A Streptococcal (GAS) infections are not considered a rare disease. The condition is relatively common, with an estimated 616 million cases of GAS pharyngitis and over 100 million cases of invasive GAS disease occurring globally each year. This is significantly higher than the criteria for a rare disease, which is typically defined as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
Not applicable, as this is not a rare disease.",False
NCT06410976,Prospective Clinical Assessment Study in Children with Hypochondroplasia,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The clinical trial is examining a condition called hypochondroplasia (HCH), which is a form of dwarfism. According to the information provided, hypochondroplasia is a rare disease, as it affects fewer than 200,000 people in the United States, which is the accepted criteria for a rare disease in the US.

## Confidence Level
High

## Rare Disease Indicators
- The condition, hypochondroplasia, is characterized as affecting fewer than 200,000 people in the US, which meets the criteria for a rare disease.
- The study is a long-term, multicenter, non-interventional study, which is typical for rare disease research to better understand the natural history and characteristics of the condition.",True
NCT06430801,A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008),"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
Crohn's disease is a chronic inflammatory bowel disease that affects approximately 3.1 million people in the United States, which is significantly higher than the 200,000 people threshold for a rare disease in the US. Additionally, Crohn's disease affects about 3 in 1,000 people in Europe, which is also higher than the 1 in 2,000 people threshold for a rare disease in Europe. The clinical trial information provided does not indicate that this is targeting a subpopulation of Crohn's disease patients that would be considered rare.

## Confidence Level
High

## Rare Disease Indicators
None",False
NCT06439277,A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2),"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial information provided indicates that the target population is adolescents with obesity and weight-related comorbidities. Obesity is a highly prevalent condition, affecting a significant portion of the population. According to the Centers for Disease Control and Prevention (CDC), the prevalence of obesity among children and adolescents in the United States was 19.7% in 2017-2020. This suggests that the condition being studied in this trial is not a rare disease, as it affects more than 200,000 people in the US.

## Confidence Level
High

## Rare Disease Indicators
There are no indicators in the provided information that suggest this is a rare disease trial. The condition being studied, obesity, is a common and well-documented condition affecting a significant portion of the population.",False
NCT06389084,Parents Together: Supporting Parents to Promote Healthy Behaviours in Children,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on promoting healthy behaviors in children, which is a common condition rather than a rare disease. The target population is children aged 2-5 years, which suggests a much larger prevalence than the criteria for a rare disease in the US (affecting fewer than 200,000 people) or Europe (affecting no more than 1 in 2,000 people). Additionally, the conditions mentioned in the trial, such as child eating behaviors, child nutrition, and early child development, are not considered rare diseases.

## Confidence Level
High

## Rare Disease Indicators
None",False
NCT06525753,Weaning is Winning? (WeWin Study),"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is intestinal failure (IF), which requires patients to depend on parenteral nutrition (PN). According to the information provided, this is associated with various complications, and many patients are able to wean off PN and become ""PN graduates."" The low prevalence and chronic nature of intestinal failure, along with the genetic factors often involved, suggest that this condition meets the criteria for a rare disease.

## Confidence Level
High

## Rare Disease Indicators
- Condition affects fewer than 200,000 people in the US, as indicated by the description of patients with intestinal failure requiring parenteral nutrition.
- Condition is chronic and often has a genetic origin, as suggested by the details provided.",True
NCT06559865,Impact of a Paced Breathing Exercise Intervention on Autonomic Nervous System Function After Pediatric Concussion,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is concussion, which is a mild traumatic brain injury. Concussions are relatively common, affecting an estimated 1.6-3.8 million people in the United States each year. This is well above the threshold of 200,000 people for a rare disease in the US.

## Confidence Level
High

## Rare Disease Indicators
None. The condition of concussion does not meet the criteria for a rare disease.",False
NCT06411288,Global Study of Del-desiran for the Treatment of DM1,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The clinical trial is targeting myotonic dystrophy type 1 (DM1), which is a rare genetic disorder. According to the information provided, DM1 is characterized as a ""rare disease"" with various synonymous conditions listed, including ""Myotonic Dystrophy"", ""Steinert Disease"", and ""Myotonic Muscular Dystrophy"". The prevalence of DM1 is estimated to be around 1 in 8,000 people, which is well below the threshold of 1 in 2,000 people for a rare disease in Europe, and the 200,000 people threshold in the US.

## Confidence Level
High

## Rare Disease Indicators
- Prevalence of DM1 is around 1 in 8,000 people, which is below the rare disease thresholds in both the US and Europe.
- DM1 is characterized as a rare, genetic, and chronic condition.",True
NCT06412666,A Study to Evaluate the Effect of Aficamten in Pediatric Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on evaluating the efficacy and safety of a drug called aficamten in a pediatric population with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Hypertrophic cardiomyopathy is a rare genetic heart condition that affects the heart muscle, causing it to thicken and can lead to obstructions in blood flow. The condition is generally characterized by low prevalence, chronicity, and genetic origin, which aligns with the definition of a rare disease.

## Confidence Level
High

## Rare Disease Indicators
- The trial is focused on a condition (hypertrophic cardiomyopathy) that is generally considered a rare disease.
- The trial is specifically targeting a pediatric population with the condition, which further indicates the rarity of the disease.
- The trial is evaluating the efficacy and safety of a drug in this rare disease population, suggesting the need for more treatment options for this patient group.",True
NCT06160778,Intravenous Ketorolac Vs. Morphine In Children With Acute Abdominal Pain,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial information provided indicates that the condition being studied, acute appendicitis in children, is a common condition affecting approximately 8,000 children annually in Canada. This is significantly higher than the criteria for a rare disease, which is defined as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe. Additionally, the trial is being conducted across multiple Canadian pediatric emergency departments, further indicating that the condition is not considered rare.

## Confidence Level
High

## Rare Disease Indicators
None. The information provided does not indicate that this is a trial for a rare disease.",False
NCT06055608,Advancing Transplantation Outcomes in Children,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is kidney transplant, which is not considered a rare disease. Kidney transplant is a relatively common procedure, and kidney disease affects a significant portion of the population. The trial is specifically targeting pediatric kidney transplant patients, but the overall condition of kidney transplant is not rare.

## Confidence Level
High

## Rare Disease Indicators
None. The information provided does not indicate that this trial is targeting a rare disease.",False
NCT06133972,Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that affects approximately 16-150 per 100,000 people in the United States, according to the National Institutes of Health. This falls outside the accepted criteria for a rare disease in the US (affecting fewer than 200,000 people). Additionally, the condition is described as affecting ""adolescent and adult participants,"" suggesting a broader population, rather than a rare and specialized patient group.

## Confidence Level
High

## Rare Disease Indicators
There are no clear indicators that this is a rare disease trial based on the provided information.",False
NCT06237452,VE303 for Prevention of Recurrent Clostridioides Difficile Infection,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is Clostridioides Difficile Infection (CDI), which is not considered a rare disease. CDI is a common healthcare-associated infection, with an estimated 223,900 cases in the United States in 2017 according to the Centers for Disease Control and Prevention (CDC). This exceeds the threshold of 200,000 cases in the US for a rare disease.

## Confidence Level
High

## Rare Disease Indicators
None applicable",False
NCT06079359,Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The information provided indicates that the condition being studied is hypophosphatasia (HPP), which is a rare genetic disorder. According to the details, HPP affects fewer than 200,000 people in the US, which meets the criteria for a rare disease in the US. Additionally, HPP is described as a generally rare, chronic, and genetically-originated condition, further supporting the classification as a rare disease.

## Confidence Level
High

## Rare Disease Indicators
- Affects fewer than 200,000 people in the US
- Chronic and genetic in origin
- Low prevalence",True
NCT06407934,A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Monotherapy Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is atopic dermatitis, which is a common skin condition. According to the information provided, the trial is targeting participants aged 12 years and older with moderate-to-severe atopic dermatitis. Atopic dermatitis is not considered a rare disease, as it is estimated to affect a significant portion of the population, especially in the pediatric and adolescent age groups.

## Confidence Level
High

## Rare Disease Indicators
None. The condition of atopic dermatitis does not meet the criteria for a rare disease, which is typically defined as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.",False
NCT06138639,A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE),"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
Duchenne muscular dystrophy (DMD) is a rare genetic disorder that affects approximately 1 in 3,500 to 5,000 male births worldwide. This falls within the definition of a rare disease, which is typically characterized as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
- Duchenne muscular dystrophy is a rare genetic disorder that affects a small population.
- The clinical trial is specifically targeting participants with Duchenne muscular dystrophy, which is a rare condition.",True
NCT06195423,Stopping OsteoARthritis After an ACL Tear,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial information provided indicates that the condition being studied, knee osteoarthritis, is not a rare disease. The brief summary states that by 2040, 25% of Canadians will have osteoarthritis, a disabling joint condition. This suggests that osteoarthritis is a relatively common condition, not a rare one. Additionally, the target population for the trial is young people aged 16-35 years who have had an anterior cruciate ligament (ACL) tear and reconstruction surgery, a relatively common injury. This further supports that the condition being studied is not rare.

## Confidence Level
High

## Rare Disease Indicators
None of the rare disease indicators are present in the provided information. The condition being studied (knee osteoarthritis) is characterized as having a high prevalence, not low prevalence, which is one of the key characteristics of a rare disease.",False
NCT05417789,Study of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT),"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is Tenosynovial Giant Cell Tumor (TGCT), which meets the criteria for a rare disease. According to the information provided:

- TGCT is a condition that affects fewer than 200,000 people in the United States, which is the threshold for a rare disease in the US.
- TGCT is also generally characterized by low prevalence, chronicity, and often genetic origin, which are common features of rare diseases.

## Confidence Level
High

## Rare Disease Indicators
- Affects fewer than 200,000 people in the US
- Chronic condition
- Likely genetic origin",True
NCT06537609,A Platform Trial for Gram Negative Bloodstream Infections,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The information provided indicates that the condition being studied in this clinical trial, Gram-negative bloodstream infections (GN BSIs), is not considered a rare disease. Gram-negative bloodstream infections are a significant public health concern with high morbidity and mortality rates, and the trial is designed to address the challenge of antimicrobial resistance in the management of these infections. The condition is not characterized as having a low prevalence, as it is a common healthcare-associated infection that affects a significant number of people.

## Confidence Level
High

## Rare Disease Indicators
None. The clinical trial information does not mention any indicators that would suggest this is a rare disease trial.",False
NCT05972551,Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is Osteogenesis Imperfecta, which is a rare genetic disorder that affects the development and maintenance of bones. According to the provided criteria, a rare disease is typically characterized by low prevalence, chronicity, and often genetic origin, which aligns with the description of Osteogenesis Imperfecta.

## Confidence Level
High

## Rare Disease Indicators
- Osteogenesis Imperfecta is a genetic disorder, which is a common characteristic of rare diseases.
- The condition is described as affecting children and adolescents, which suggests a low prevalence in the overall population.",True
NCT06114888,Optimizing Care for Children Hospitalized With Community-acquired Pneumonia: Novel Diagnostics,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is community-acquired pneumonia, which is a relatively common condition and not considered a rare disease. The brief summary indicates that children are commonly hospitalized due to community-acquired pneumonia, suggesting that it is not a rare condition.

## Confidence Level
High

## Rare Disease Indicators
None. The information provided does not indicate that this clinical trial is for a rare disease as defined by the criteria provided.",False
NCT06125340,Optimizing Care for Children Hospitalized With Community-acquired Pneumonia: Short-course Therapy,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this trial is community-acquired pneumonia (CAP), which is a common and well-studied condition. According to the information provided, children are commonly hospitalized due to CAP, indicating that it is not a rare disease.

## Confidence Level
High

## Rare Disease Indicators
There are no indicators in the provided information that suggest this is a rare disease. The brief summary and condition description do not mention anything about low prevalence, chronicity, or genetic origin, which are typical characteristics of rare diseases.",False
NCT06253221,A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
Hypertrophic cardiomyopathy (HCM) is a rare genetic disorder that affects the heart muscle, causing it to become abnormally thick. The condition is generally characterized by low prevalence, chronicity, and genetic origin, which aligns with the accepted criteria for a rare disease.

## Confidence Level
High

## Rare Disease Indicators
- Cardiomyopathy, Hypertrophic is the condition being studied, which is a rare genetic disorder.
- The trial is focusing on adolescent patients, which is a specific subpopulation of the rare disease.",True
NCT06170385,Pediatric Early Rehabilitation in Acute Lymphoblastic Leukemia,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The brief summary and detailed description indicate that the condition being studied, acute lymphoblastic leukemia (ALL), is the most common childhood cancer, representing approximately 25% of cancers in children. This suggests that the prevalence of the condition is well above the criteria for a rare disease, which is defined as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
The condition being studied, acute lymphoblastic leukemia, does not meet the criteria for a rare disease based on the information provided.",False
NCT06079372,Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is hypophosphatasia (HPP), which is a rare genetic metabolic disorder. According to the information provided, HPP is generally characterized by low prevalence, chronicity, and genetic origin, which are the accepted criteria for a rare disease. Additionally, the trial is targeting a pediatric population (2 to < 12 years of age) with HPP, which further supports the rare disease classification.

## Confidence Level
High

## Rare Disease Indicators
- Condition: Hypophosphatasia (HPP)
- Low prevalence
- Chronic condition
- Genetic origin
- Pediatric population (2 to < 12 years of age)",True
NCT06221358,Pharmacogenomics of Stimulant Treatment Response,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
Attention-Deficit/Hyperactivity Disorder (ADHD) is a common neurodevelopmental disorder that affects a significant portion of the population, particularly children and adolescents. The information provided indicates that ADHD is a well-recognized condition, and the clinical trial is focused on understanding the pharmacogenomics of a commonly used treatment (methylphenidate) for this disorder.

The prevalence of ADHD in the United States is estimated to be around 5-11% of children and adolescents, which is significantly higher than the threshold of 200,000 people (or 1 in 2,000 people in Europe) used to define a rare disease.

## Confidence Level
High

## Rare Disease Indicators
This clinical trial does not meet the criteria for a rare disease, as ADHD is a common condition affecting a significant portion of the population.",False
NCT06287840,Canadian Bone Strength Development Study,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this trial is type-1 diabetes, which is not considered a rare disease. According to the information provided, type-1 diabetes is a common chronic condition that affects a significant number of people, not meeting the criteria for a rare disease in either the US or Europe.

## Confidence Level
High

## Rare Disease Indicators
None. The information provided does not indicate that this trial is targeting a rare disease.",False
NCT06065215,Early-life MRI Biomarkers of Longer-term Respiratory Morbidity in Infants Born Extremely Preterm (EMBLEM),"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is bronchopulmonary dysplasia (BPD), which is a common complication of premature birth. The brief summary indicates that BPD is a ""common, major complication of premature birth,"" suggesting that it is not a rare disease. Additionally, the trial plans to recruit 319 infants born less than 29 weeks gestation, which is a relatively large sample size and further indicates that the condition is not rare.

## Confidence Level
High

## Rare Disease Indicators
There are no clear indicators that this is a rare disease trial based on the provided information. The condition being studied, BPD, is described as a common complication of premature birth.",False
NCT05828069,"A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis","## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
Langerhans cell histiocytosis is a rare disease that meets the accepted criteria for a rare disease. According to the provided information, Langerhans cell histiocytosis is ""a type of disease that occurs when the body makes too many immature Langerhans cells (a type of white blood cell)."" The clinical trial specifically focuses on patients with ""relapsed and refractory Langerhans Cell Histiocytosis,"" indicating that this is a rare and difficult-to-treat condition.

## Confidence Level
High

## Rare Disease Indicators
- Langerhans cell histiocytosis is described as a ""type of disease"" rather than a common or widespread condition.
- The clinical trial is specifically targeted at patients with ""relapsed and refractory"" Langerhans cell histiocytosis, suggesting it is a rare and challenging-to-treat condition.
- The condition is characterized as ""more common in children and young adults,"" further indicating it is a rare disease.",True
NCT05939492,Mindfulness for Pediatric Chest Pain,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on idiopathic chest pain in pediatric patients, which is a relatively common condition. The summary does not provide any information indicating that the condition being studied affects fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe, which are the accepted criteria for a rare disease. Additionally, the condition is not described as being generally characterized by low prevalence, chronicity, and often genetic origin, which are typical features of rare diseases.

## Confidence Level
High

## Rare Disease Indicators
None",False
NCT06380283,The Feasibility and Clinical Utility of the Use of Virtual Reality for the Management of Pediatric Dental Anxiety,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is dental anxiety in children, which is not considered a rare disease. Dental anxiety is a common condition that affects a significant portion of the population, both children and adults. The trial does not mention any rare or genetic conditions that would meet the criteria for a rare disease.

## Confidence Level
High

## Rare Disease Indicators
None. The condition of pediatric dental anxiety does not meet the criteria for a rare disease, as it is not characterized by low prevalence, chronicity, and genetic origin, and it is not affecting fewer than 200,000 people in the US or 1 in 2,000 people in Europe.",False
NCT06381570,Pilot Study of Vinblastine and Tovorafenib in Pediatric Patients With Recurrent/Progressive RAF Altered Low Grade Gliomas,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The clinical trial is targeting pediatric patients with recurrent or progressive low-grade gliomas (LGG), which are considered a rare disease. According to the provided information, low-grade gliomas are characterized by low prevalence, chronicity, and often genetic origin, which aligns with the general characteristics of rare diseases.

Additionally, the trial is specifically focused on patients with CRAF or BRAF alterations, including BRAF V600 mutations and KIAA1549:BRAF fusions, which further narrows the target population. These genetic alterations are likely to affect a relatively small number of individuals, as they are not commonly found in the general population.

## Confidence Level
High

## Rare Disease Indicators
- Targeting a specific type of low-grade glioma, a condition that is generally considered a rare disease
- Focus on patients with CRAF or BRAF alterations, which are likely to affect a small subset of the population
- Chronic and genetic nature of the condition, as indicated in the rare disease definition",True
NCT05286177,Does Volume-based Enteral Feeding Improve Nutrient Delivery in Hospitalized Critically Ill Children?,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The information provided in the clinical trial details does not indicate that it is targeting a rare disease. The condition being studied is ""Enteral Feeding"", which is a common issue in critically ill children, and the trial is being conducted at a single center (Alberta Children's Hospital) without any mention of a rare or uncommon disease. Additionally, the prevalence data for rare diseases, as defined in the prompt, suggests that a condition affecting less than 200,000 people in the US or 1 in 2,000 people in Europe is considered rare, and the clinical trial details do not indicate that the target population falls within these criteria.

## Confidence Level
High

## Rare Disease Indicators
There are no clear indicators in the provided information that this is a clinical trial for a rare disease.",False
NCT06634264,"Comparison of Two Reeducation Methods in Children With Persistent Sleep Apnea, a Randomized Controlled Trial","## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on pediatric obstructive sleep apnea (PedOSA), which is a relatively common condition. According to the information provided, PedOSA is a ""multifactorial condition, associated with significant comorbidities, affecting cardiovascular health, cognitive development and quality of life."" Additionally, the condition is stated to be ""usually performed after adenotonsillectomy,"" suggesting it is a well-recognized and commonly treated condition.

The criteria for a rare disease, as provided, include affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe, and being generally characterized by low prevalence, chronicity, and often genetic origin. The information given about PedOSA does not indicate that it meets these criteria for a rare disease.

## Confidence Level
High

## Rare Disease Indicators
There are no specific indicators in the provided information that this is a clinical trial for a rare disease.",False
NCT05514665,Functional Imaging of Baby Brains,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial information provided indicates that the condition being studied, perinatal hypoxic-ischemic brain injury, is a relatively common condition affecting newborn infants. The detailed description mentions that this condition is a ""major cause of childhood disabilities"" and that ""prognostic tools"" are needed to identify infants at risk of developing neurological deficits. This suggests that the condition is not considered a rare disease.

## Confidence Level
High

## Rare Disease Indicators
None provided. The condition does not meet the criteria for a rare disease, which is typically defined as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.",False
NCT05835310,An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that affects a larger population. According to the information provided, SLE is the condition being studied in this clinical trial. SLE is not considered a rare disease, as it is estimated to affect around 1.5 million people in the United States, which is significantly higher than the threshold of 200,000 people for a rare disease in the US.

## Confidence Level
High

## Rare Disease Indicators
There are no specific indicators in the provided information that suggest this is a rare disease trial. The condition being studied, SLE, is a relatively common autoimmune disorder.",False
NCT05509777,A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
Crohn's disease, the condition being studied in this clinical trial, is not considered a rare disease. According to the information provided, Crohn's disease is a common chronic condition, and the trial is being conducted in pediatric patients with this disease. The criteria for a rare disease, as defined in the US and Europe, are that the condition affects fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe. Crohn's disease is a much more prevalent condition and does not meet these criteria for a rare disease.

## Confidence Level
High

## Rare Disease Indicators
None",False
NCT05967871,Pilot Feasibility Study of Fecal Microbiota Transplant for the Treatment of Small Intestinal Bacterial Overgrowth,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is for the treatment of small intestinal bacterial overgrowth (SIBO), which is not considered a rare disease. According to the information provided, SIBO is a condition that may affect patients with short bowel syndrome, which involves intestinal resection, dysmotility, and altered enteral feeding. The trial specifically targets pediatric patients with SIBO, which suggests a broader population affected by this condition.

## Confidence Level
High

## Rare Disease Indicators
The information provided does not indicate that SIBO meets the criteria for a rare disease, as defined in the question. The prevalence of SIBO is not specified, and there is no evidence that it affects fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe. Additionally, while SIBO may have a genetic component in some cases, the information suggests it is more broadly characterized by intestinal resection, dysmotility, and altered enteral feeding, which are not necessarily genetic in origin.",False
NCT06216899,Reverse-Engineering of Exclusive Enteral Nutrition (RE-EEN) in Crohn's Disease: A Multi-Center Trial,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
Crohn's disease, the condition being studied in this trial, is not considered a rare disease. According to the information provided, Crohn's disease is a chronic, inflammatory bowel disease, which is generally characterized by a higher prevalence than the criteria for a rare disease.

## Confidence Level
High

## Rare Disease Indicators
None. The information provided does not indicate that this trial is targeting a rare disease.",False
NCT06314802,Learning Curve of the Shouldice Procedure,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is evaluating the learning curve and outcomes of the Shouldice procedure, which is a widely used surgical technique for the repair of primary inguinal hernias. Inguinal hernias are a common condition, affecting around 27 per 1,000 men and 3 per 1,000 women in the United States. Therefore, the target condition of this trial does not meet the criteria for a rare disease, which is typically defined as affecting fewer than 200,000 people in the United States or no more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
None. The information provided indicates that inguinal hernias, the target condition of this clinical trial, are a common condition and do not meet the criteria for a rare disease.",False
NCT06031259,Extension Study of Idursulfase-IT Along With Elaprase in Children and Adults With Hunter Syndrome and Cognitive Impairment,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
According to the provided information, the clinical trial is for Hunter syndrome, which is a rare genetic disorder. The brief summary states that the study is focused on children and adults with Hunter syndrome and cognitive impairment. Additionally, the study aims to enroll up to approximately 8 patients, which is well below the thresholds for a rare disease in the US (fewer than 200,000 people) and Europe (no more than 1 in 2,000 people).

## Confidence Level
High

## Rare Disease Indicators
1. The condition being studied, Hunter syndrome, is a rare genetic disorder.
2. The study is expected to enroll a small number of participants (up to approximately 8 patients), which is characteristic of a rare disease clinical trial.",True
NCT06087224,The TELENEO Trial: a Multicenter Trial of Telemedicine for Advanced Neonatal Resuscitations in Community Hospitals,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The information provided does not indicate that the condition being studied (death, neonatal morbidity, and newborn conditions) affects fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe, which are the accepted criteria for a rare disease. The study appears to be focused on neonatal care and outcomes, which are relatively common conditions. Additionally, the detailed description suggests this is a multicenter trial, indicating the condition is not considered rare.

## Confidence Level
High

## Rare Disease Indicators
This trial does not appear to have any indicators of a rare disease based on the provided information.",False
NCT05789901,The MARVIN Chatbots to Provide Information for Different Health Conditions,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial information provided does not indicate that the conditions being studied (HIV infections, breast cancer, and pediatric emergency medicine) are rare diseases. Breast cancer and HIV infections are both relatively common conditions, and while pediatric emergency medicine may involve some rare conditions, the overall scope of the trial is not focused on a rare disease.

## Confidence Level
High

## Rare Disease Indicators
None provided. The conditions mentioned do not meet the criteria for a rare disease, which is typically defined as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.",False
NCT06241118,A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The information provided indicates that the clinical trial is for the treatment of moderate-to-severe atopic dermatitis (AD) in participants aged 12 years and older. Atopic dermatitis is a common skin condition, with a prevalence of up to 20% in children and 10% in adults in developed countries. This does not meet the criteria for a rare disease, which is typically defined as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
None. The information provided does not suggest that this is a rare disease clinical trial.",False
NCT06343779,Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The clinical trial is for the treatment of hereditary angioedema (HAE), which is a rare genetic disorder that affects fewer than 200,000 people in the United States, meeting the criteria for a rare disease. HAE is characterized by recurrent episodes of severe swelling (angioedema) in various parts of the body, and it is a chronic and often genetic condition, further confirming its status as a rare disease.

## Confidence Level
High

## Rare Disease Indicators
- Affects fewer than 200,000 people in the US, meeting the US definition of a rare disease.
- Hereditary and genetic in origin, which is a characteristic of rare diseases.
- Chronic condition, which is also a characteristic of rare diseases.",True
NCT04235335,Healing Circles: An Intervention for Canadian Indigenous Mothers & Children Affected by IPV,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The given information indicates that the clinical trial is focused on evaluating interventions for Indigenous mothers and children affected by intimate partner violence (IPV) in Canada. IPV is a relatively common public health issue, and is not considered a rare disease.

The prevalence of IPV in Canada is estimated to be around 4-7% of the population, which is significantly higher than the criteria for a rare disease (affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe).

## Confidence Level
High

## Rare Disease Indicators
This clinical trial does not meet the criteria for a rare disease, as it is focused on a condition (IPV) that is not considered rare.",False
NCT06030063,The Society for Obstetric Anesthesia and Perinatology Research Network General Anesthesia Registry,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being investigated in this clinical trial is cesarean delivery under general anesthesia, which is not considered a rare disease. Cesarean deliveries are a common procedure, and general anesthesia is a widely used anesthetic technique for these surgeries. The study aims to investigate the factors associated with the use of general anesthesia for cesarean deliveries, which is a relatively common clinical scenario.

## Confidence Level
High

## Rare Disease Indicators
None. The condition being studied does not meet the criteria for a rare disease, which typically affect fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe, and are generally characterized by low prevalence, chronicity, and often genetic origin.",False
NCT05933057,"Efficacy, Safety and Tolerability of Givinostat in Non-ambulant Patients With Duchenne Muscular Dystrophy","## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
Duchenne muscular dystrophy (DMD), the condition being studied in this clinical trial, is a rare genetic disorder that affects approximately 1 in 3,500 to 5,000 male births globally. This falls well within the definition of a rare disease, which is typically defined as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
- Duchenne muscular dystrophy is a rare, progressive, debilitating, and life-threatening genetic condition.
- The trial is specifically targeting non-ambulant patients with DMD, which represents a subset of the already rare DMD patient population.
- The trial is aiming to enroll a total of 138 patients, which is a relatively small sample size, further indicating the rarity of the condition.",True
NCT06075251,Online Support 4 CHD Kids & Caregivers,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is Congenital Heart Disease (CHD), which is not considered a rare disease. According to the information provided, CHD is a chronic condition that is generally characterized by low prevalence. However, it does not meet the accepted criteria for a rare disease, which is defined as affecting fewer than 200,000 people in the United States or no more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
None. The condition, Congenital Heart Disease, does not meet the criteria for a rare disease.",False
NCT06651944,Invisalign® System with Mandibular Advancement,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The conditions described in the clinical trial (Class II Malocclusion, Mandibular Advancement, Mandibular Retrognathism, Excessive Overjet) are not considered rare diseases based on the provided criteria. These conditions are relatively common dental and orthodontic issues, and they do not meet the definition of a rare disease affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
None. The conditions described in the clinical trial are not considered rare diseases.",False
NCT06033196,Tocilizumab in Lung Transplantation,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The information provided indicates that the clinical trial is targeting lung transplant recipients, which is not considered a rare disease. Lung transplants are performed for various conditions, including chronic obstructive pulmonary disease (COPD), cystic fibrosis, and idiopathic pulmonary fibrosis, which are not rare diseases. The brief summary mentions that the trial will enroll 350 primary lung transplant recipients, which is a much larger sample size than what is typically associated with rare diseases.

## Confidence Level
High

## Rare Disease Indicators
None. The condition being studied (lung transplantation) does not meet the criteria for a rare disease, as it is not characterized by low prevalence, chronicity, and often genetic origin, and it affects more than 200,000 people in the US.",False
NCT06506474,"Low-value Care, and Variation in Practice for Children Hospitalized with Bronchiolitis","## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The provided information indicates that the clinical trial is focused on the use of low-value healthcare services in children hospitalized with bronchiolitis, which is a common respiratory illness in young children. Bronchiolitis is not considered a rare disease based on the criteria provided:

- In the United States, bronchiolitis is estimated to affect more than 200,000 children annually, exceeding the threshold of 200,000 people for a rare disease.
- In Europe, bronchiolitis is a common condition that affects up to 1 in 50 children under the age of 1 year, which is well within the limit of 1 in 2,000 people for a rare disease.
- Bronchiolitis is generally characterized by a high prevalence, acute nature, and non-genetic origin, which are not typical characteristics of rare diseases.

## Confidence Level
High

## Rare Disease Indicators
Not applicable, as this is not a clinical trial for a rare disease.",False
NCT06721923,Continuous Vs Bolus Protein (Protein Regimen Outcomes) in Critically Ill Children (Kids in Distress),"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial information provided does not indicate that the condition being studied (critical illness, pediatric intensive care, enteral nutrition therapy, dietary protein) is a rare disease. The target population is critically ill children aged 1-11 years, which does not meet the criteria for a rare disease defined as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe. The information given suggests that the condition is more common and not considered a rare disease.

## Confidence Level
High

## Rare Disease Indicators
None provided in the given information.",False
NCT06150820,A Study About Antibody Levels and Biomarkers in the Blood in People With Late-onset Pompe Disease,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The clinical trial information provided indicates that the condition being studied is Pompe disease, which is a genetic condition that causes muscle weakness over time. According to the brief summary, Pompe disease is a rare disease that can happen at any age, and the late-onset form, which is the focus of this study, generally starts from 12 months old onwards.

The definition of a rare disease in the US is a condition that affects fewer than 200,000 people, and in Europe, a condition that affects no more than 1 in 2,000 people. The information provided suggests that Pompe disease, including the late-onset form, meets these criteria for a rare disease.

## Confidence Level
High

## Rare Disease Indicators
- Pompe disease is a genetic condition, which is a characteristic of rare diseases.
- The late-onset form of Pompe disease, which is the focus of this study, generally starts from 12 months old onwards, indicating a low prevalence.
- The brief summary states that Pompe disease can happen at any age, further suggesting a low prevalence.",True
NCT06239519,JoyPop Mobile Mental Health App With Youth,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The information provided indicates that the clinical trial is focused on evaluating a mobile mental health app (JoyPop) for youth aged 12-17 in Canada, particularly in the Northwestern Ontario region. The conditions being targeted include emotion regulation, depression, anxiety, and stress, which are relatively common mental health challenges in this age group. The prevalence of these conditions is not specified, but they are not typically considered rare diseases. The trial is aimed at improving access to mental health support for a broader population of youth, rather than a specific rare disease population.

## Confidence Level
High

## Rare Disease Indicators
There are no clear indicators that this is a rare disease trial based on the information provided. The target population and conditions do not fit the typical definition of a rare disease, which is characterized by low prevalence, chronicity, and often genetic origin.",False
NCT06261424,Effects of a Supervised Rehabilitation Program on Disease Severity in Spastic Ataxias,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The clinical trial is investigating treatments for two specific conditions: Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS) and Spastic Paraplegia 7 (SPG7). Both of these are considered rare diseases based on the provided criteria:

- ARSACS is an extremely rare genetic disorder, with an estimated prevalence of less than 1 in 100,000 people.
- SPG7 is also a rare genetic disorder, with an estimated prevalence of 1-9 per 100,000 people.

Both of these conditions fall well below the threshold of 200,000 people in the US or 1 in 2,000 people in Europe, which are the accepted criteria for a rare disease.

## Confidence Level
High

## Rare Disease Indicators
- Low prevalence (less than 1 in 100,000 for ARSACS and 1-9 per 100,000 for SPG7)
- Genetic origin
- Chronicity (lifelong, progressive conditions)",True
NCT06282133,Behavioural Experiments for Generalized Anxiety in Adolescents - Pilot Study,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The provided information indicates that the condition being studied, Generalized Anxiety Disorder (GAD), is not considered a rare disease. The brief summary states that in Canada, 3 to 4% of the population (between 0.9% and 2.7% among adolescents) suffers from GAD at any given time in their lives. This prevalence rate is significantly higher than the criteria for a rare disease, which is defined as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
There are no specific indicators that this is a rare disease trial. The prevalence of GAD in the population clearly exceeds the criteria for a rare disease.",False
NCT06019078,"pEEG Monitoring Effect on Delirium, Ventilator Days, and PICS","## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The provided information indicates that the clinical trial is focused on studying the impact of using a processed electroencephalography (pEEG) monitor to guide sedation and analgesia management in ventilated patients in the intensive care unit (ICU). The conditions being studied, such as critical illness, post-intensive care unit syndrome, delirium, and sedative-related disorders, are common and not considered rare diseases.

## Confidence Level
High

## Rare Disease Indicators
None of the information provided suggests this is a rare disease trial. The conditions described are generally characterized as common, rather than rare, based on the accepted criteria for rare diseases.",False
NCT01344200,CELECOXIB Plasma and Cerebral Spinal Fluid Pharmacokinetics in Children,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The information provided in the clinical trial details does not indicate that the condition being studied, ""Pharmacokinetics of Celecoxib in Children"", is a rare disease. The trial is focused on understanding the pharmacokinetics (absorption, distribution, metabolism, and elimination) of the drug celecoxib in children, which is a common medication used for pain management. The trial is not targeting a specific rare disease, but rather investigating the appropriate dosing of a widely used drug in the pediatric population.

## Confidence Level
High

## Rare Disease Indicators
There are no specific indicators in the provided information that this is a rare disease trial. The condition being studied is a common one, and the trial is not focused on a rare disease population.",False
NCT06143891,"A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.","## Classification
Yes, this appears to be a clinical trial for a rare disease.

## Reasoning
Chronic graft-versus-host disease (cGVHD) is a rare complication of hematopoietic stem cell transplantation, affecting approximately 14% of allogeneic transplant recipients. The incidence of cGVHD is estimated to be around 30,000-40,000 cases per year in the United States, which is well below the 200,000 threshold for a rare disease in the US.

## Confidence Level
High

## Rare Disease Indicators
- Chronic, debilitating condition
- Low prevalence (affecting fewer than 200,000 people in the US)
- Genetic origin (related to hematopoietic stem cell transplantation)",False
NCT06156865,Using Neuroimaging and Behavioral Assessments to Understand Late Talking,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The information provided indicates that the condition being studied, Developmental Language Disorder (DLD) and late talking, affects 10-20% of children under 3 years of age. This prevalence rate falls well above the criteria for a rare disease, which is defined as affecting fewer than 200,000 people in the United States or no more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
None. The prevalence of the condition being studied does not meet the criteria for a rare disease.",False
NCT06163326,A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is investigating the use of ritlecitinib for the treatment of non-segmental vitiligo, which is an autoimmune disorder characterized by well-defined pale white patches of skin. Vitiligo is not considered a rare disease, as it is estimated to affect 0.5-2% of the global population, which is significantly higher than the criteria for a rare disease in the US (affecting fewer than 200,000 people) and Europe (affecting no more than 1 in 2,000 people).

## Confidence Level
High

## Rare Disease Indicators
None. Vitiligo does not meet the criteria for a rare disease.",False
NCT05546359,Study of Intravenous Amisulpride for Prophylaxis of Post-operative Nausea and Vomiting (PONV) in Pediatric Patients,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial information provided indicates that the condition being studied is post-operative nausea and vomiting (PONV) in pediatric patients. PONV is a common condition that affects a significant portion of the population undergoing surgery, and is not considered a rare disease. The condition is not characterized by low prevalence, chronicity, or genetic origin, which are typical indicators of a rare disease.

## Confidence Level
High

## Rare Disease Indicators
None. The information provided does not indicate that this trial is for a rare disease.",False
NCT06224348,A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is atopic dermatitis, which is a common skin condition. According to the information provided, atopic dermatitis is a ""moderate-to-severe"" condition, but it does not meet the criteria for a rare disease. The rare disease definition states that a rare disease typically affects fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe. Atopic dermatitis is a much more prevalent condition.

## Confidence Level
High

## Rare Disease Indicators
None of the provided information suggests this is a rare disease clinical trial. The condition, atopic dermatitis, is a common skin condition and does not meet the criteria for a rare disease.",False
NCT05568459,A Trial That Evaluates Disease Characteristics in Hemophilia B Adult Male Participants Receiving Prophylaxis With Standard of Care Factor IX Protein (FIX) Replacement Therapy,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is Hemophilia B, which is a rare genetic disorder that affects the blood's ability to clot. According to the information provided, Hemophilia B is characterized by low prevalence, chronicity, and genetic origin, which are key features of a rare disease.

## Confidence Level
High

## Rare Disease Indicators
- Affects fewer than 200,000 people in the US, which is the accepted criterion for a rare disease in the US.
- Hemophilia B is a chronic, genetic condition, which are also characteristics of a rare disease.",True
NCT05961176,Exploratory Study on Bio-signal Telemonitoring Using Electronic Textiles in a Pediatric Acute and Critical Care Setting,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on heart failure, which is not considered a rare disease. Heart failure affects a relatively large population, with an estimated prevalence of around 6.2 million adults in the United States as of 2019. This exceeds the criteria for a rare disease, which is typically defined as affecting fewer than 200,000 people in the United States.

## Confidence Level
High

## Rare Disease Indicators
None. The condition being studied, heart failure, is not a rare disease.",False
NCT06169800,Biologic Augment of the Medial Patellofemoral Ligament Following Primary Lateral Patellofemoral Dislocation (BioPPD),"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial information provided does not indicate that the condition being studied, patellofemoral dislocation, is a rare disease. Patellofemoral instability and dislocation are relatively common knee joint injuries, and the information suggests that the target patient population is not limited to fewer than 200,000 people in the US or 1 in 2,000 people in Europe, which are the accepted criteria for a rare disease.

## Confidence Level
High

## Rare Disease Indicators
None provided. The information suggests that patellofemoral dislocation is a well-recognized and common knee joint injury.",False
NCT06366334,Study of IV Ketamine for Emergency Department Treatment of Adolescent Suicidal Ideation,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is suicidal ideation, which is not considered a rare disease. The clinical trial information indicates that suicidal ideation is a common condition, with approximately 20% of Canadian adolescents experiencing thoughts of suicide. Additionally, the trial is being conducted at a pediatric emergency department, which suggests that the condition is not rare. The target population of adolescents further indicates that this is not a rare disease.

## Confidence Level
High

## Rare Disease Indicators
None. The information provided does not indicate that this is a rare disease trial.",False
NCT06208215,RZ358 Treatment for Congenital Hyperinsulinism,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The detailed description of the trial indicates that the condition being studied, congenital hyperinsulinism, has an incidence of approximately 1 in 25,000 to 1 in 50,000 live births in the general population, and as high as 1 in 2,500 in certain populations with substantial consanguinity. This meets the criteria for a rare disease in both the US (affecting fewer than 200,000 people) and Europe (affecting no more than 1 in 2,000 people).

## Confidence Level
High

## Rare Disease Indicators
- Incidence of approximately 1 in 25,000 to 1 in 50,000 live births in the general population, and as high as 1 in 2,500 in certain populations
- Chronicity and genetic origin of the condition",True
NCT05852158,Antibiotics for Prevention of Infection Following Orthognathic Surgery,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on orthognathic surgery, which is a common procedure aimed at correcting developmental or acquired deformities of the jaws and facial skeleton. The target condition, surgical site infection following orthognathic surgery, is not considered a rare disease. The background information provided indicates that surgical site infections occur in 10-15% of cases, which is not within the criteria for a rare disease (affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe).

## Confidence Level
High

## Rare Disease Indicators
None. The condition and target population do not meet the criteria for a rare disease.",False
NCT05166343,POHCA Resuscitation: Evaluation of IM Epinephrine,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on the use of intramuscular epinephrine in the management of pediatric out-of-hospital cardiac arrest (POHCA). Cardiac arrest is a relatively common medical emergency, and it is not considered a rare disease. The trial's detailed description does not mention any specific rare disease or condition that affects fewer than 200,000 people in the US or fewer than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
None. The condition being studied, pediatric out-of-hospital cardiac arrest, is not a rare disease.",False
NCT06079736,A Study Of PGN-EDO51 In Participants With Duchenne Muscular Dystrophy Amenable To Exon 51-Skipping Treatment,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is Duchenne Muscular Dystrophy (DMD), which is a rare genetic disorder. According to the information provided, DMD is a rare disease that is generally characterized by low prevalence, chronicity, and genetic origin.

## Confidence Level
High

## Rare Disease Indicators
- Duchenne Muscular Dystrophy is a rare genetic disorder.
- Duchenne Muscular Dystrophy affects fewer than 200,000 people in the US, which meets the criteria for a rare disease in the US.",True
NCT06191315,Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS),"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on asthma and recurrent severe asthmatic wheeze in children aged 2 to <6 years. Asthma is a common chronic respiratory condition, and it is not considered a rare disease. The brief summary indicates that the study aims to evaluate the efficacy and safety of dupilumab, a medication, in this patient population.

## Confidence Level
High

## Rare Disease Indicators
None. The clinical condition being studied, asthma, is not considered a rare disease.",False
NCT05709132,iP2P Mentorship Program for Teen HF Patients,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is heart failure, which is not considered a rare disease. Heart failure affects approximately 6.2 million adults in the United States, which is significantly more than the 200,000 people threshold for a rare disease in the US. Additionally, the prevalence of heart failure is generally high, and it is not typically characterized by low prevalence, chronicity, and genetic origin, which are generally associated with rare diseases.

## Confidence Level
High

## Rare Disease Indicators
N/A",False
NCT05981664,Level Up! Adaptive Gaming for Children With Upper Limb Differences,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The conditions listed in the trial include upper limb amputations, which are not considered rare diseases based on the provided criteria. The trial is focused on children with upper limb differences, which, while not a common condition, does not meet the definition of a rare disease affecting fewer than 200,000 people in the US or 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
None of the conditions listed in the trial meet the criteria for a rare disease.",False
NCT06141733,2 Year Follow up of COSGOD III,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The information provided in the clinical trial summary does not indicate that the conditions being studied (neurodevelopmental disability and death) are considered rare diseases. The trial is an observational follow-up study of a previous trial, COSGOD III, which included neonates. Rare diseases are generally characterized by low prevalence, chronicity, and often genetic origin. The conditions mentioned in this trial, while serious, do not appear to meet the established criteria for rare diseases, which are defined as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
None provided. The information given does not suggest this is a rare disease trial.",False
NCT06402240,The Pocket Skills Adjunct Project,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The conditions being studied in this clinical trial (substance use disorders, alcohol use disorder, depression, and anxiety) are not considered rare diseases. Substance use disorders and alcohol use disorder are relatively common, affecting a significant portion of the population. Similarly, depression and anxiety are also prevalent mental health conditions. Based on the information provided, the target population for this study does not meet the criteria for a rare disease, which is typically defined as affecting fewer than 200,000 people in the United States or no more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
None of the indicators for a rare disease are present in this clinical trial. The conditions being studied are not characterized by low prevalence, chronicity, or genetic origin.",False
NCT06137118,AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is B-cell Acute Lymphoblastic Leukemia (B-ALL), which is a type of blood cancer that affects the B-cells. According to the information provided, B-ALL is considered a rare disease based on the following criteria:

1. In the United States, B-ALL is estimated to affect fewer than 200,000 people, which meets the definition of a rare disease in the US.
2. B-ALL is generally characterized by low prevalence, chronicity, and often genetic origin, which are common features of rare diseases.

## Confidence Level
High

## Rare Disease Indicators
- Affects fewer than 200,000 people in the US
- Chronic and genetic condition
- Low prevalence",True
NCT05383495,Anxiolysis for Laceration Repair in Children,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is investigating the use of anxiolytic agents for the management of distress and pain during laceration repair in children. Laceration is a common condition, affecting a large population of children. The detailed description indicates that laceration is ""the most common reason for an ED visit in children"", suggesting that it is a widespread condition and not a rare disease.

## Confidence Level
High

## Rare Disease Indicators
None of the rare disease indicators are present in this case. The condition being studied (laceration) is not considered a rare disease, as it affects a large number of children and is a common reason for emergency department visits.",False
NCT06153459,Cord Clamping Among Neonates with Congenital Heart Disease,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
Congenital heart disease (CHD) is not considered a rare disease according to the criteria provided. The clinical trial description states that the study will enroll term-born infants with a prenatal diagnosis of congenital heart disease. CHD is a relatively common condition, affecting approximately 1 in 100 live births globally. This is well above the thresholds for a rare disease, which is defined as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
The clinical trial information does not indicate that this is a study for a rare disease. The condition being studied, congenital heart disease, is a relatively common birth defect and does not meet the criteria for a rare disease.",False
NCT05336136,Custom Non-invasive Ventilation Masks in Children,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial in the given information is focused on children who require non-invasive ventilation (NIV) and have difficulties with mask fit and adherence to treatment. While craniofacial abnormalities and differences may be more common in children using NIV, the condition being targeted in this trial (i.e., the need for customized NIV masks) does not appear to meet the criteria for a rare disease. The brief summary and detailed description indicate that the target population for this trial includes children who are already established on long-term NIV, which suggests that the condition is not considered rare.

## Confidence Level
High

## Rare Disease Indicators
The information provided does not indicate that this is a rare disease trial. The target population, while potentially including children with craniofacial differences, does not appear to be a rare disease based on the accepted criteria of affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.",False
NCT06184100,Virtual Self-Management Program for JIA,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is juvenile idiopathic arthritis (JIA), which is not considered a rare disease. According to the information provided, JIA is a relatively common chronic condition affecting children and adolescents. The prevalence of JIA is estimated to be around 1 in 1,000 children, which is well above the threshold for a rare disease in both the US (fewer than 200,000 people) and Europe (no more than 1 in 2,000 people).

## Confidence Level
High

## Rare Disease Indicators
None of the provided information suggests that this is a rare disease clinical trial. The condition, juvenile idiopathic arthritis, is a well-recognized and relatively common chronic condition in children and adolescents.",False
NCT06152237,Safety and Efficacy of TSHA-102 in Pediatric Females with Rett Syndrome (REVEAL Pediatric Study),"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is Rett Syndrome, which is a rare genetic disorder that predominantly affects females. According to the information provided, Rett Syndrome is a rare disease, as it is generally characterized by low prevalence, chronicity, and genetic origin.

## Confidence Level
High

## Rare Disease Indicators
- Rett Syndrome is a rare genetic disorder that affects fewer than 200,000 people in the United States, which meets the criteria for a rare disease in the US.
- The clinical trial is targeting pediatric females with Rett Syndrome, which further indicates the rarity of the condition.",True
NCT05763953,The NODE-202 Study (Study of Etripamil Nasal Spray in Pediatric Patients),"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The information provided indicates that the clinical trial is for the treatment of paroxysmal supraventricular tachycardia (PSVT), which is a relatively common heart condition. While the trial is focused on the pediatric population, PSVT is not considered a rare disease. The prevalence of PSVT is not explicitly stated, but it is not characterized as a rare disease in the provided criteria.

## Confidence Level
High

## Rare Disease Indicators
None provided. The condition being studied, PSVT, is not considered a rare disease based on the given criteria.",False
NCT05995353,"A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease","## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
Crohn's disease, the condition being studied in this clinical trial, is not considered a rare disease. According to the provided criteria, a rare disease is typically defined as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe. Crohn's disease, on the other hand, is a relatively common chronic inflammatory bowel disease, with an estimated prevalence of 201 per 100,000 people in the US and 322 per 100,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
None. The information provided indicates that Crohn's disease is a common chronic condition, not a rare disease.",False
NCT06111586,FrexalimAB in Preservation of Endogenous insULIN Secretion Compared to Placebo in adUlts and Adolescents on Top of inSulin Therapy (FABULINUS),"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
Type 1 diabetes is a common condition, not a rare disease. According to the information provided, type 1 diabetes affects a significant number of people, as it is a well-known and prevalent condition. The clinical trial is specifically focused on newly diagnosed type 1 diabetes in adults and adolescents, which further indicates that it is not a rare disease.

## Confidence Level
High

## Rare Disease Indicators
None. The information provided does not indicate that this trial is for a rare disease.",False
NCT05790785,Vascular Complications in Children From T1D Diagnosis,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on the development of cardiovascular complications in children and adolescents with type 1 diabetes, which is a relatively common condition. The brief summary indicates that type 1 diabetes is a ""life-long disease, usually diagnosed in childhood,"" suggesting that it affects a significant number of people, not a rare disease.

## Confidence Level
High

## Rare Disease Indicators
The information provided does not indicate that this is a trial for a rare disease. Type 1 diabetes is not considered a rare disease, as it is estimated to affect over 1 million people in the United States and around 30 million people worldwide.",False
NCT05337033,Cannabis for Chronic Headaches in Adolescents: the CAN-CHA Trial,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial information provided indicates that the condition being studied is chronic migraine, which is not considered a rare disease. Chronic migraine affects a significant number of people, with an estimated prevalence of 1-2% in the general population. This falls outside the typical definition of a rare disease, which is generally characterized by a low prevalence affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
None",False
NCT06173531,Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
Prader-Willi syndrome (PWS) is a rare genetic disorder that is estimated to affect between 1 in 12,000 to 1 in 15,000 people in the United States. This falls well within the accepted criteria for a rare disease in the US (affecting fewer than 200,000 people) and in Europe (affecting no more than 1 in 2,000 people). Additionally, PWS is a chronic, lifelong condition that is generally characterized by genetic origin, which aligns with the general characteristics of rare diseases.

## Confidence Level
High

## Rare Disease Indicators
- Prader-Willi syndrome (PWS) is a rare genetic disorder.
- The condition is estimated to affect between 1 in 12,000 to 1 in 15,000 people in the United States, which is well below the 200,000 people threshold for a rare disease in the US.
- PWS is a chronic, lifelong condition that is generally characterized by genetic origin.",True
NCT06093386,Promoting Intensive Transitions for Children and Youth With Medical Complexity From Pediatric to Adult Care,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on ""Children and Youth With Medical Complexity"", which does not meet the criteria for a rare disease as defined in the information provided. The condition of ""Children and Youth With Medical Complexity"" is not specified to affect fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe, which are the accepted criteria for a rare disease. Additionally, the brief summary does not indicate that the condition is generally characterized by low prevalence, chronicity, and often genetic origin, which are also typical characteristics of rare diseases.

## Confidence Level
High

## Rare Disease Indicators
None",False
NCT06087744,NeuroN-QI: An Intervention to Promote Preterm Infants' Neurodevelopment,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this trial is ""Neurodevelopmental Disorders"", which is a broad category and not a specific rare disease. The brief summary indicates that the trial is focused on preterm infants, which is a common condition and not considered a rare disease. There is no information provided about the prevalence of the specific condition or the target population size, which are key criteria for defining a rare disease.

## Confidence Level
High

## Rare Disease Indicators
None provided in the given information.",False
NCT05784246,A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
Ulcerative colitis is a form of inflammatory bowel disease that is relatively common, with a prevalence of approximately 100-200 cases per 100,000 people in the United States and Europe. This is well above the thresholds for a rare disease, which are defined as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
None identified. The condition of ulcerative colitis does not meet the accepted criteria for a rare disease.",False
NCT05766267,Short-course Regimens for the Treatment of Pulmonary Tuberculosis,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is for the treatment of pulmonary tuberculosis, which is a common infectious disease and not considered a rare disease. According to the provided criteria, a rare disease is typically defined as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe. Tuberculosis is a global health problem, with an estimated 10 million new cases and 1.5 million deaths worldwide in 2020, indicating that it is not a rare disease.

## Confidence Level
High

## Rare Disease Indicators
None of the provided information suggests that this clinical trial is for a rare disease. The condition being studied, pulmonary tuberculosis, is a common infectious disease and does not meet the criteria for a rare disease.",False
NCT05863910,Real World Evidence on the Use of Medical Cannabis in Pediatrics,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The conditions mentioned in the clinical trial information (cancer, epilepsy, and neurodevelopmental disorders) are not considered rare diseases based on the provided criteria. Cancer and epilepsy are relatively common conditions, and neurodevelopmental disorders, while potentially having some rare subtypes, are generally not considered rare diseases. Additionally, the study is following 500 children, which is a larger sample size than the typical definition of a rare disease affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
None",False
NCT05793944,SmartMom: Teaching by Texting to Promote Health Behaviours in Pregnancy,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is investigating the effectiveness of a text messaging-based program to promote healthy behaviors during pregnancy. Pregnancy is a common condition that affects a large number of people, and it is not considered a rare disease. The information provided does not indicate that this trial is targeting a specific rare disease.

## Confidence Level
High

## Rare Disease Indicators
None. The condition being studied, pregnancy, is a common and widespread condition, not a rare disease.",False
NCT06130566,A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The information provided in the clinical trial details indicates that the condition being studied, atopic dermatitis, is not a rare disease. Atopic dermatitis is a common skin condition that affects a significant number of people, rather than a rare disease that affects fewer than 200,000 people in the US or 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
None. The information provided does not indicate that this trial is for a rare disease.",False
NCT06000397,Reminder Emails to Improve Pneumococcal Vaccine Completion at 12 Months of Age,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on improving pneumococcal vaccine coverage and timely completion of the immunization series in children at the 12-month visit. Pneumococcal disease, which the vaccine is designed to prevent, is not considered a rare disease. The condition being studied (immunization coverage) is a common public health concern and does not meet the criteria for a rare disease.

## Confidence Level
High

## Rare Disease Indicators
None. The information provided does not indicate that this clinical trial is targeting a rare disease.",False
NCT05782907,"Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.","## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is ulcerative colitis, which is a type of inflammatory bowel disease. Ulcerative colitis is not considered a rare disease, as it is estimated to affect approximately 1 in 2,500 people in the United States. This falls outside the criteria for a rare disease, which is defined as affecting fewer than 1 in 2,000 people in Europe or fewer than 200,000 people in the United States.

## Confidence Level
High

## Rare Disease Indicators
None. The condition being studied, ulcerative colitis, does not meet the criteria for a rare disease.",False
NCT06046820,The ENERGY 3 Study: Evaluation of Efficacy and Safety of INZ-701 in Children With ENPP1 Deficiency,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The detailed description states that ENPP1 Deficiency, the condition being studied in this trial, has an incidence of 1 in 64,000 pregnancies. This meets the criteria for a rare disease in both the US (affecting fewer than 200,000 people) and Europe (affecting no more than 1 in 2,000 people). The trial also mentions that ENPP1 Deficiency is an ""ultra-rare genetic disorder"", further indicating its rare nature.

## Confidence Level
High

## Rare Disease Indicators
- Incidence of 1 in 64,000 pregnancies
- Described as an ""ultra-rare genetic disorder""",True
NCT05636397,Safety and PK-PD Study of Oral L-CIT in Preterm Infants with BPD±PH and NEC,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial information provided indicates that the conditions being studied, BPD (Bronchopulmonary Dysplasia), Pulmonary Hypertension, and NEC (Necrotizing Enterocolitis), are not considered rare diseases based on the accepted criteria. BPD is a common complication of prematurity, affecting up to 50% of infants born before 28 weeks of gestation, and NEC is a serious gastrointestinal disorder that affects approximately 7% of preterm infants. While the combination of these conditions in preterm infants may be less common, the individual conditions themselves are not considered rare.

## Confidence Level
High

## Rare Disease Indicators
None. The conditions mentioned in the clinical trial are not considered rare diseases based on the provided criteria.",False
NCT06038019,Thresholds In Food Allergy evaluaTion And predictioN,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is for food allergy, which is a relatively common condition. The brief summary mentions that the aim is to quantify food allergy thresholds in Canada, which suggests that food allergy is not a rare disease in the region. According to the provided criteria, a rare disease typically affects fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe, and is generally characterized by low prevalence, chronicity, and often genetic origin. The information provided about this clinical trial does not indicate that food allergy meets these criteria for a rare disease.

## Confidence Level
High

## Rare Disease Indicators
None.",False
NCT06182462,Virtual Reality Distraction for Dental Anxiety (RCT),"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial information provided does not indicate that the target population has a rare disease. The trial is focused on dental anxiety and fear in children, which is not considered a rare condition. The prevalence of dental anxiety and fear in children is estimated to be between 13.3% to 29.3%, which is much higher than the criteria for a rare disease (affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe).

## Confidence Level
High

## Rare Disease Indicators
None identified. The information provided does not suggest this is a trial for a rare disease.",False
NCT05965401,Pharmacogenetic-Guided Antidepressant Prescribing in Adolescents,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is depression in adolescents, which is not considered a rare disease. The brief summary indicates that the trial will enroll 452 adolescents aged 12-17 years, which is a sufficiently large sample size that is not characteristic of rare diseases.

## Confidence Level
High

## Rare Disease Indicators
None",False
NCT06052059,A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001),"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is ulcerative colitis, which is not considered a rare disease. According to the information provided, ulcerative colitis is a common chronic inflammatory bowel disease. The prevalence of ulcerative colitis is estimated to be much higher than the criteria for a rare disease, which is defined as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
None, as ulcerative colitis is not a rare disease.",False
NCT06129058,Home-based Transcranial Direct Current Stimulation (tDCS) to Promote Social Communication and Behaviour in Children With Autism Spectrum Disorder (ASD),"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
Autism Spectrum Disorder (ASD) is a relatively common condition, with a prevalence of about 1 in 44 children in the United States as of 2018. This falls well outside the criteria for a rare disease, which is defined as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
None of the provided information indicates that this is a trial for a rare disease. The condition being studied, Autism Spectrum Disorder, is a relatively common neurodevelopmental disorder.",False
NCT06408012,An Innovative Master Platform for Clinical Trials in Mood Disorders,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The information provided indicates that the clinical trial is focused on mood disorders, such as depression and bipolar disorder, which are not considered rare diseases. The brief summary states that mood disorders ""affect over 350 million people around the world,"" which is significantly higher than the criteria for a rare disease in the US (affecting fewer than 200,000 people) or Europe (affecting no more than 1 in 2,000 people).

## Confidence Level
High

## Rare Disease Indicators
There are no clear indicators that this is a rare disease trial based on the information provided. The conditions being studied (mood disorders, depressive disorder, bipolar and related disorders) are common and have a high prevalence.",False
NCT06075667,A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is obesity and overweight, which are relatively common conditions. Based on the information provided, the trial is targeting adolescents who have obesity or overweight with at least one weight-related comorbidity. Obesity and overweight are not considered rare diseases, as they affect a much larger population than the criteria for rare diseases in the US (fewer than 200,000 people) or Europe (affecting no more than 1 in 2,000 people).

## Confidence Level
High

## Rare Disease Indicators
None. The condition being studied, obesity and overweight, is not considered a rare disease.",False
NCT05867472,Advancing Brain Outcomes in Pediatric Critically Ill Patients Sedated With Volatile AnEsthestic Agents,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial information provided does not indicate that the condition being studied, specifically ""Intensive Care Units, Pediatric, Anesthetics, Inhalation"", is a rare disease. The trial is focused on studying sedation in critically ill pediatric patients, which is a relatively common condition, not a rare disease.

## Confidence Level
High

## Rare Disease Indicators
There are no clear indicators in the provided information that this is a rare disease trial. The condition being studied, while potentially serious, does not meet the criteria for a rare disease as defined in the question (affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe).",False
NCT06099704,Observational Study of Canadian Patients (6 Years or Older) Receiving Dupixent® for Moderate to Severe Atopic Dermatitis,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is for the treatment of moderate to severe atopic dermatitis, a common skin condition. Atopic dermatitis is not considered a rare disease, as it is estimated to affect up to 20% of children and 3% of adults worldwide, which is significantly higher than the criteria for a rare disease.

## Confidence Level
High

## Rare Disease Indicators
None. The information provided does not indicate that the condition being studied (moderate to severe atopic dermatitis) meets the criteria for a rare disease.",False
NCT05755386,Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The clinical trial is studying idiopathic immune-complex-mediated membranoproliferative glomerulonephritis (IC-MPGN), which is a rare kidney disorder. According to the information provided, IC-MPGN is generally characterized by low prevalence, chronicity, and often genetic origin, which aligns with the accepted criteria for a rare disease.

## Confidence Level
High

## Rare Disease Indicators
- Low prevalence: The trial is specifically targeting IC-MPGN, which is a rare condition.
- Chronicity: IC-MPGN is a chronic kidney disorder.
- Genetic origin: The trial mentions that alternative complement pathway (AP) dysregulation, which can have a genetic component, is believed to underlie the clinical manifestations and progression of IC-MPGN.",True
NCT06058455,An Evaluation of an Online Sexual Assault Resistance Program (IDEA3),"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is sexual assault, which is not considered a rare disease. Sexual assault is a relatively common occurrence, particularly among young women. The brief summary indicates that up to 40% of young women experience sexual assault during their time in college. This prevalence is significantly higher than the accepted criteria for a rare disease, which is defined as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
This clinical trial does not meet the criteria for a rare disease based on the information provided. The condition being studied, sexual assault, is a relatively common occurrence and does not fit the definition of a rare disease.",False
NCT05610891,Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The clinical trial is for children, adolescents, and young adults with relapsed or refractory high-grade glioma (HGG), which is a type of brain cancer. According to the information provided, HGG is considered a rare disease, as it affects a small population of people, typically less than 200,000 individuals in the United States. Additionally, the trial is targeting a specific subgroup of HGG patients, those with inoperable, relapsed, or refractory disease, which further narrows the patient population.

## Confidence Level
High

## Rare Disease Indicators
- The trial is targeting a condition (high-grade glioma) that affects fewer than 200,000 people in the United States, which meets the criteria for a rare disease.
- The trial is specifically focused on a subgroup of HGG patients with inoperable, relapsed, or refractory disease, which further reduces the potential patient population.
- The trial is being conducted in children, adolescents, and young adults, which is a specific demographic that is often affected by rare diseases.",True
NCT05916339,AWARE: Management of ADHD in Autism Spectrum Disorder,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The information provided indicates that the clinical trial is focused on autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD), which are not considered rare diseases. According to the detailed description, 1 in 54 children in the United States are diagnosed with ASD, which is significantly higher than the criteria for a rare disease in the US (affecting fewer than 200,000 people). Additionally, ADHD is a relatively common condition, and the study is examining the management of ADHD in children and adolescents with ASD.

## Confidence Level
High

## Rare Disease Indicators
This clinical trial does not meet the criteria for a rare disease based on the information provided. The prevalence of ASD and ADHD is higher than the thresholds for rare diseases in the US and Europe.",False
NCT05997680,A Parent-child Yoga Intervention for Reducing Attention Deficits in Children with Congenital Heart Disease: a Feasibility Study,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial information provided indicates that the condition being studied is congenital heart disease (CHD), which affects up to 1% of newborns. This prevalence is higher than the accepted criteria for a rare disease, which is typically defined as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
None. The condition being studied, congenital heart disease, does not meet the criteria for a rare disease.",False
NCT06079671,Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical),"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is locally advanced cervical cancer, which is not considered a rare disease. Cervical cancer is the fourth most common cancer in women globally, with an estimated 604,000 new cases and 342,000 deaths in 2020. Locally advanced cervical cancer, which includes stage IIIA to IVA, is a specific subset of cervical cancer, but it is still not considered a rare disease.

## Confidence Level
High

## Rare Disease Indicators
This clinical trial does not meet the criteria for a rare disease, as cervical cancer is not considered a rare disease. The prevalence of locally advanced cervical cancer is likely higher than the thresholds defined for rare diseases in the United States (fewer than 200,000 people) and Europe (no more than 1 in 2,000 people).",False
NCT05987449,"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A","## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
Hemophilia A is a rare genetic disorder that affects the blood's ability to clot. According to the information provided, the trial is specifically targeting individuals with severe or moderate hemophilia A, which is generally considered a rare disease. The estimated prevalence of hemophilia A in the United States is around 20,000 people, which falls within the accepted criteria for a rare disease (fewer than 200,000 people).

## Confidence Level
High

## Rare Disease Indicators
- The condition being studied, hemophilia A, is generally characterized as a rare disease.
- The prevalence of severe or moderate hemophilia A is estimated to be around 20,000 people in the United States, which is well below the 200,000 threshold for a rare disease.
- The trial is specifically targeting individuals with a rare genetic disorder, which is a common characteristic of rare diseases.",True
NCT06285786,Patient Handling Techniques and New Technology for Health Care Workers,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial described in the information provided is focused on investigating techniques and technology to reduce musculoskeletal demands and injuries for healthcare workers during patient handling tasks. The target condition is ""work-related injury"", which is not considered a rare disease. The trial does not mention any rare or genetic diseases, and the sample size of 30 nursing students is consistent with a study of a common condition rather than a rare disease.

## Confidence Level
High

## Rare Disease Indicators
None provided. The information given does not indicate this is a trial for a rare disease.",False
NCT05754567,CONCEPTT Kids International Neurodevelopmental Outcomes Among Offspring of Women With Type 1 Diabetes,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The information provided indicates that this is a study of neurodevelopmental outcomes in children of mothers with type 1 diabetes. Type 1 diabetes is not considered a rare disease, as it affects an estimated 1.6 million individuals in the United States. Additionally, the potential number of recruits for this study is 225, which is significantly higher than the threshold of 200,000 individuals for a rare disease in the United States.

## Confidence Level
High

## Rare Disease Indicators
None. The condition being studied (neurodevelopmental disorders in children of mothers with type 1 diabetes) is not considered a rare disease based on the provided criteria.",False
NCT06012084,The Development and Evaluation of iCF-PWR for Healthy Siblings of Individuals With Cystic Fibrosis,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on evaluating an internet-delivered mental health program for healthy siblings of individuals with cystic fibrosis (CF). Cystic fibrosis is not considered a rare disease based on the provided criteria. In the United States, CF affects approximately 30,000 people, which is significantly more than the 200,000 threshold for a rare disease. Additionally, CF is a well-known chronic genetic condition and is not considered a rare disease.

## Confidence Level
High

## Rare Disease Indicators
None. The information provided indicates that this clinical trial is not for a rare disease.",False
NCT06645639,Implementation of P-INPAC,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial described in the information provided is focused on implementing a nutrition pathway for hospitalized children, which targets the conditions of malnutrition, child, and poor nutrition. These are not considered rare diseases. The trial aims to evaluate the implementation and effectiveness of the Pediatric Integrated Nutrition Pathway for Acute Care (P-INPAC) in three Canadian pediatric centers. The information indicates that the study will involve a significant number of patients, with an anticipated 480-600 patients across the three sites during the third phase of the study. This suggests that the target population is not considered a rare disease, as rare diseases are typically defined as affecting fewer than 200,000 people in the United States or no more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
There are no specific indicators in the provided information that suggest this is a clinical trial for a rare disease.",False
NCT05521711,TRADE Trial - Tree Nut Immunotherapy Route Development and Evaluation,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
Based on the information provided, the condition being studied in this clinical trial is tree nut allergy, which does not meet the criteria for a rare disease. Tree nut allergy is a common food allergy, affecting an estimated 1.1% to 3.9% of the population in the United States and Europe. This is significantly higher than the accepted thresholds for a rare disease, which are affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
The information provided does not indicate that the condition being studied (tree nut allergy) is a rare disease.",False
NCT05626595,PROmoting Early Childhood Outside 2.0,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial described in the information provided is focused on promoting outdoor play in early learning and childcare centers, which is a common condition and not a rare disease. The condition being studied, ""Child Development"", is a broad category that does not meet the criteria for a rare disease, which is typically defined as a condition affecting fewer than 200,000 people in the United States or no more than 1 in 2,000 people in Europe. The information provided does not indicate that the study is targeting a rare condition.

## Confidence Level
High

## Rare Disease Indicators
None identified. The condition being studied, ""Child Development"", is a common and widespread condition, not a rare disease.",False
NCT05759039,SHould You TransFer the Tubercle?,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition described in the clinical trial, patellofemoral dislocation, is not considered a rare disease. Patellofemoral instability and dislocation are relatively common orthopedic conditions, affecting up to 7% of the general population. This is significantly higher than the accepted criteria for a rare disease, which is defined as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
None. The condition described in the clinical trial does not meet the criteria for a rare disease.",False
NCT05879770,Is the Use of Prolene as Sufficient as the Use of Wire in Shouldice Surgery to Keep the Recurrence Rate Low After One Year?,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on inguinal hernia, which is a relatively common condition. The brief summary indicates that the 1-year recurrence rate for the Shouldice procedure is around 1.15% at the Shouldice Hospital and 2% in Europe. These prevalence rates are significantly higher than the criteria for a rare disease, which is defined as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
None. The information provided in the clinical trial details does not indicate that this is a trial for a rare disease.",False
NCT05922462,Effects of Increased Greek Yogurt Consumption in Youth and Young Adult Athletes,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial described aims to investigate the effects of increased Greek yogurt consumption on bone metabolism and inflammation in youth and young adult athletes. The target population consists of a relatively large group of individuals, including both varsity and club athletes aged 15-22 years. This does not fit the definition of a rare disease, which is typically characterized by low prevalence, affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
There are no rare disease indicators present in the provided information. The conditions being studied, bone growth abnormalities and inflammation, are not considered rare diseases based on the given criteria.",False
NCT05957276,Global Patient Registry of Inherited Retinal Diseases,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is ""Inherited Retinal Diseases (IRD)"". According to the provided information, IRDs are generally characterized as rare diseases. While the exact prevalence is not given, the brief summary indicates that the purpose of the study is to understand the natural history of these inherited retinal diseases, which aligns with the definition of a rare disease.

## Confidence Level
High

## Rare Disease Indicators
- Inherited, genetic origin
- Low prevalence, as indicated by the need to conduct a global patient registry to better understand the condition",True
NCT06052267,A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is asthma, which is a common chronic respiratory condition that affects a significant portion of the population. According to the information provided, asthma does not meet the criteria for a rare disease, as it is not characterized by a low prevalence (affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe).

## Confidence Level
High

## Rare Disease Indicators
None identified. The condition of asthma is not considered a rare disease based on the provided criteria.",False
NCT05597748,Modified Herbst Approach to Improve Chin Projection,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The information provided indicates that the condition being studied, Class II malocclusion, is a common orthodontic problem. The prevalence of Class II malocclusion is estimated to be around 15-20% in the general population, which is significantly higher than the criteria for a rare disease (affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe). The clinical trial is focused on evaluating different treatment approaches for this relatively common condition, rather than a rare disease.

## Confidence Level
High

## Rare Disease Indicators
The provided information does not indicate any signs of this being a rare disease clinical trial. The condition being studied, Class II malocclusion, is a well-known and relatively common orthodontic problem.",False
NCT05602194,Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is studying the use of levocarnitine in patients with acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LL), and mixed phenotype acute leukemia (MPAL). These conditions are not considered rare diseases based on the provided criteria:

- In the US, acute lymphoblastic leukemia affects around 6,000 people per year, which is more than the 200,000 threshold for a rare disease.
- In Europe, the incidence of acute lymphoblastic leukemia is around 1 in 100,000 people, which is also above the 1 in 2,000 threshold for a rare disease.

Additionally, the trial is specifically studying adolescents and young adults (ages 15-39 years), which further suggests that the target population is not considered a rare disease.

## Confidence Level
High

## Rare Disease Indicators
None. The conditions being studied in this clinical trial do not meet the criteria for a rare disease.",False
NCT05757128,Optimizing Mental Health for Young People at Clinical High Risk for Psychosis (CHR),"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The information provided in the clinical trial description does not indicate that the condition being studied, psychosis, is a rare disease. Psychosis is a relatively common mental health condition, with an estimated prevalence of around 3% in the general population. The clinical trial is targeting individuals at ""clinical high risk for psychosis,"" which suggests a larger patient population than a typical rare disease.

## Confidence Level
High

## Rare Disease Indicators
None provided. The clinical trial information does not mention any details that would suggest this is a rare disease trial, such as the prevalence or number of affected individuals.",False
NCT06023589,A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial information provided indicates that the condition being studied is asthma, which is not considered a rare disease. Asthma is a common chronic respiratory condition that affects a significant number of people, far exceeding the thresholds for rare disease classification in both the US (affecting fewer than 200,000 people) and Europe (affecting no more than 1 in 2,000 people).

## Confidence Level
High

## Rare Disease Indicators
None. The information provided does not suggest that this trial is targeting a rare disease.",False
NCT05705531,A Study About How Blood Cell Growth Patterns Relate to Heart Health After Treatment for Hodgkin Lymphoma,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is investigating the relationship between clonal hematopoiesis and cardiovascular disease in Hodgkin lymphoma survivors. Hodgkin lymphoma is not considered a rare disease, as it affects around 8,000 new cases per year in the United States, which is well above the 200,000 cases threshold for a rare disease in the US.

## Confidence Level
High

## Rare Disease Indicators
None. The condition being studied, Hodgkin lymphoma, does not meet the criteria for a rare disease.",False
NCT05907304,A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The information provided indicates that the clinical trial is targeting patients with advanced or metastatic solid tumors with RAS Q61X mutations. While RAS Q61X mutations may be present in a subset of solid tumors, the overall prevalence of the targeted condition is not considered rare based on the accepted criteria.

The trial is expected to enroll a total of approximately 115 patients, including both adults and adolescents. This suggests that the targeted patient population is larger than the typical threshold for a rare disease, which is defined as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
None. The information provided does not indicate that the targeted condition meets the criteria for a rare disease.",False
NCT06021522,"A Study to Evaluate Long-term Safety of Ecopipam Tablets in Children, Adolescents and Adults With Tourette's Disorder","## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
According to the provided information, the condition being studied in this clinical trial is Tourette's Syndrome (TS), which is a neurological disorder that affects fewer than 200,000 people in the United States, meeting the accepted criteria for a rare disease.

## Confidence Level
High

## Rare Disease Indicators
- The condition being studied, Tourette's Syndrome, is characterized as affecting fewer than 200,000 people in the United States, which meets the definition of a rare disease.
- The condition is also generally characterized by low prevalence, chronicity, and often genetic origin, further supporting the classification as a rare disease.",True
NCT04203316,Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The clinical trial is studying the treatment of relapsed or refractory acute myeloid leukemia (AML) in pediatric patients, which meets the criteria for a rare disease. Acute myeloid leukemia is a type of blood cancer that is generally considered a rare disease, with an estimated incidence of 3-4 cases per 100,000 people per year in the United States. The trial is specifically focused on pediatric patients with AML, which further reduces the patient population size and meets the definition of a rare disease.

## Confidence Level
High

## Rare Disease Indicators
- Affects fewer than 200,000 people in the US (AML has an estimated incidence of 3-4 cases per 100,000 people per year)
- Characterized by low prevalence and chronicity (AML is a rare and often difficult-to-treat form of blood cancer)
- Focused on a specific genetic subtype (IDH2-mutant AML) which further narrows the target patient population",True
NCT05993351,Objective Concussion Assessment Using MRI and Metabolomics,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial information provided does not indicate that the condition being studied, mild traumatic brain injury (mTBI), also known as concussions, is a rare disease. According to the information given, concussions ""affect millions of people around the world,"" which is significantly higher than the criteria for a rare disease in the US (affecting fewer than 200,000 people) or in Europe (affecting no more than 1 in 2,000 people). The information also notes that it is estimated that there are 300,000 sport-related concussions annually in the United States among youth and collegiate athletes, further indicating that this is not a rare condition.

## Confidence Level
High

## Rare Disease Indicators
No specific indicators of a rare disease are present in the provided information.",False
NCT05794789,"""We Are an Active Family"": Promoting Child Physical Activity Through Social Identity Formation in the Family System","## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial information provided does not indicate that the study is focused on a rare disease. The conditions being investigated are physical activity and social identity, which are not typically considered rare diseases. The study aims to explore the effectiveness of physical activity identity formation in the family system, which is a more common and widespread health issue rather than a rare disease.

## Confidence Level
High

## Rare Disease Indicators
None. The information provided does not mention any indicators of a rare disease, such as low prevalence, chronicity, or genetic origin.",False
NCT05894772,Evaluating a Virtual Stepped Care Portal in Youth Awaiting Tertiary Chronic Pain Care: An Implementation-Effectiveness Hybrid Type III Study,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The information provided in the clinical trial description indicates that chronic pain is affecting 1 in 5 Canadian youth, which is a much higher prevalence than the accepted criteria for a rare disease in the United States (fewer than 200,000 people) or Europe (affecting no more than 1 in 2,000 people). The condition being studied, chronic pain, is characterized as a common problem, not a rare disease.

## Confidence Level
High

## Rare Disease Indicators
There are no indicators in the provided information that suggest this is a rare disease trial. The prevalence of chronic pain in youth is stated to be relatively high, which is not consistent with the definition of a rare disease.",False
NCT05615779,Personalized B-fructan Diet in Inflammatory Bowel Disease Patients,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is inflammatory bowel diseases (IBD), which includes ulcerative colitis. IBD is a group of chronic, relapsing, and remitting inflammatory conditions of the gastrointestinal tract. According to epidemiological data, IBD is not considered a rare disease. The prevalence of IBD in the United States is estimated to be around 3.1 million people, which is well above the threshold of 200,000 people for a rare disease. Similarly, the prevalence of IBD in Europe is estimated to be around 2.5-3 million people, which exceeds the criteria of affecting no more than 1 in 2,000 people for a rare disease.

## Confidence Level
High

## Rare Disease Indicators
There are no specific indicators in the provided information that suggest this is a rare disease trial. The conditions being studied, inflammatory bowel diseases and ulcerative colitis, are not considered rare diseases.",False
NCT06037304,Quality of Life After Shouldice Repair,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is inguinal hernia, which is a common medical condition affecting a large number of people. According to the information provided, inguinal hernia is not considered a rare disease based on the accepted criteria:

- In the US, a rare disease is typically defined as affecting fewer than 200,000 people. The clinical trial does not mention the prevalence of inguinal hernia, but it is a common condition that is unlikely to affect fewer than 200,000 people.
- In Europe, a rare disease is defined as affecting no more than 1 in 2,000 people. Again, inguinal hernia is a common condition that is unlikely to meet this criterion.
- The information provided does not indicate that inguinal hernia is generally characterized by low prevalence, chronicity, and often genetic origin, which are some of the general characteristics of rare diseases.

## Confidence Level
High

## Rare Disease Indicators
None applicable. The clinical trial is focused on a common medical condition, inguinal hernia, which does not meet the criteria for a rare disease.",False
NCT06039800,Patient-reported Outcomes for Patients Undergoing Surgery at Shouldice Hospital.,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The provided information indicates that this is a clinical trial for patients undergoing hernia surgery at the Shouldice Hospital. Hernia is a relatively common condition and is not considered a rare disease. The study population includes all patients aged 16-90 years who had a hernia operation at the Shouldice Hospital, without any specific exclusion criteria related to the rarity of the condition.

## Confidence Level
High

## Rare Disease Indicators
There are no specific indicators in the provided information that this is a rare disease trial. The condition being studied, hernia, is a common condition and does not meet the criteria for a rare disease, which is typically defined as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.",False
NCT05631743,VR-CBT with Inuit in Quebec,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on emotion regulation, which is not considered a rare disease. The target population is Inuit individuals in Montreal, which suggests a larger patient population compared to the rare disease definition of fewer than 200,000 people in the US or affecting no more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
None of the information provided indicates that this is a rare disease. The condition being studied, emotion regulation, is a common mental health concern and not a rare disease.",False
NCT05715021,RCT Evaluating First Time Shoulder Dislocation,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The information provided indicates that shoulder dislocation is a relatively common condition, with an incidence of 15 to 25 per 100,000 people and an estimated 70,000 shoulder dislocations occurring annually in the United States. This is significantly higher than the criteria for a rare disease in the US, which is defined as affecting fewer than 200,000 people. Additionally, the condition is not characterized as generally rare, chronic, and of genetic origin.

## Confidence Level
High

## Rare Disease Indicators
None. The clinical trial information does not suggest that this is a rare disease.",False
NCT05677451,"24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up","## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is chronic spontaneous urticaria (CSU), which is not considered a rare disease. According to the information provided, CSU is a condition characterized by the sudden appearance of hives, swelling, or redness of the skin that lasts for 6 weeks or longer. While the exact prevalence of CSU is not provided, it is generally not considered a rare disease.

## Confidence Level
High

## Rare Disease Indicators
None of the key criteria for a rare disease are met in this case:
- The condition, chronic spontaneous urticaria, is not affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.
- The condition is not generally characterized by low prevalence, chronicity, and often genetic origin.",False
NCT05589831,Respiratory Support and Brain Health in Preterm Infants,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial described in the information provided is focused on premature infants born before 32 weeks of gestation, which is a relatively common condition. Preterm births are estimated to affect about 1 in 10 infants in the United States, which is significantly higher than the rare disease criteria of affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
There are no specific indicators in the provided information that suggest this is a rare disease clinical trial. The conditions being studied, such as sleep, cerebral oxygenation, and respiratory support in premature infants, are common issues associated with preterm births, which are not considered a rare disease.",False
NCT05549258,Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is neuromyelitis optica spectrum disorder (NMOSD), which is a rare autoimmune disease that affects the optic nerves and spinal cord. According to the information provided, NMOSD is characterized by a low prevalence, chronic nature, and genetic origin, which aligns with the criteria for a rare disease.

## Confidence Level
High

## Rare Disease Indicators
- The condition being studied, NMOSD, is characterized by low prevalence, chronicity, and genetic origin, which are indicators of a rare disease.
- The trial is targeting a small population of pediatric patients (2 to < 18 years of age) with NMOSD, with a planned enrollment of approximately 15 participants.",True
NCT05653024,INhaled Salbutamol vs Placebo for the Treatment of Acute IgE-mediated Abdominal Pain From Allergic Food REactions,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial information provided indicates that the condition being studied is IgE-mediated abdominal pain, which is a common symptom associated with food allergies. Food allergies are not considered a rare disease, as they are estimated to affect approximately 2-10% of the population in developed countries. The trial is specifically targeting children and adults aged 6 to 55, which is a broad population and not a small or niche group.

## Confidence Level
High

## Rare Disease Indicators
None of the provided information suggests this is a rare disease trial. The condition, population, and goals of the study are consistent with a common medical condition rather than a rare disease.",False
NCT05815433,Comparing Impacts of Donor Human Milk to Formula Supplementation on the Gut Microbiome of Full-term Infants,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial information provided does not indicate that the condition being studied, ""Microbial Colonization,"" is a rare disease. The trial is focused on examining the impacts of donor human milk (DHM) versus formula supplementation on the gut microbiome of full-term infants exposed to antibiotics during labor, which is a common scenario and not a rare condition. The trial population includes vaginally born, full-term infants, which is a typical, non-rare population.

## Confidence Level
High

## Rare Disease Indicators
There are no specific indicators in the provided information that suggest this is a rare disease trial. The condition being studied, microbial colonization in full-term infants, does not meet the criteria for a rare disease, which is typically defined as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe, and is generally characterized by low prevalence, chronicity, and often genetic origin.",False
NCT05898529,COVID Infection in Pediatric Surgical Patient,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on studying the prevalence of asymptomatic COVID-19 infection in pediatric surgical patients. COVID-19 is not considered a rare disease, as it has affected millions of people worldwide. The trial is not targeting a specific rare disease, but rather investigating the epidemiology of COVID-19 in a particular patient population.

## Confidence Level
High

## Rare Disease Indicators
This trial does not meet the criteria for a rare disease clinical trial. COVID-19 is not considered a rare disease, as it affects far more than 200,000 people in the United States or 1 in 2,000 people in Europe.",False
NCT05864846,A Study to Investigate Behavioral and Other Co-Occurring Outcomes With Epidiolex as Add-On Therapy in Participants Aged 1 to 65 Years of Age With Tuberous Sclerosis Complex,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The clinical trial is for participants with tuberous sclerosis complex (TSC), which is a rare genetic disorder that affects approximately 1 in 6,000 people worldwide. This meets the accepted criteria for a rare disease, which is defined as affecting fewer than 200,000 people in the United States or no more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
- The condition, tuberous sclerosis complex (TSC), is a rare genetic disorder that affects approximately 1 in 6,000 people worldwide.
- The trial is specifically targeting participants with seizures associated with tuberous sclerosis complex, which is a chronic and often genetically-based condition.",True
NCT05882357,Evaluation of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis (CF) Participants 12 to Less Than 24 Months of Age,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
Cystic fibrosis (CF) is a rare genetic disorder that affects fewer than 200,000 people in the United States, which meets the accepted criteria for a rare disease. The clinical trial is specifically targeting CF patients aged 12 to less than 24 months, which is a subset of the overall CF population, further indicating that this is a trial for a rare disease.

## Confidence Level
High

## Rare Disease Indicators
- Cystic fibrosis is a genetic disorder with low prevalence, affecting fewer than 200,000 people in the US.
- The trial is specifically targeting a subset of the CF population (12 to less than 24 months of age), further indicating the rarity of the condition.",True
NCT05881031,Home Initiation of Noninvasive Positive Pressure Ventilation in Children With Medical Complexity,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The information provided in the clinical trial details does not indicate that the target condition, sleep-disordered breathing in children with medical complexity, is a rare disease. The brief summary and detailed description suggest that this is a relatively common condition in a specific patient population (children with medical complexity), but there is no mention of the condition affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe, which are the accepted criteria for a rare disease.

## Confidence Level
High

## Rare Disease Indicators
None provided. The condition described, sleep-disordered breathing in children with medical complexity, does not meet the criteria for a rare disease.",False
NCT05889182,A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The information provided indicates that the condition being studied, Hidradenitis Suppurativa (HS), is not considered a rare disease. HS is a chronic inflammatory skin condition that affects approximately 1% of the population, which is significantly higher than the rare disease criteria of affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
None. The prevalence of HS is not considered low, and there is no information provided about its genetic origin.",False
NCT05781152,"Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease","## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is Crohn's disease, which is not considered a rare disease. According to the information provided, Crohn's disease is a condition that causes inflammation of the small or large intestine, and it is a relatively common condition. The brief summary indicates that the study is targeting children ages 6-17 years who are newly diagnosed with Crohn's disease, which suggests that the disease is not extremely rare.

## Confidence Level
High

## Rare Disease Indicators
None. The information provided does not indicate that Crohn's disease meets the criteria for a rare disease, which are:
- Affecting fewer than 200,000 people in the US
- Affecting no more than 1 in 2,000 people in Europe
- Generally characterized by low prevalence, chronicity, and often genetic origin",False
NCT05841537,An Observational Study to Assess Change in Disease Activity and Adverse Events In Adult Participants With Moderate to Severe Active Crohn's Disease (CD),"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
Crohn's disease, the condition being studied in this clinical trial, is not considered a rare disease. The information provided states that approximately 1000 participants will be enrolled worldwide, which is significantly higher than the criteria for a rare disease (fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe). Additionally, Crohn's disease is a chronic inflammatory disorder that is generally well-known and not considered a rare condition.

## Confidence Level
High

## Rare Disease Indicators
None. The provided information does not indicate that this is a trial for a rare disease.",False
NCT05897320,A Study of Eptinezumab in Pediatric Participants With Episodic Migraine,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial information provided does not indicate that the condition being studied, episodic migraine, is a rare disease. Migraine, including episodic migraine, is a relatively common condition, affecting around 15% of the global population. The prevalence of episodic migraine in the pediatric population is also not considered rare, with estimates ranging from 3% to 10% of children and adolescents.

## Confidence Level
High

## Rare Disease Indicators
None provided. The information given does not suggest that episodic migraine meets the criteria for a rare disease, which typically affect fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.",False
NCT05898100,Virtual Reality Distraction for Dental Anxiety (PILOT),"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The information provided does not indicate that the conditions being studied (dental anxiety, dental phobia, dental trauma, and dental diseases) are rare diseases. The brief summary states that dental fear and anxiety affects approximately a quarter of children and adolescents, which is a relatively common condition and does not meet the criteria for a rare disease.

## Confidence Level
High

## Rare Disease Indicators
None. The conditions being studied are not considered rare diseases based on the provided information.",False
NCT05093075,Therapeutic Plasma Exchange in Septic Shock: a Pilot Study,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is septic shock, which is a severe complication of a serious infection. Septic shock is not considered a rare disease. According to the information provided, septic shock is a common and serious condition that affects a significant number of people, rather than a rare disease that affects fewer than 200,000 people in the United States or 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
None. The information provided does not indicate that septic shock meets the criteria for a rare disease.",False
NCT05641363,Comparison of Ketorolac at Three Doses in Children With Acute Pain,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is investigating the use of ketorolac, a non-steroidal anti-inflammatory drug (NSAID), for acute pain management in children. The conditions listed in the trial, such as abdominal pain, migraine, appendicitis, renal colic, and biliary colic, are generally not considered rare diseases. These are common acute pain conditions that affect a significant number of children.

## Confidence Level
High

## Rare Disease Indicators
There are no specific indicators in the provided information that suggest this is a clinical trial for a rare disease. The trial is focused on common acute pain conditions in children, which do not meet the criteria for a rare disease as defined in the problem statement.",False
NCT05894187,The Impact of an Animated Video on Preoperative Anxiety in Children Undergoing Elective Otoplasty,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is related to preoperative anxiety in children undergoing elective otoplasty, which is a common surgical procedure to correct prominent or protruding ears. Otoplasty is not considered a rare disease, as it is a relatively common condition that affects a larger population. The trial does not mention any rare or genetic conditions, and the target population appears to be a general pediatric population undergoing a routine surgical procedure.

## Confidence Level
High

## Rare Disease Indicators
None. The information provided does not indicate that this is a trial for a rare disease.",False
NCT05714085,"Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)","## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The information provided indicates that the clinical trial is for heart failure due to left ventricular systolic dysfunction, which is not a rare disease. Heart failure is a relatively common condition, affecting millions of people worldwide. The condition described in the trial details does not meet the criteria for a rare disease, which is typically defined as affecting fewer than 200,000 people in the United States or no more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
None of the information provided suggests this is a rare disease clinical trial.",False
NCT05882877,"A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)","## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
Atopic dermatitis, also known as eczema, is a common skin condition that affects a significant portion of the population. According to the information provided, the clinical trial is specifically targeting ""adult and adolescent subjects with moderate-to-severe atopic dermatitis (AD),"" which indicates that the condition is not considered a rare disease.

## Confidence Level
High

## Rare Disease Indicators
None provided. The information given does not suggest that atopic dermatitis meets the criteria for a rare disease, which typically affects fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.",False
NCT05733676,Comparison of MI Paste Plus and Resin Infiltration in White Spot Lesions Following Orthodontic Treatment,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on the treatment of white spot lesions, which are a common complication of orthodontic treatment. The condition affects a significant number of people undergoing fixed orthodontic treatment, and it is not considered a rare disease based on the provided criteria. The trial is investigating the efficacy of two different treatment methods for a relatively common dental condition, rather than a rare disease.

## Confidence Level
High

## Rare Disease Indicators
The provided information does not indicate that this is a rare disease trial. The clinical condition being studied, white spot lesions, is not a rare disease as it affects a relatively large number of people undergoing orthodontic treatment.",False
NCT05898516,JoyPop Mobile Mental Health App With Indigenous Youth,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial information provided does not indicate that the condition being studied (emotion regulation, depression, anxiety, stress) is a rare disease. The trial is focused on Indigenous youth aged 12-17 in Northwestern Ontario, Canada, which is a specific population, but not one typically associated with a rare disease. The trial aims to evaluate the effectiveness of a mobile mental health app in supporting this population, which suggests a more common mental health condition rather than a rare disease.

## Confidence Level
High

## Rare Disease Indicators
None present in the provided information.",False
NCT02615184,A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is erosive esophagitis (EE), which is a complication of gastroesophageal reflux disease (GERD). GERD is a common condition, affecting up to 20% of the population in the United States. While EE is a more severe form of GERD, it is not considered a rare disease. The information provided does not indicate that the prevalence of EE in the target population (children aged 2-11 years) is below the threshold for a rare disease, which is typically defined as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
None provided. The information given suggests that this is a study for a common condition, not a rare disease.",False
NCT05310799,Personalized Estimates of Response and Severity Outcomes in Newly-diagnosed JIA,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
Juvenile Idiopathic Arthritis (JIA), the condition being studied in this clinical trial, is not considered a rare disease. According to the information provided, JIA is a chronic arthritis of unknown cause starting before the 16th birthday. While the specific prevalence of JIA is not mentioned, it is generally characterized as a condition that affects a larger population than the criteria for a rare disease.

The criteria for a rare disease in the US is affecting fewer than 200,000 people, and in Europe is affecting no more than 1 in 2,000 people. The information provided does not indicate that JIA meets these thresholds.

## Confidence Level
High

## Rare Disease Indicators
There are no specific indicators in the provided information that suggest this is a rare disease trial. The description of JIA as a chronic condition affecting children does not meet the established criteria for a rare disease.",False
NCT05734066,Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
Ewing sarcoma is a rare type of cancer that typically affects children and young adults. According to the information provided, this clinical trial is specifically targeting pediatric and young adult participants with relapsed/refractory Ewing sarcoma. Ewing sarcoma is considered a rare disease as it affects fewer than 200,000 people in the United States, which meets the accepted criteria for a rare disease.

## Confidence Level
High

## Rare Disease Indicators
- Ewing sarcoma is a rare type of cancer that affects fewer than 200,000 people in the U.S.
- The trial is specifically targeting pediatric and young adult participants with relapsed/refractory Ewing sarcoma, which is a rare patient population.",True
NCT05442567,A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD),"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial information provided indicates that the study is evaluating the long-term safety of vedolizumab in pediatric patients with ulcerative colitis (UC) or Crohn's disease (CD). These are not considered rare diseases based on the accepted criteria:

- In the US, UC and CD are estimated to affect over 1 million people, which is significantly more than the 200,000 threshold for a rare disease.
- In Europe, the prevalence of UC and CD is estimated to be between 0.5-24.5 per 10,000 people, which is also higher than the 1 in 2,000 (0.05%) threshold for a rare disease.

## Confidence Level
High

## Rare Disease Indicators
None. The conditions being studied, UC and CD, are not considered rare diseases based on the provided information.",False
NCT05949164,The IPAd Study: Exploring the Association Between Insomnia and Positive Airway Pressure Adherence in Children,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on exploring the association between insomnia and positive airway pressure (PAP) adherence in children with sleep-disordered breathing (SDB), which includes conditions such as obstructive sleep apnea, hypoventilation, and central sleep apnea. These conditions are not considered rare diseases based on the provided criteria:

- In the US, conditions affecting fewer than 200,000 people are considered rare.
- In Europe, conditions affecting no more than 1 in 2,000 people are considered rare.
- The brief summary indicates that SDB is ""prevalent in children and adolescents"", suggesting that the conditions being studied are not rare.

## Confidence Level
High

## Rare Disease Indicators
None. The information provided indicates that the conditions being studied are not rare diseases.",False
NCT05589714,Universal Rare Gene Study: A Registry and Natural History Study of Retinal Dystrophies Associated With Rare Disease-Causing Genetic Variants,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The information provided indicates that this trial is focused on retinal dystrophies associated with rare disease-causing genetic variants. Retinitis pigmentosa, which is one of the conditions studied in this trial, is a rare inherited eye disorder that typically affects fewer than 200,000 people in the United States, meeting the established criteria for a rare disease. Additionally, the study aims to establish genetically and clinically well-characterized cohorts of patients across hundreds of genetic variants associated with retinal dystrophy, further supporting the rare disease nature of the conditions being investigated.

## Confidence Level
High

## Rare Disease Indicators
- Affecting fewer than 200,000 people in the United States (the provided criteria for a rare disease)
- Focus on rare disease-causing genetic variants associated with retinal dystrophies
- Establishing well-characterized cohorts of patients across hundreds of genetic variants associated with retinal dystrophy",True
NCT05675410,"A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab","## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial information provided indicates that the condition being studied is Hodgkin lymphoma, which is not considered a rare disease. Hodgkin lymphoma affects approximately 8,000 new cases per year in the United States, which is well above the defined threshold of 200,000 cases for a rare disease in the US. Additionally, the incidence of Hodgkin lymphoma in Europe is estimated to be around 2-3 per 100,000 people, which is also above the 1 in 2,000 (or 0.05%) threshold for a rare disease in Europe.

## Confidence Level
High

## Rare Disease Indicators
None. The condition being studied, Hodgkin lymphoma, is not a rare disease.",False
NCT05831176,A Trial to Learn if Dupilumab is Safe for and Helps Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The clinical trial is investigating the use of dupilumab for the treatment of eosinophilic gastritis (EoG) with or without eosinophilic duodenitis (EoD). Based on the information provided, EoG and EoD are described as ""uncommon, persistent, allergic/immune diseases."" This suggests that these conditions have a low prevalence, which is a key characteristic of rare diseases.

## Confidence Level
High

## Rare Disease Indicators
- The trial is investigating eosinophilic gastritis and eosinophilic duodenitis, which are described as ""uncommon"" conditions.
- The trial is targeting a specific patient population, which is typical of rare disease studies.
- The rare disease definition of affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe is met, as the conditions being studied are characterized as ""uncommon.""",True
NCT05231200,Alberta Collaborative QI Strategies to Improve Outcomes of Moderate and Late Preterm Infants (ABC-QI Trial),"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial information provided indicates that the study is targeting preterm infants between 32-36 weeks gestation, which is a relatively common condition. Preterm infants are not considered a rare disease, as they are estimated to affect approximately 1 in 10 births in the United States. The study population does not meet the criteria for a rare disease, which is defined as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
There are no rare disease indicators mentioned in the provided information. The condition being studied, preterm infants between 32-36 weeks gestation, is a relatively common condition and does not meet the criteria for a rare disease.",False
NCT05711394,A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is for the treatment of episodic migraine in pediatric participants aged 6-17 years. Migraine is a relatively common condition, with an estimated prevalence of around 10% in the general population, including children and adolescents. The clinical trial information does not indicate that the target population for this study has a prevalence of less than 200,000 people in the US or less than 1 in 2,000 people in Europe, which are the commonly accepted criteria for defining a rare disease.

## Confidence Level
High

## Rare Disease Indicators
There are no specific indicators that this is a rare disease trial based on the information provided.",False
NCT05564494,Surgical Treatment of Recurrent Shoulder Dislocations,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The information provided indicates that the condition being studied, shoulder instability, is not a rare disease. The details suggest that shoulder instability, particularly recurrent shoulder dislocations, is a relatively common condition affecting a significant portion of the population. The prevalence and incidence of the condition are not explicitly stated, but the information provided does not suggest that it meets the criteria for a rare disease (affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe).

## Confidence Level
High

## Rare Disease Indicators
None. The condition being studied, shoulder instability, does not meet the accepted criteria for a rare disease.",False
NCT05658289,Latarjet vs Anatomic Glenoid Reconstruction,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition described in the clinical trial, shoulder dislocation with glenoid bone loss, is not considered a rare disease. The trial information indicates that anterior shoulder dislocations are ""highly prevalent"" and that the risk of recurrence can be up to or greater than 90% if left untreated. This suggests that the condition is relatively common, not meeting the criteria for a rare disease in the United States (affecting fewer than 200,000 people) or Europe (affecting no more than 1 in 2,000 people).

## Confidence Level
High

## Rare Disease Indicators
None of the information provided indicates that this is a rare disease. The condition is described as highly prevalent and common.",False
NCT05548283,Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is for the treatment of cystic fibrosis, which is a chronic genetic condition that affects the lungs and other organs. According to the information provided, cystic fibrosis is not considered a rare disease based on the accepted criteria. In the United States, cystic fibrosis is estimated to affect around 30,000 people, which is significantly higher than the 200,000 people threshold for a rare disease. Additionally, cystic fibrosis is generally characterized as a chronic condition, which is one of the typical features of a rare disease.

## Confidence Level
High

## Rare Disease Indicators
None. The condition being studied, cystic fibrosis, does not meet the criteria for a rare disease.",False
NCT05832294,Finding a Biomarker for Acute Neuromodulation Effects in Adolescent Depression,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is studying the use of repetitive transcranial magnetic stimulation (rTMS) in the treatment of adolescent depression. Depression is a common mental health condition, not a rare disease. The trial aims to recruit 30 participants, which is well above the criteria for a rare disease (fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe).

## Confidence Level
High

## Rare Disease Indicators
This trial does not exhibit any of the typical indicators of a rare disease clinical trial, such as low prevalence, chronicity, or genetic origin.",False
NCT05633693,Postural Sway and Counterpressure Maneuvers for Pediatric Syncope,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial described in the information provided is investigating the impact of postural sway and counterpressure maneuvers on cardiovascular control in pediatric patients with syncope, vasovagal syncope, postural orthostatic tachycardia syndrome, and orthostatic intolerance. These conditions are not considered rare diseases based on the accepted criteria:

- In the United States, a rare disease is typically defined as affecting fewer than 200,000 people.
- In Europe, a rare disease is defined as affecting no more than 1 in 2,000 people.

The conditions being studied in this clinical trial, such as syncope and orthostatic intolerance, are relatively common and do not meet the criteria for rare diseases.

## Confidence Level
High

## Rare Disease Indicators
There are no specific indicators in the provided information that suggest this is a clinical trial for a rare disease.",False
NCT05405426,Trial of Indication-Based Transfusion of Red Blood Cells in ECMO,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on extracorporeal membrane oxygenation (ECMO), which is a treatment for critically ill children, not a rare disease. The trial aims to determine the optimal strategy for red blood cell (RBC) transfusion in children on ECMO support, with the goal of reducing organ dysfunction and improving neurodevelopmental outcomes. The conditions listed in the trial (Extracorporeal Membrane Oxygenation, Red Blood Cell Transfusion, Organ Failure, Multiple) are not considered rare diseases.

## Confidence Level
High

## Rare Disease Indicators
The trial does not meet the criteria for a rare disease, as it is not focused on a condition that affects fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe. The conditions being studied are more common and not characterized by low prevalence, chronicity, and genetic origin.",False
NCT05286788,MEKTOVI® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The clinical trial is focusing on the treatment of Adamantinomatous Craniopharyngioma, which is a type of brain tumor that primarily affects children. According to the information provided, Adamantinomatous Craniopharyngioma is a ""highly debilitating pediatric brain tumor that lacks medical anti-tumor therapies."" This suggests that the condition is rare, as it is a specific and uncommon type of brain tumor.

## Confidence Level
High

## Rare Disease Indicators
- The condition is described as a ""highly debilitating pediatric brain tumor,"" indicating that it primarily affects children, which is a characteristic of rare diseases.
- The detailed description mentions that the current therapy for the condition is challenging and risky, particularly in the setting of recurrent disease, further suggesting that it is a rare and difficult-to-treat condition.
- The study is enrolling up to 38 patients, which is a relatively small sample size, consistent with the definition of a rare disease affecting fewer than 200,000 people in the United States.",True
NCT05446597,SMART Concussion Trial: Symptom Management vs Alternative Randomized Treatment of Concussion Trial,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial information provided indicates that the condition being studied is mild traumatic brain injury, also known as concussion, which is not considered a rare disease. Concussions are relatively common, especially in youth ages 10-19, as mentioned in the brief summary. The detailed description also notes that the study is focused on this target population, further suggesting that concussion is not a rare disease.

## Confidence Level
High

## Rare Disease Indicators
None. The information provided does not indicate that this is a rare disease trial.",False
NCT05692180,"A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)","## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is severe eosinophilic asthma, which is not considered a rare disease. Asthma is a common chronic respiratory condition, affecting an estimated 25 million people in the United States alone, which is well above the threshold of 200,000 people for a rare disease in the US.

## Confidence Level
High

## Rare Disease Indicators
None. The information provided does not indicate that this clinical trial is for a rare disease.",False
NCT05747924,Phase 1/2 Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD),"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The condition being studied in this trial is Facioscapulohumeral Muscular Dystrophy (FSHD), which is a rare genetic disorder. According to the information provided, FSHD is generally characterized by low prevalence, chronicity, and genetic origin, which are all indicators of a rare disease.

## Confidence Level
High

## Rare Disease Indicators
- Affects fewer than 200,000 people in the US (the accepted criteria for a rare disease in the US)
- Characterized by low prevalence, chronicity, and genetic origin",True
NCT05769777,"Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis","## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
Atopic dermatitis (also known as eczema) is a common chronic inflammatory skin condition that affects a significant portion of the population. According to the provided information, the condition being studied in this clinical trial is ""Dermatitis Atopic"", which is not considered a rare disease.

## Confidence Level
High

## Rare Disease Indicators
None. The information provided does not indicate that this clinical trial is for a rare disease as defined by the criteria provided (affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe).",False
NCT05979077,Children's Hospital Academic Medical Organization (CHAMO) MyChart Study,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial information provided indicates that the study is focused on type 1 diabetes, which is not considered a rare disease. According to the accepted criteria, a rare disease is typically defined as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe. Type 1 diabetes is a much more common condition, with an estimated prevalence of 1.6 million people in the US and 1 in 300-600 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
This clinical trial does not exhibit any of the typical indicators of a rare disease, such as low prevalence, chronicity, or genetic origin.",False
NCT05562310,"Phenylalanine, Methionine and Histidine Requirements in TPN Fed Neonates","## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The information provided in the clinical trial details indicates that the study is focused on determining the requirements for three essential amino acids (phenylalanine, methionine, and histidine) in total parenteral nutrition (TPN) fed neonates. This condition, being stable neonates receiving TPN, does not meet the criteria for a rare disease, as it is not characterized by low prevalence, chronicity, and genetic origin.

## Confidence Level
High

## Rare Disease Indicators
None applicable. The clinical trial is focused on a common condition in neonatal care, not a rare disease.",False
NCT05748990,Does Abnormal Insulin Action in the Brain Underlie Cognitive and Metabolic Dysfunction in Schizophrenia,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is schizophrenia, which is not considered a rare disease. According to the information provided, schizophrenia is a common mental health disorder that affects a significant portion of the population, with almost half of the patients being obese and the prevalence of type 2 diabetes being 3-6 times higher compared to the general population. The brief summary and detailed description do not indicate that schizophrenia meets the criteria for a rare disease, which is typically defined as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
The clinical trial information does not provide any indicators that this is a rare disease trial. The condition being studied, schizophrenia, is a common mental health disorder that does not meet the criteria for a rare disease.",False
NCT05802160,The Good Start Matters - Parenting Program,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial information provided does not indicate that the condition or target population is considered a rare disease. The trial is focused on promoting healthy parenting practices and child behaviors, which are not typically associated with rare diseases. The conditions listed, such as parenting practices, child eating and dietary behaviors, and child physical activity, are common and widespread rather than rare.

## Confidence Level
High

## Rare Disease Indicators
There are no rare disease indicators present in the given information. The trial does not mention any specific rare conditions or diseases affecting fewer than 200,000 people in the US or 1 in 2,000 people in Europe.",False
NCT05774743,Pediatric Anesthesia Consent - Visual Aids,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial described does not involve a rare disease. The condition being studied is anesthesia and surgery, which are common medical conditions that affect a large population. The trial is focused on improving the consent process for pediatric anesthesia, which is a general medical practice, not a rare disease.

## Confidence Level
High

## Rare Disease Indicators
There are no indicators in the provided information that this is a rare disease trial. The conditions of ""Anesthesia"" and ""Surgery"" are not considered rare diseases, and the study population is not limited to a small patient population.",False
NCT05779813,Genetic Frontotemporal Dementia Initiative for Neurodevelopment,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is frontotemporal dementia (FTD), which is a rare neurodegenerative disorder. The detailed description of the trial indicates that it is focusing on individuals with known genetic mutations in MAPT, GRN, or C9ORF72, which are associated with familial forms of FTD. According to the information provided, FTD is generally characterized as a rare disease, with low prevalence and often a genetic origin.

## Confidence Level
High

## Rare Disease Indicators
- FTD is a rare neurodegenerative disorder.
- The trial is specifically focused on individuals with known genetic mutations associated with familial forms of FTD.
- The target population is first-degree and second-degree relatives of known genetic mutation carriers, which further indicates the rare nature of the condition.",True
NCT05543044,Impact of Peer Mentors on Individuals Transitioning to Adult Eating Disorder Treatment,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
Based on the information provided, the clinical trial is focused on individuals with eating disorders, which are not considered rare diseases. Eating disorders, such as anorexia nervosa, bulimia nervosa, and binge-eating disorder, are relatively common mental health conditions that affect a significant number of people, especially in the age group targeted by this study (16-24 years old).

## Confidence Level
High

## Rare Disease Indicators
None of the rare disease indicators are present in this clinical trial:
- The conditions being studied (eating disorders) are not considered rare diseases, as they affect a larger population.
- The study does not mention that the target population is fewer than 200,000 people in the US or affects no more than 1 in 2,000 people in Europe, which are the typical criteria for rare diseases.
- Eating disorders, while often chronic, are not necessarily characterized by a genetic origin.",False
NCT05738837,An Evaluation of a Sexual Assault Resistance Program for Adolescent Girls,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on evaluating the efficacy of a sexual assault resistance program for adolescent girls, which does not meet the criteria for a rare disease. According to the information provided, sexual violence perpetrated against adolescent girls is a common occurrence, with research suggesting that 1 in 7 teen girls experiences sexual violence. This indicates that the condition being studied, sexual assault, does not affect fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe, which are the accepted criteria for a rare disease.

## Confidence Level
High

## Rare Disease Indicators
None. The information provided does not indicate that this clinical trial is targeting a rare disease.",False
NCT05563649,Confirming the Effectiveness of Online Guided Self-Help Family-Based Treatment for Adolescent Anorexia Nervosa,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
According to the information provided, Anorexia Nervosa (AN) has an incidence rate of about 1%, which suggests that it is not a rare disease. The accepted criteria for a rare disease in the US is affecting fewer than 200,000 people, and in Europe, affecting no more than 1 in 2,000 people. The brief summary indicates that AN is a serious mental disorder, but it is not characterized as a rare disease.

## Confidence Level
High

## Rare Disease Indicators
None",False
NCT06402929,"Honest, Open, Proud - College for Post-Secondary Students With Mental Health Challenges","## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The information provided indicates that the clinical trial is focused on mental health issues and stigmatization among Canadian post-secondary students, which is not considered a rare disease. The conditions being studied, such as stigmatization and mental health issues, are relatively common and widespread among the general population, especially within the post-secondary student population. The trial is not targeting a disease or condition that affects fewer than 200,000 people in the US or 1 in 2,000 people in Europe, which are the commonly accepted criteria for a rare disease.

## Confidence Level
High

## Rare Disease Indicators
None. The information provided does not contain any indicators that this clinical trial is targeting a rare disease.",False
NCT05457556,"Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome","## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial information provided indicates that the study is evaluating hematopoietic cell transplantation (HCT) in children, adolescents, and young adults with acute leukemia (acute lymphoblastic leukemia, acute myeloid leukemia, mixed phenotype acute leukemia) or myelodysplastic syndrome (MDS). These conditions, while potentially serious, are not considered rare diseases based on the accepted criteria.

## Confidence Level
High

## Rare Disease Indicators
None. The conditions being studied (acute leukemia and MDS) are not considered rare diseases, as they affect more than 200,000 people in the United States.",False
NCT05731609,Resistance Intensive Personal Training for Youth with Cerebral Palsy,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The provided information indicates that the clinical trial is focused on exploring the effectiveness and feasibility of a personalized power training program for youth with cerebral palsy. Cerebral palsy is a relatively common condition, with an estimated prevalence of 2-3 per 1,000 live births in the United States. This prevalence falls well above the criteria for a rare disease, which is defined as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
None of the provided information suggests that this clinical trial is for a rare disease. The condition being studied, cerebral palsy, is a relatively common neurological disorder.",False
NCT05606614,Safety and Efficacy of TSHA-102 in Adolescent and Adult Females with Rett Syndrome (REVEAL Adult Study),"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The condition being studied in this trial is Rett syndrome, which is a rare genetic disorder that primarily affects girls and women. According to the information provided, Rett syndrome is characterized by low prevalence, chronicity, and genetic origin, which are key characteristics of a rare disease.

## Confidence Level
High

## Rare Disease Indicators
- Rett syndrome is a rare genetic disorder that affects fewer than 200,000 people in the United States, meeting the criteria for a rare disease in the US.
- Rett syndrome is a chronic condition, as indicated by the estimated study duration of up to 63 months.
- Rett syndrome is a genetically-based disorder, as stated in the brief summary.",True
NCT05625399,A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is melanoma, which is not considered a rare disease. Melanoma is a type of skin cancer, and according to the American Cancer Society, the lifetime risk of developing melanoma is about 2.6% (1 in 38) for men and 1.7% (1 in 59) for women in the United States. This prevalence is significantly higher than the criteria for a rare disease in the US (affecting fewer than 200,000 people) or Europe (affecting no more than 1 in 2,000 people).

## Confidence Level
High

## Rare Disease Indicators
None",False
NCT05639114,Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1),"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that affects approximately 1 in 2,000 people in Europe, which is within the accepted criteria for a rare disease. However, in the United States, it is estimated to affect up to 322,000 people, which exceeds the 200,000 people threshold for a rare disease.

## Confidence Level
High

## Rare Disease Indicators
The only rare disease indicator present is the European prevalence of SLE, which meets the criteria of affecting no more than 1 in 2,000 people. However, the prevalence in the United States exceeds the rare disease threshold, leading to the overall conclusion that this is not a clinical trial for a rare disease.",False
NCT06115798,Laryngoscope Force During Suspension for Adenotonsillectomy,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The information provided indicates that the condition being studied, postoperative pain following adenotonsillectomy, is a common and widespread condition. The brief summary states that adenotonsillectomy is the most common surgery performed in North America, with an annual caseload of 500,000 in the United States. This suggests that the condition being studied is not a rare disease, as rare diseases are typically defined as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
None. The information provided does not indicate that this is a rare disease trial.",False
NCT05723198,A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is alopecia areata, which is a type of hair loss disorder. According to the information provided, alopecia areata is considered a rare disease based on the accepted criteria:

1. In the United States, alopecia areata is estimated to affect fewer than 200,000 people, which meets the criteria for a rare disease.
2. The condition is generally characterized by low prevalence, chronicity, and often genetic origin, further supporting its classification as a rare disease.

## Confidence Level
High

## Rare Disease Indicators
- Affecting fewer than 200,000 people in the US
- Chronic and often genetic in origin",True
NCT05503797,A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The brief summary indicates that the trial is evaluating the efficacy of the drug plixorafenib in participants with rare solid tumors, melanoma, thyroid, or recurrent primary central nervous system (CNS) tumors harboring BRAF V600E mutation. These types of cancers are generally considered rare, as they affect a small percentage of the population.

## Confidence Level
High

## Rare Disease Indicators
- The trial is evaluating treatments for rare solid tumors, melanoma, thyroid, and recurrent primary CNS tumors, which are generally characterized by low prevalence.
- The trial is specifically focused on participants with BRAF V600E mutations, which are present in a small subset of these cancer types.",True
NCT02616302,A Study to Check the Safety of Dexlansoprazole and Learn if it Can Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Children 2 to 11 Years Old,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is gastroesophageal reflux disease (GERD), which is a common condition that affects a significant portion of the population, particularly in children. According to the information provided, GERD is a condition where food or acid comes up from the stomach into the esophagus, causing symptoms like heartburn and difficulty eating. GERD is not considered a rare disease, as it is not characterized by low prevalence or a genetic origin.

## Confidence Level
High

## Rare Disease Indicators
There are no specific indicators in the provided information that would suggest this is a rare disease trial. The target population for the study is children aged 2 to 11 years, which is a relatively broad group, further indicating that GERD is not a rare condition in this age range.",False
NCT05667142,A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is evaluating the use of XEN1101 as an adjunctive therapy for primary generalized tonic-clonic seizures (PGTCS), which is a type of generalized epilepsy. Generalized epilepsy is not considered a rare disease, as it is estimated to affect around 3 million people in the United States.

## Confidence Level
High

## Rare Disease Indicators
None of the provided information indicates that this is a rare disease trial. The condition being studied, primary generalized tonic-clonic seizures, is a common form of generalized epilepsy, which does not meet the criteria for a rare disease as defined in the United States (affecting fewer than 200,000 people) or Europe (affecting no more than 1 in 2,000 people).",False
NCT05682378,Long-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Adolescent ORION-16 or ORION-13 Studies,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The clinical trial is investigating the long-term safety and tolerability of inclisiran in participants with heterozygous or homozygous familial hypercholesterolemia (HeFH or HoFH). Familial hypercholesterolemia is a rare genetic disorder that affects the body's ability to remove low-density lipoprotein (LDL) cholesterol from the blood, leading to high cholesterol levels and an increased risk of heart disease.

According to the information provided, HeFH and HoFH are considered rare diseases:
- In the US, familial hypercholesterolemia is estimated to affect fewer than 200,000 people, which meets the criteria for a rare disease.
- In Europe, the prevalence of familial hypercholesterolemia is estimated to be no more than 1 in 2,000 people, also meeting the criteria for a rare disease.

## Confidence Level
High

## Rare Disease Indicators
- Low prevalence: Familial hypercholesterolemia affects fewer than 200,000 people in the US and no more than 1 in 2,000 people in Europe.
- Genetic origin: Familial hypercholesterolemia is a genetic disorder.",True
NCT05279664,RIC-NEC Randomized Controlled Trial,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial information provided indicates that the condition being studied, necrotizing enterocolitis (NEC), is a serious intestinal disease that affects preterm and term neonates. While NEC can have a high mortality rate (up to 30-50%), the trial specifically mentions that it ""remains a major cause of intestinal failure, and an unsolved clinical challenge in pediatrics."" This suggests that NEC is a relatively common condition in the target population of preterm and term neonates.

Additionally, the trial aims to enroll 78 patients across 12 international collaborating centers, which implies a significant patient population that can be accessed for the study. This is not indicative of a rare disease, which is typically defined as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
None of the provided information suggests that this is a clinical trial for a rare disease. The prevalence and target population size indicated in the trial details do not meet the established criteria for a rare disease.",False
NCT05347238,Dopamine vs. Norepinephrine for Hypotension in Very Preterm Infants With Late-onset Sepsis,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The information provided indicates that the condition being studied, late-onset neonatal sepsis in very preterm infants, is not considered a rare disease. The brief summary states that in Canada, approximately 250 very preterm neonates receive cardiotropic drugs for late-onset sepsis-related fluid-unresponsive hypotension every year, which suggests a higher prevalence than the criteria for a rare disease (fewer than 200,000 people in the US or affecting no more than 1 in 2,000 people in Europe).

## Confidence Level
High

## Rare Disease Indicators
There are no clear indicators that this clinical trial is for a rare disease. The conditions being studied, late-onset neonatal sepsis, extreme prematurity, and neonatal hypotension, do not meet the accepted criteria for a rare disease.",False
NCT06198712,A Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell Disease,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
Sickle cell disease (SCD) is a group of inherited red blood cell disorders that affect approximately 100,000 people in the United States and millions worldwide. The prevalence of SCD in the US is estimated to be around 1 in 365 African American births, which exceeds the typical definition of a rare disease (affecting fewer than 200,000 people in the US). Therefore, this clinical trial for a SCD treatment does not meet the criteria for a rare disease.

## Confidence Level
High

## Rare Disease Indicators
None",False
NCT05711992,Rare Embryonal Tumors of the Central Nervous System: International Registry,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on rare embryonal tumors of the central nervous system, which meet the criteria for a rare disease:

1. In the US, these tumors are estimated to affect fewer than 200,000 people.
2. The conditions being studied, such as Embryonal Tumor with Multilayered Rosettes (ETMR), FOXR2-activated CNS neuroblastoma, cribriform neuroepithelial tumor, and CNS tumor with BCOR internal tandem duplication, are described as ""extremely rare"" in the trial information.
3. The trial notes that these tumor types were only recently described in the latest edition of the World Health Organization (WHO) Classification of Tumors of the Central Nervous System, indicating their rarity.
4. The trial also mentions the difficulty of conducting randomized controlled trials for these rare conditions due to the limited number of patients.

## Confidence Level
High

## Rare Disease Indicators
- Affecting fewer than 200,000 people in the US
- Described as ""extremely rare"" in the trial information
- Recently described in the latest WHO classification, indicating rarity
- Difficulty in conducting randomized controlled trials due to the limited number of patients",True
NCT05827666,The Effect of Dairy and Dairy-Free Alternative Beverages on Post-Exercise Anabolism in Active Youth,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on the effect of dairy and non-dairy milk alternatives on post-exercise protein synthesis in active youth, which does not meet the criteria for a rare disease. The target population includes children and adolescents, which are not considered a rare group. The conditions being studied, such as dietary proteins and indicator amino acid oxidation, are common and not associated with a rare disease.

## Confidence Level
High

## Rare Disease Indicators
None. The clinical trial does not indicate that it is targeting a rare disease as defined by the criteria provided.",False
NCT05863117,Syphilis and HIV Point of Care Testing (POCT) in Saskatchewan,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on studying the performance and utility of point-of-care testing for syphilis and HIV infections, which are not considered rare diseases. Syphilis and HIV infections have a significantly higher prevalence than the criteria used to define a rare disease, both in the United States (affecting more than 200,000 people) and Europe (affecting more than 1 in 2,000 people).

## Confidence Level
High

## Rare Disease Indicators
This trial does not exhibit any of the typical indicators of a rare disease clinical trial, such as low prevalence, chronicity, or genetic origin.",False
NCT05600426,"A Trial Comparing Unrelated Donor BMT with IST for Pediatric and Young Adult Patients with Severe Aplastic Anemia (TransIT, BMT CTN 2202)","## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on treating severe aplastic anemia (SAA), which is a rare condition. According to the information provided, SAA is a condition in which the body stops producing enough new blood cells. The brief summary indicates that SAA can be cured with immune suppressive therapy or a bone marrow transplant, and that regular treatment for patients with aplastic anemia who do not have a matched sibling or family donor is immune suppressive therapy.

The rare disease criteria mentioned in the prompt are:
- In the US: affecting fewer than 200,000 people
- In Europe: affecting no more than 1 in 2,000 people
- Generally characterized by low prevalence, chronicity, and often genetic origin

The information provided about SAA aligns with these criteria. SAA is a rare and chronic condition, and it is often of genetic origin. While the exact prevalence is not provided, the description of SAA as a ""rare condition"" and the fact that regular treatment for patients without a matched family donor is immune suppressive therapy, suggests that it affects a small population, likely fewer than 200,000 people in the US.

## Confidence Level
High

## Rare Disease Indicators
- Low prevalence of the condition (described as a ""rare condition"")
- Chronic nature of the disease
- Genetic origin of the disease",True
NCT05602857,"Can Training Balance, or Enjoying Music, Improve Attention, Problem-solving and/or Behavior Control Abilities?","## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The conditions being studied in this clinical trial, Executive Functions and Postural Balance, are not considered rare diseases. The brief summary and detailed description provided do not indicate that the target population has a rare disease. The study population consists of children aged 8-12 years old, which is a common age range and not typically associated with rare diseases.

## Confidence Level
High

## Rare Disease Indicators
None. The information provided does not suggest this is a rare disease trial.",False
NCT05516069,Our Healthbox - Evaluating Interactive Dispensing Systems for Low-Barrier Access to HIV Testing and Harm Reduction.,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The information provided in the clinical trial description indicates that the target population is individuals with HIV, which is not considered a rare disease. According to the World Health Organization, there are approximately 38 million people living with HIV globally, which is well above the threshold for a rare disease as defined in the US (affecting fewer than 200,000 people) and Europe (affecting no more than 1 in 2,000 people).

## Confidence Level
High

## Rare Disease Indicators
None provided. The clinical trial is focused on addressing barriers to HIV testing, self-testing, and harm reduction services, which are not indicative of a rare disease.",False
NCT05669378,A Good Start Matters Intervention Study,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial described in the information provided is focused on investigating the impact of an intervention to enhance physical activity and motor skill development in childcare centers. The conditions being studied, physical inactivity and motor activity, are not considered rare diseases. The brief summary and detailed description indicate that the target population is children enrolled in childcare facilities, which is a common and widespread population, not a rare disease population.

## Confidence Level
High

## Rare Disease Indicators
None of the indicators for a rare disease are present in the provided information. The trial is not focused on a condition that affects fewer than 200,000 people in the US or 1 in 2,000 people in Europe, and the condition is not characterized by low prevalence, chronicity, and genetic origin.",False
NCT04616313,Novel Pulmonary Imaging of Lung Structure and Function in E-cigarette Smokers,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial described in the information provided is focused on studying the long-term health impact of e-cigarette smoking on the lungs. E-cigarette use is a relatively common condition, and the trial is not targeting a disease that affects fewer than 200,000 people in the US or 1 in 2,000 people in Europe, which are the typical criteria for a rare disease.

## Confidence Level
High

## Rare Disease Indicators
None. The condition being studied (e-cigarette use) does not meet the criteria for a rare disease.",False
NCT05535946,ABTECT - Maintenance,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
Ulcerative colitis, the condition being studied in this clinical trial, is not considered a rare disease. According to the information provided, ulcerative colitis is a moderately to severely active condition, which indicates that it affects a significant number of people. The trial is also a multicenter, randomized, placebo-controlled study, which is typical for a non-rare disease condition.

## Confidence Level
High

## Rare Disease Indicators
There are no clear indicators in the provided information that this is a rare disease trial. The condition, ulcerative colitis, is not considered a rare disease based on the criteria given (affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe).",False
NCT05608291,A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
Melanoma, the condition being studied in this clinical trial, is not considered a rare disease. According to the information provided, melanoma is a common type of cancer, and the trial is focused on patients with high-risk melanoma who have undergone surgical removal of the tumor. The brief summary indicates that pembrolizumab, the comparator drug, is an approved treatment in some countries for this clinical setting, suggesting that melanoma is not a rare disease.

## Confidence Level
High

## Rare Disease Indicators
None identified. The information provided does not indicate that the condition being studied (melanoma) meets the criteria for a rare disease, which typically affects fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.",False
NCT05142735,Effects of NAC on Symptoms of CHR Patients,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on investigating the effects of N-acetylcysteine (NAC) on psychosis-like symptoms and neurophysiological biomarkers in individuals with the ""clinical high-risk"" (CHR) state for schizophrenia. Schizophrenia is a chronic and debilitating psychotic disorder, but it is not considered a rare disease. According to the information provided, schizophrenia is a common mental disorder, not a rare disease.

## Confidence Level
High

## Rare Disease Indicators
The information provided does not indicate that this trial is for a rare disease. The condition being studied, the ""clinical high-risk"" state for schizophrenia, is not considered a rare disease.",False
NCT05694260,A Clinical Study in Children With Heterozygous Familial Hypercholesterolemia (HeFH) Aged 6 to 17 Treated Once Daily With Bempedoic Acid Oral Dosing (CLEAR Path 1),"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
Heterozygous familial hypercholesterolemia (HeFH) is a rare genetic disorder that affects the ability to remove low-density lipoprotein (LDL) cholesterol from the blood. According to the information provided, the clinical trial is targeting pediatric patients (6 to 17 years of age) with HeFH, which is generally considered a rare disease.

## Confidence Level
High

## Rare Disease Indicators
- HeFH is a rare genetic disorder
- The trial is targeting a specific patient population (pediatric patients aged 6 to 17 years with HeFH)
- Heterozygous familial hypercholesterolemia affects fewer than 200,000 people in the United States, which falls under the criteria for a rare disease.",True
NCT05592119,Effect of Stimulant Medication on Loss of Control Eating in Youth With Attention Deficit/Hyperactivity Disorder,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The information provided in the clinical trial description indicates that the target conditions are Loss of Control Eating (LOC-E) and Attention Deficit/Hyperactivity Disorder (ADHD), which are not considered rare diseases. ADHD is estimated to affect around 5-11% of children and adolescents in the United States, which is well above the threshold of affecting fewer than 200,000 people (the criteria for a rare disease in the US). While LOC-E is a precursor to eating disorders like binge-eating disorder, it is not a distinct disease itself and is not considered a rare condition.

## Confidence Level
High

## Rare Disease Indicators
There are no specific indicators in the provided information that suggest this is a rare disease trial. The conditions being studied, ADHD and LOC-E, are relatively common and do not meet the criteria for rare diseases.",False
NCT05680818,Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With ADH1,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The clinical trial is evaluating the efficacy and safety of a treatment for Autosomal Dominant Hypocalcemia Type 1 (ADH1), which is described as a ""rare genetic form of hypoparathyroidism"" in the detailed description. Additionally, the condition is characterized as affecting a small population, as it may be ""passed down from affected parents to their children.""

## Confidence Level
High

## Rare Disease Indicators
- According to the information provided, ADH1 is a rare genetic condition.
- The trial is specifically targeting participants with ADH1, which is described as a ""rare genetic form of hypoparathyroidism.""
- The low prevalence of the condition, as it is passed down from affected parents, is an indicator of a rare disease.",True
NCT05615623,Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric DIPG,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
Based on the information provided, this clinical trial is for the treatment of diffuse intrinsic pontine glioma (DIPG), which is a rare type of brain tumor that primarily affects children. According to the criteria provided, a rare disease is typically defined as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe. The brief summary states that this study is targeting pediatric patients with DIPG, which is a rare condition.

## Confidence Level
High

## Rare Disease Indicators
- Low prevalence: DIPG is a rare type of brain tumor that primarily affects children.
- Chronicity: DIPG is a serious and often fatal condition.
- Genetic origin: DIPG is generally believed to have a genetic component.",True
NCT05507216,ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is ulcerative colitis, which is a type of inflammatory bowel disease. According to the information provided, ulcerative colitis is not considered a rare disease. The brief summary indicates that the study population includes subjects with ""moderately to severely active ulcerative colitis"", which suggests that the condition has a higher prevalence than what is typically defined as a rare disease.

## Confidence Level
High

## Rare Disease Indicators
None. The information provided does not indicate that ulcerative colitis meets the criteria for a rare disease, which is defined as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.",False
NCT05335876,Long-term Follow-up of Patients With Spinal Muscular Atrophy Treated With OAV101 in Clinical Trials,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is Spinal Muscular Atrophy (SMA), which is a rare genetic disorder that affects fewer than 200,000 people in the United States, meeting the accepted criteria for a rare disease. Additionally, SMA is generally characterized by low prevalence, chronicity, and genetic origin, further supporting the classification as a rare disease.

## Confidence Level
High

## Rare Disease Indicators
- Affects fewer than 200,000 people in the US, meeting the US criteria for a rare disease
- Characterized by low prevalence, chronicity, and genetic origin, typical of rare diseases",True
NCT05233397,ACTEMRA® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The clinical trial is targeting pediatric patients with adamantinomatous craniopharyngioma, a type of brain tumor. According to the information provided, adamantinomatous craniopharyngioma is a ""highly debilitating pediatric brain tumor that lacks medical anti-tumor therapies."" Additionally, the trial is specifically targeting ""unresectable"" cases of this disease, indicating it is a more severe and difficult-to-treat form of the condition.

The rare disease criteria are met based on the low prevalence of this condition. The detailed description states that it is a ""rare pediatric brain tumor,"" and no specific prevalence numbers are provided. However, given the general rarity of pediatric brain tumors and the lack of effective treatments, it is reasonable to conclude that adamantinomatous craniopharyngioma likely affects fewer than 200,000 people in the US and no more than 1 in 2,000 people in Europe, meeting the accepted criteria for a rare disease.

## Confidence Level
High

## Rare Disease Indicators
- Highly debilitating pediatric brain tumor
- Lack of effective medical treatments
- Targeting unresectable cases, indicating a severe and difficult-to-treat form of the disease
- Likely low prevalence based on the rarity of pediatric brain tumors in general",True
NCT05404932,Treatment of Ligneous Conjunctivitis in Children With Plasminogen Deficiency,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The clinical trial information provided indicates that the condition being studied, plasminogen deficiency, is an extremely rare autosomal recessive disorder, with more than 200 cases reported in the literature. This meets the accepted criteria for a rare disease, which in the US is defined as affecting fewer than 200,000 people. The detailed description also mentions that there are less than 5 patients with this condition in the entire country of Canada, and only one known patient in the province of Saskatchewan, where the trial is being conducted.

## Confidence Level
High

## Rare Disease Indicators
- Affects fewer than 200,000 people in the US
- Extremely rare autosomal recessive disorder, with less than 5 patients in Canada and only one known patient in the province of Saskatchewan",True
NCT05677139,A Study for Observing Severe Asthma in Patients Treated With Tezepelumab,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The information provided indicates that the clinical trial is studying severe asthma, a condition that is not considered a rare disease. Asthma is a common chronic respiratory condition that affects millions of people worldwide. The prevalence of severe asthma, specifically, is also not low enough to be considered a rare disease.

## Confidence Level
High

## Rare Disease Indicators
None. The condition being studied, severe asthma, does not meet the criteria for a rare disease based on the information provided.",False
NCT05611801,A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The information provided indicates that this clinical trial is targeting hemophilia A and hemophilia B, which are both rare genetic disorders. Hemophilia A, the more common type, is estimated to affect around 20,000 people in the United States, which is well below the 200,000 threshold for a rare disease. Hemophilia B is even rarer, with an estimated prevalence of around 5,000 people in the U.S. Additionally, hemophilia is characterized by low prevalence, chronicity, and genetic origin, all of which are typical traits of rare diseases.

## Confidence Level
High

## Rare Disease Indicators
- Affecting fewer than 200,000 people in the U.S.
- Genetic origin
- Chronic condition",True
NCT05664737,A Study to Determine the Efficacy and Safety of Luspatercept in Adult Participants and to Evaluate the Safety and Pharmacokinetics in and Adolescent Participants With Alpha (α)-Thalassemia,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is alpha (α)-thalassemia, which is a rare genetic disorder affecting the production of hemoglobin. Alpha-thalassemia is generally characterized by low prevalence, chronicity, and genetic origin, which are key indicators of a rare disease. Additionally, the study is specifically targeting adults and adolescents with alpha-thalassemia hemoglobin H (HbH) disease, which further supports the classification of this as a rare disease trial.

## Confidence Level
High

## Rare Disease Indicators
- Low prevalence: Alpha-thalassemia is a rare genetic disorder, with a low number of affected individuals.
- Chronicity: Alpha-thalassemia is a chronic condition that requires lifelong management.
- Genetic origin: Alpha-thalassemia is caused by genetic mutations, a key characteristic of rare diseases.
- Specific target population: The trial is focusing on adults and adolescents with alpha-thalassemia HbH disease, a subtype of the rare condition.",True
NCT05365347,Piloting of an Intervention to Reduce Problematic Alcohol Use in Early Phase Psychosis Patients,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial information provided indicates that the study is focused on reducing problematic alcohol use in individuals with early phase psychosis. Psychosis and alcohol use disorder are not considered rare diseases based on the provided criteria:

- In the US, psychosis affects an estimated 3 million people, which is well above the 200,000 threshold for a rare disease.
- Alcohol use disorder affects approximately 15 million adults in the US, again exceeding the rare disease criteria.

The brief summary and detailed description do not mention any rare disease characteristics such as low prevalence, chronicity, or genetic origin. The conditions being studied, psychosis and alcohol use disorder, are relatively common.

## Confidence Level
High

## Rare Disease Indicators
None provided. The conditions being studied, psychosis and alcohol use disorder, are not considered rare diseases.",False
NCT05538130,A Study to Learn About the Study Medicine Called PF-07799544 in People With Advanced Solid Tumors,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The conditions listed in the trial include several common types of cancer, such as melanoma, non-small cell lung cancer, and colorectal cancer. These cancers are generally not considered rare diseases, as they affect a larger population. The trial is also seeking participants with ""advanced solid tumors,"" which suggests a broader population than a rare disease trial.

## Confidence Level
High

## Rare Disease Indicators
None. The information provided does not indicate that this trial is targeting a rare disease that affects fewer than 200,000 people in the US or 1 in 2,000 people in Europe.",False
NCT05699928,Accuracy of Community General Pediatrician Diagnosis of Autism Compared to a Multidisciplinary Team Assessment,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on autism spectrum disorder (ASD), which is not considered a rare disease. According to the information provided, ASD is a condition that has increasing rates of diagnosis, indicating a relatively high prevalence. The accepted criteria for a rare disease states that it should affect fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe, which does not appear to be the case for ASD.

## Confidence Level
High

## Rare Disease Indicators
There are no specific indicators that this is a rare disease trial. The condition being studied, ASD, is a relatively common neurodevelopmental disorder.",False
NCT04575883,HIIT in Youth With Congenital Heart Disease (MedBIKE),"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial information provided indicates that the condition being studied, congenital heart disease (CHD), is present in nearly 1% of the population. This prevalence rate does not meet the criteria for a rare disease, which is defined as affecting fewer than 200,000 people in the United States or no more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
The condition of congenital heart disease (CHD) does not meet the criteria for a rare disease, as it is present in nearly 1% of the population, which is higher than the thresholds for a rare disease.",False
NCT05107154,iCARE 2.0: A Pilot Intervention of Dialectical Behavioural Therapy for Youth With Type 2 Diabetes.,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is Type 2 Diabetes in youth, which does not meet the criteria for a rare disease. According to the information provided, in the US, a rare disease is typically defined as affecting fewer than 200,000 people, and in Europe, it is defined as affecting no more than 1 in 2,000 people. Type 2 Diabetes, even in youth, is a relatively common condition and does not fall under the definition of a rare disease.

## Confidence Level
High

## Rare Disease Indicators
None. The condition of Childhood-Onset Type 2 Diabetes does not meet the criteria for a rare disease.",False
NCT05295290,A Study to Learn About The COVID-19 (Study) Vaccine (Called COMIRNATY) in People That Are Less Than 21 Years Old.,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on studying the potential long-term effects of myocarditis/pericarditis associated with the COVID-19 vaccine (COMIRNATY) in people under 21 years of age. Myocarditis is a condition that affects the heart muscle and can be caused by various factors, including viral infections and vaccinations.

While myocarditis can be a serious condition, it is not considered a rare disease according to the criteria provided. The trial aims to enroll approximately 300 prospectively and retrospectively ascertained cases of myocarditis/pericarditis associated with the COMIRNATY vaccine, and approximately 100 cases of COVID-19-associated myocarditis/pericarditis, including MIS-C (Multisystem Inflammatory Syndrome in Children).

The prevalence of myocarditis in the general population is not provided, but the targeted enrollment numbers suggest that the condition is not considered a rare disease, as the trial aims to study a substantial number of cases.

## Confidence Level
High

## Rare Disease Indicators
None. The clinical trial is not focused on a rare disease based on the information provided.",False
NCT05286801,Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The conditions listed in the clinical trial information indicate that the target diseases are SMARCB1 or SMARCA4 deficient tumors, which include atypical teratoid/rhabdoid tumor, epithelioid sarcoma, kidney medullary carcinoma, and other rare malignant solid neoplasms. These types of tumors are generally considered rare diseases, as they affect a small population of patients.

## Confidence Level
High

## Rare Disease Indicators
- The conditions listed in the trial are characterized as rare, affecting a small population of patients.
- The trial specifically targets SMARCB1 or SMARCA4 deficient tumors, which are known to be rare and aggressive cancers.
- The trial is designed to evaluate the safety and efficacy of the investigational treatments in both pediatric and adult populations with these rare tumors.",True
NCT05631301,Move&Connect: A Program for Youth With Concussion and Their Caregivers.,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The information provided indicates that the clinical trial is focused on post-concussion syndrome, which is a condition that affects a significant number of people. The brief summary mentions that the intervention is designed for ""youth with persistent post-concussion symptoms (PPCS),"" suggesting that this is a relatively common condition rather than a rare disease.

## Confidence Level
High

## Rare Disease Indicators
None provided. The condition being studied, post-concussion syndrome, does not meet the criteria for a rare disease as defined in the provided information (affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe).",False
NCT05583227,Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
Eosinophilic esophagitis (EoE) is a chronic, allergic inflammatory condition of the esophagus that affects the swallowing of food. According to the information provided, the study plans to enroll approximately 360 participants, which suggests that the condition is not considered a rare disease. The criteria for a rare disease in the US is affecting fewer than 200,000 people, and in Europe, affecting no more than 1 in 2,000 people. The brief summary and detailed description of the study do not indicate that EoE meets these criteria for a rare disease.

## Confidence Level
High

## Rare Disease Indicators
None provided. The information given does not suggest that this clinical trial is for a rare disease.",False
NCT05627492,Pragmatic Patient-oriented Extension Study of Dialectical Behavior Therapy Booster Sessions for Youth With and/or at Familial Risk for Bipolar Disorder,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is bipolar disorder, which is not considered a rare disease. According to the information provided, bipolar disorder is a common mental health condition, and the study is targeting youth with or at familial risk of developing bipolar disorder. The prevalence of bipolar disorder in the U.S. is estimated to be around 2.8% of the adult population, which is significantly higher than the criteria for a rare disease (affecting fewer than 200,000 people in the U.S.).

## Confidence Level
High

## Rare Disease Indicators
None of the provided information indicates that this is a clinical trial for a rare disease.",False
NCT05457283,A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The information provided indicates that the clinical trial is focused on treating chronic kidney disease (CKD) and proteinuria in children and young adults aged 1 to 18 years. While CKD can be a serious condition, it is not considered a rare disease based on the given criteria:

- In the US, CKD is estimated to affect more than 200,000 children and adolescents, exceeding the threshold of less than 200,000 people for a rare disease.
- In Europe, the prevalence of CKD in children and adolescents is estimated to be higher than 1 in 2,000 people, again exceeding the criteria for a rare disease.

Additionally, CKD is generally characterized as a chronic condition, often with a genetic component, but it is not considered a rare disease.

## Confidence Level
High

## Rare Disease Indicators
None. The information provided does not indicate that this is a rare disease trial.",False
NCT05575492,A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is cytomegalovirus (CMV), which is not considered a rare disease. CMV is a common virus that infects people of all ages, and it is estimated to affect a significant portion of the population, not just a small number of people. The trial is also being conducted in relatively large age groups (9-15 years and 16-25 years), further indicating that this is not a rare disease.

## Confidence Level
High

## Rare Disease Indicators
There are no clear indicators that this is a rare disease trial based on the information provided. The condition, target population, and study design do not align with the accepted criteria for a rare disease.",False
NCT05992519,Diagnostic and Translational Values of Point-of-care Blood Eosinophils and Exhaled Nitric Oxide (FeNO) in People Referred by Primary Care for Suspected Asthma,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
Based on the information provided, the clinical trial is focused on asthma, which is not considered a rare disease. The brief summary states that asthma ""affects 10% of the Canadian population and is the most common chronic disease in childhood."" This indicates that the condition being studied is not a rare disease, as it affects a significant portion of the population, well above the criteria for a rare disease (fewer than 200,000 people in the US or affecting no more than 1 in 2,000 people in Europe).

## Confidence Level
High

## Rare Disease Indicators
There are no rare disease indicators present in the provided information. The condition being studied, asthma, is a common chronic disease.",False
NCT06076889,Power Over Pain Portal: A Stepped-care Virtual Solution to Deliver Early Intervention to Canadian Youth With Chronic Pain,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The information provided in the clinical trial description indicates that the condition being studied is chronic pain, which is a common condition and not considered a rare disease. Chronic pain is a widespread problem that affects a significant portion of the population, rather than a condition that affects fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe, which are the typical criteria for a rare disease.

## Confidence Level
High

## Rare Disease Indicators
This clinical trial does not meet the accepted criteria for a rare disease, as chronic pain is a common condition that affects a large number of people.",False
NCT05511922,PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is Hereditary Angioedema (HAE), which is a rare genetic disorder. HAE is characterized by episodes of severe swelling, often in the face, extremities, gastrointestinal tract, and upper airway, and it is generally considered a rare disease.

## Confidence Level
High

## Rare Disease Indicators
- The condition, Hereditary Angioedema, is specifically mentioned as the target of the clinical trial.
- Hereditary Angioedema is a genetic disorder, which is a characteristic of rare diseases.
- The trial is focused on adolescent patients, which is a specific subpopulation of the broader HAE patient population.",True
NCT05345171,Clinical Study of DTX301 AAV- Mediated Gene Transfer for Ornithine Transcarbamylase(OTC) Deficiency,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The clinical trial is for a condition called ornithine transcarbamylase (OTC) deficiency, which is a rare genetic disorder. According to the information provided, OTC deficiency is typically characterized by low prevalence, chronicity, and genetic origin, which are all indicators of a rare disease.

## Confidence Level
High

## Rare Disease Indicators
- The condition, OTC deficiency, affects fewer than 200,000 people in the US, which is the accepted criteria for a rare disease in the US.
- The condition is described as a rare genetic disorder, which aligns with the general characterization of rare diseases.",True
NCT05559359,A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
Atopic dermatitis (also known as eczema) is a common skin condition that affects a large portion of the population, especially children. According to the information provided, the clinical trial is targeting participants aged 6 months to <18 years with moderate-to-severe atopic dermatitis, which is not considered a rare disease.

## Confidence Level
High

## Rare Disease Indicators
None. The condition being studied, atopic dermatitis, does not meet the criteria for a rare disease as defined in the information provided.",False
NCT05545839,Transition to Adulthood Through Coaching and Empowerment in Rheumatology,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The conditions listed in the clinical trial information, such as Juvenile Idiopathic Arthritis, Juvenile Rheumatoid Arthritis, Juvenile Dermatomyositis, Juvenile Psoriatic Arthritis, Autoinflammatory Disease, Autoimmune Diseases, and Lupus Erythematosus, are not considered rare diseases according to the provided criteria. These conditions are not known to affect fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
None of the conditions listed in the clinical trial information meet the criteria for a rare disease.",False
NCT05459935,Photobiomodulation for Pediatric Hypertrophic Tonsils,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on the treatment of pediatric hypertrophic tonsils and pediatric obstructive sleep apnea, which are not considered rare diseases. Obstructive sleep apnea affects approximately 2-5% of children, which is significantly higher than the rare disease criteria of affecting fewer than 1 in 2,000 people in Europe or fewer than 200,000 people in the US.

## Confidence Level
High

## Rare Disease Indicators
None. The condition being studied, pediatric obstructive sleep apnea, does not meet the criteria for a rare disease.",False
NCT05603000,Emotion Focused Family Therapy for Parents of Children With Mental Health Difficulties,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The information provided indicates that the clinical trial is targeting conditions such as anxiety, depression, and behavior problems in children, which are not considered rare diseases. The conditions described are relatively common and affect a larger population, not meeting the criteria for a rare disease.

## Confidence Level
High

## Rare Disease Indicators
None
",False
NCT05309226,Cannabis Use in Pregnancy and Downstream Effects on Maternal and Infant Health,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is cannabis use in pregnancy, which is not considered a rare disease. The summary indicates that cannabis use is increasing, even among pregnant individuals, suggesting a relatively high prevalence of the condition. The criteria for a rare disease, as provided, are that it affects fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe, and is generally characterized by low prevalence, chronicity, and often genetic origin. The information provided about this clinical trial does not suggest that the condition being studied meets these criteria for a rare disease.

## Confidence Level
High

## Rare Disease Indicators
None identified. The condition being studied, cannabis use in pregnancy, does not appear to meet the criteria for a rare disease.",False
NCT05507203,ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is for the treatment of ulcerative colitis, which is a common inflammatory bowel disease. According to the information provided, ulcerative colitis is not considered a rare disease, as it does not meet the criteria for rare diseases in the United States (affecting fewer than 200,000 people) or Europe (affecting no more than 1 in 2,000 people).

## Confidence Level
High

## Rare Disease Indicators
There are no rare disease indicators present in the information provided. The condition being studied, ulcerative colitis, is a common chronic condition.",False
NCT05206357,Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on pediatric patients with relapsed/refractory aggressive mature B-cell neoplasms, which include Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL). The brief summary states that these types of mature B-cell lymphomas are the ""most common"" in children, but the initial treatment cures 90-95% of cases, leaving a ""very small population"" with relapsed/refractory disease. This indicates that the target population for this trial is likely to be fewer than 200,000 people in the US, which meets the criteria for a rare disease.

## Confidence Level
High

## Rare Disease Indicators
- Affecting a small population of patients, with the brief summary indicating a ""very small population"" remaining after initial treatment
- Targeting a specific type of cancer (mature B-cell neoplasms) that predominantly affects children",True
NCT05411302,Augmenting Mental Health Support Through a Supportive Text Messaging Program,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on patients with major depressive disorder, generalized anxiety disorder, and mental health wellness, which are not considered rare diseases based on the provided criteria. The conditions described in the trial do not meet the rare disease definition of affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
This clinical trial does not contain any indicators that would classify it as a rare disease trial.",False
NCT05183035,Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML),"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The information provided indicates that the condition being studied is acute myeloid leukemia (AML). AML is not considered a rare disease based on the accepted criteria. In the United States, AML is estimated to affect approximately 20,000 people per year, which exceeds the 200,000 threshold for a rare disease. Additionally, AML is not characterized by low prevalence, as it is a relatively common form of cancer.

## Confidence Level
High

## Rare Disease Indicators
None. The condition being studied, acute myeloid leukemia, does not meet the criteria for a rare disease.",False
NCT05376696,Behavioural and Physiological Measures of Young Students With Dyslexia,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The information provided indicates that the clinical trial is focused on studying reading intervention in school-age children with dyslexia, which is a common learning disability. According to the details in the description, the condition being studied (dyslexia) affects a significant portion of the population, with statistics showing that 3.2% of children in Canada have a learning disability, making it the most prevalent type of childhood condition. This is well above the criteria for a rare disease, which is typically defined as affecting fewer than 200,000 people in the United States or no more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
This clinical trial does not have any indicators of a rare disease. The condition being studied, dyslexia, is a common learning disability affecting a significant percentage of the population.",False
NCT05589064,Evaluation of the Impact of a Dietary and Nutritional Intervention on Persistent Post-concussive Symptoms,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial information provided does not indicate that the condition being studied (persistent post-concussive symptoms) is a rare disease. Concussions, the underlying condition, are a common occurrence, affecting ""thousands of Canadians every year."" While 10-15% of adults may experience persistent symptoms, this does not meet the criteria for a rare disease, which is typically defined as affecting fewer than 200,000 people in the United States or no more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
None. The information provided does not suggest this is a rare disease trial.",False
NCT05637320,Big Feelings: A Study on Children's Emotions in Therapy,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on children and adolescents aged 8-15 with common mental health conditions, such as anxiety disorders, depressive disorder, conduct disorder, and trauma-related disorders. These conditions are not considered rare diseases, as they are relatively prevalent in the general population. The trial is not specifically targeting a disease that affects fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe, which are the accepted criteria for a rare disease.

## Confidence Level
High

## Rare Disease Indicators
None. The conditions mentioned in the trial are not considered rare diseases based on the provided definition.",False
NCT06373484,Matching Assessment and Treatment for Children With Disruptive Behaviour and Their Parents,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial information provided indicates that the study is investigating disruptive behavior disorders, emotional disorders, behavioral disorders, attention deficit hyperactivity disorder, conduct disorder, and oppositional defiant disorder. These conditions are not considered rare diseases based on the accepted criteria of affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe. The conditions described in the trial are relatively common and have a higher prevalence.

## Confidence Level
High

## Rare Disease Indicators
None of the indicators provided suggest this is a rare disease trial. The conditions being studied are not considered rare according to the provided definition.",False
NCT05531604,Appetitive Conditioning in Anorexia Nervosa,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on studying the mechanisms of anorexia nervosa, a mental health condition that is not considered a rare disease. Anorexia nervosa is a relatively common eating disorder, with an estimated lifetime prevalence of 0.6% in the United States. This falls well above the criteria for a rare disease in the US (affecting fewer than 200,000 people) and Europe (affecting no more than 1 in 2,000 people).

## Confidence Level
High

## Rare Disease Indicators
There are no indicators in the provided information that this is a rare disease clinical trial. The details about anorexia nervosa suggest it is a common mental health condition.",False
NCT05219110,Hyperhydration in Children With Shiga Toxin-Producing E. Coli Infection,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial information provided indicates that the condition being studied, Shiga Toxin-Producing Escherichia Coli (E. Coli) Infection and Hemolytic-Uremic Syndrome, is not considered a rare disease based on the given criteria. While the exact prevalence is not stated, the condition is described as affecting up to 20% of children following STEC infection, which suggests a higher prevalence than the criteria for a rare disease (fewer than 200,000 people in the US or affecting no more than 1 in 2,000 people in Europe).

## Confidence Level
High

## Rare Disease Indicators
None. The information provided does not indicate that this condition meets the criteria for a rare disease.",False
NCT04811235,Optical Monitoring With Near-Infrared Spectroscopy for Spinal Cord Injury Trial,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial, acute spinal cord injury, is not considered a rare disease based on the provided criteria. Spinal cord injuries are estimated to affect approximately 17,000 people annually in the United States, which is significantly higher than the threshold of 200,000 people for a rare disease in the US. Additionally, the prevalence of spinal cord injuries is not characterized as low, and they are not predominantly of genetic origin.

## Confidence Level
High

## Rare Disease Indicators
None of the rare disease indicators are present in this clinical trial. The condition being studied, acute spinal cord injury, is a relatively common condition that affects a larger population than the defined rare disease thresholds.",False
NCT05899101,The Impact of Opioid and Cannabis Exposure on Fetal Growth,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial information provided does not indicate that the condition being studied (pregnancy-related substance use and its impact on fetal growth) is a rare disease. The trial aims to recruit a total of 546 participants, which is significantly higher than the typical criteria for a rare disease in the United States (affecting fewer than 200,000 people) or Europe (affecting no more than 1 in 2,000 people). Additionally, the condition is described as common, with cannabis exposure being prevalent in opioid-exposed pregnancies (36-75%). Therefore, this does not meet the generally accepted criteria for a rare disease.

## Confidence Level
High

## Rare Disease Indicators
There are no clear indicators in the provided information that this is a rare disease clinical trial.",False
NCT05235919,Treatment to Promote Self-regulation in Children With Autism Spectrum Disorder,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is Autism Spectrum Disorder (ASD), which is not considered a rare disease. According to the information provided, ASD is a common condition that affects a significant number of people, rather than a rare disease that affects fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
None. The prevalence of ASD does not meet the criteria for a rare disease.",False
NCT05425433,Serial Casting for Upper Extremity Burn Contractures,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The information provided in the clinical trial description indicates that the condition being studied, burn contracture of the skin, is not considered a rare disease. Burn injuries are relatively common, and the development of contractures following a burn injury is also not an uncommon condition. The trial is specifically targeting adults with upper extremity burn contractures, which suggests a broader patient population than a rare disease would typically have.

## Confidence Level
High

## Rare Disease Indicators
None of the provided indicators for a rare disease are present in this clinical trial. The condition being studied (burn contractures) does not meet the criteria of affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe. Additionally, the description does not indicate that the condition is generally characterized by low prevalence, chronicity, and often genetic origin.",False
NCT04887337,Early arthroscoPic Stabilization veRsus rehabilitatiOn of the Shoulder in Adolescents With a trauMatic First-time Anterior Shoulder Dislocation ePisode,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The information provided indicates that the condition being studied, shoulder dislocation, is not a rare disease. The brief summary states that each year within Canada and the US, more than 30,000 children and adolescents will have a shoulder dislocation. This is significantly higher than the criteria for a rare disease, which is defined as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
None. The condition being studied, shoulder dislocation, does not meet the criteria for a rare disease.",False
NCT05489887,Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is high-risk neuroblastoma, which is a rare form of cancer that typically occurs in young children. Neuroblastoma affects fewer than 1 in 100,000 children in the United States, which falls well below the threshold of 200,000 people for a rare disease in the US. Additionally, neuroblastoma is characterized as a rare disease due to its low prevalence, chronicity, and genetic origin.

## Confidence Level
High

## Rare Disease Indicators
- Affects fewer than 200,000 people in the US
- Low prevalence, chronicity, and genetic origin of the condition (high-risk neuroblastoma)",True
NCT05081245,ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD),"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
Autism Spectrum Disorder (ASD) is not considered a rare disease based on the prevalence criteria provided. According to the information given, ASD affects a larger population than the thresholds for rare diseases in the US (fewer than 200,000 people) and Europe (affecting no more than 1 in 2,000 people). The brief summary indicates that the study will enroll approximately 150 adolescent and adult subjects with ASD, suggesting a larger patient population.

## Confidence Level
High

## Rare Disease Indicators
None present in the provided information.",False
NCT05480696,Soluble Fibre Supplementation in NAFLD,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is non-alcoholic fatty liver disease (NAFLD), which is a common condition affecting a significant portion of the population. According to the information provided, NAFLD is characterized as a condition that is ""generally characterized by low prevalence, chronicity, and often genetic origin."" However, the prevalence of NAFLD is estimated to be around 25-30% in the general population, which is significantly higher than the criteria for a rare disease.

## Confidence Level
High

## Rare Disease Indicators
None. The information provided indicates that NAFLD is a common condition and does not meet the criteria for a rare disease.",False
NCT05440643,Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is peanut allergy, which is not considered a rare disease. Peanut allergy is a common food allergy, affecting up to 2% of the population in the United States and Europe, which exceeds the criteria for a rare disease (affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe).

## Confidence Level
High

## Rare Disease Indicators
None. The prevalence of peanut allergy is well above the threshold for a rare disease.",False
NCT05555771,Paediatric Syncope in the Emergency Department,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on studying syncope and associated conditions, such as vasovagal syncope, postural orthostatic tachycardia syndrome, and orthostatic intolerance, in pediatric patients. These conditions are not considered rare diseases based on the provided criteria. The trial is specifically looking to recruit pediatric patients aged 7-19 years, which suggests a broader patient population rather than a rare disease.

## Confidence Level
High

## Rare Disease Indicators
None of the provided information indicates that this is a rare disease trial. The conditions being studied are not considered rare diseases, and the target patient population is not limited to a small number of individuals.",False
NCT04912817,PR-VR At-home Program During and After COVID-19,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The information provided in the clinical trial details indicates that the condition being studied, chronic pain in adolescents, is not a rare disease. The brief summary states that chronic pain affects 1 in 5 or 2 million Canadian children and adolescents, which is well above the criteria for a rare disease in the US (affecting fewer than 200,000 people) and Europe (affecting no more than 1 in 2,000 people). Additionally, the condition is described as a common problem with negative impacts on quality of life, rather than a rare or low-prevalence condition.

## Confidence Level
High

## Rare Disease Indicators
None of the provided information suggests this is a rare disease trial. The prevalence of chronic pain in adolescents is clearly stated to be much higher than the criteria for a rare disease.",False
NCT05280899,Weightbearing Restrictions on Postoperative Outcomes Following Arthroscopic Surgery for FAI,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is Femoroacetabular Impingement (FAI), which is a common hip condition that affects a larger population. The brief summary and detailed description do not indicate that FAI is a rare disease. Additionally, the clinical trial is targeting a common surgical procedure (arthroscopic surgery for FAI) and a relatively common rehabilitation protocol (weight-bearing restrictions), which further suggests that this is not a rare disease trial.

## Confidence Level
High

## Rare Disease Indicators
None. The information provided does not indicate that this is a rare disease clinical trial.",False
NCT05500001,Supporting Patients by Family Education in Psychotic Illness: A Prospective Cohort Study,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial information provided does not indicate that the condition being studied (psychotic disorders) is a rare disease. The conditions listed, such as psychotic disorders, family members, anosognosia, and paranoia, are relatively common and not considered rare diseases. The prevalence criteria for a rare disease in the United States and Europe are not met, as psychotic disorders are not known to affect fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
There are no specific rare disease indicators in the provided information.",False
NCT05868109,Inhaled Nitric Oxide for Cardiac Arrest in Pediatrics and Adults (iNOCAPA),"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is cardiac arrest, which is not considered a rare disease. Cardiac arrest is a leading cause of death and affects a large population, not meeting the criteria for a rare disease as defined in the information provided (affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe).

## Confidence Level
High

## Rare Disease Indicators
None, as this condition does not meet the criteria for a rare disease.",False
NCT05271409,"A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease","## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The information provided indicates that the study is for a condition called ""Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)"". This condition is not explicitly mentioned in the definition of a rare disease, but based on the general characteristics provided (low prevalence, chronicity, and often genetic origin), it can be reasonably inferred that MOGAD is a rare disease.

## Confidence Level
High

## Rare Disease Indicators
- The condition, MOGAD, is not a commonly known or prevalent disease.
- The study is a Phase III clinical trial, which suggests that the disease has a low prevalence and is not well-studied or understood.
- The study is being conducted at multiple centers, which is typical for rare disease trials to gather a sufficient number of participants.",True
NCT05492578,Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is for participants with moderate to severe atopic dermatitis, which is a common skin condition. Atopic dermatitis is not considered a rare disease, as it is estimated to affect up to 20% of children and 3% of adults globally, which is well above the criteria for a rare disease in the US (affecting fewer than 200,000 people) and Europe (affecting no more than 1 in 2,000 people).

## Confidence Level
High

## Rare Disease Indicators
None",False
NCT05524883,"Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in Participants with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping","## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
Duchenne muscular dystrophy (DMD) is considered a rare disease based on the accepted criteria. In the United States, DMD is estimated to affect fewer than 20,000 people, which is well below the threshold of 200,000 people for a rare disease. Similarly, in Europe, the prevalence of DMD is estimated to be around 1 in 3,500 to 5,000 people, which is within the 1 in 2,000 people criteria for a rare disease.

Additionally, DMD is a chronic, genetic condition, which aligns with the general characteristics of a rare disease.

## Confidence Level
High

## Rare Disease Indicators
- Affects fewer than 200,000 people in the US
- Affects no more than 1 in 2,000 people in Europe
- Chronic, genetic condition",True
NCT05996653,CEST in Low-grade Glioma Study,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is for a condition called ""Low-grade Glioma"", which is a type of brain tumor. Based on the information provided, low-grade gliomas are not considered a rare disease. The brief summary indicates that low-grade gliomas are ""malignant, infiltrative and incurable brain tumors that typically present in the younger population"", suggesting a higher prevalence than the criteria for a rare disease.

## Confidence Level
High

## Rare Disease Indicators
There are no specific indicators in the provided information that would suggest this is a rare disease clinical trial. The description of the condition does not mention it affecting fewer than 200,000 people in the US or affecting no more than 1 in 2,000 people in Europe, which are the accepted criteria for a rare disease.",False
NCT05376267,Pediatric Influence of Cooling Duration on Efficacy in Cardiac Arrest Patients (P-ICECAP),"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this trial is cardiac arrest, which is not considered a rare disease. Cardiac arrest is a relatively common medical emergency, affecting over 300,000 people in the United States each year. Additionally, the trial is focused on pediatric patients, which is a broader population than the typical rare disease criteria of affecting fewer than 200,000 people in the US or 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
None",False
NCT05446272,The Diaphragmatic Initiated Ventilatory Assist (DIVA) Trial,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The conditions mentioned in the clinical trial (extubation failure, bronchopulmonary dysplasia, and death) are not considered rare diseases. Bronchopulmonary dysplasia, in particular, is a relatively common complication of prematurity, affecting up to 40% of infants born at less than 28 weeks of gestation. The target population for this trial is preterm infants born between 23 0/7 and 28 6/7 weeks of gestation, which is a larger population than the rare disease criteria.

## Confidence Level
High

## Rare Disease Indicators
None of the criteria for a rare disease are met in this clinical trial. The conditions and target population are not consistent with the accepted definition of a rare disease.",False
NCT04039464,Mono vs. Dual Therapy for Pediatric Pulmonary Arterial Hypertension,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on pediatric pulmonary arterial hypertension (PAH), which meets the criteria for a rare disease. According to the information provided:

1. In the US, PAH is estimated to affect fewer than 200,000 people, which falls under the definition of a rare disease.
2. The condition is characterized by low prevalence, chronicity, and genetic origin, which are typical features of rare diseases.

## Confidence Level
High

## Rare Disease Indicators
- Affects fewer than 200,000 people in the US
- Chronic and genetic condition
- Targeting a pediatric population, which further reduces the overall prevalence",True
NCT04815564,Clear Aligners for the Treatment of Dental Malocclusion in OI,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
Osteogenesis Imperfecta (OI) is a rare genetic disorder that affects fewer than 200,000 people in the United States, which aligns with the definition of a rare disease in the US. The trial is specifically focused on individuals with OI, which is a chronic condition with a genetic origin, further supporting its classification as a rare disease.

## Confidence Level
High

## Rare Disease Indicators
- Affecting fewer than 200,000 people in the US
- Chronic and genetic condition
- Specific focus on Osteogenesis Imperfecta, which is a rare disease",True
NCT05656781,Brief Intervention and Contact Program Main Trial,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The information provided in the clinical trial summary indicates that the condition being studied, suicidal behavior, is not a rare disease. The summary states that suicide is a significant public health concern and causes approximately 1.5% of all deaths in the general population in Canada. This suggests that suicidal behavior is a relatively common condition, not a rare disease.

## Confidence Level
High

## Rare Disease Indicators
There are no clear indicators that this is a rare disease trial. The condition being studied, suicidal behavior, is described as a significant public health concern, which is not characteristic of a rare disease.",False
NCT05371613,A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) Vs Idursulfase in Pediatric and Young Adult Participants with Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II),"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is Mucopolysaccharidosis Type II (MPS II), also known as Hunter syndrome. According to the information provided, MPS II is a rare genetic disease that affects fewer than 200,000 people in the United States, which meets the criteria for a rare disease in the US. Additionally, MPS II is generally characterized by low prevalence, chronicity, and genetic origin, further indicating that it is a rare disease.

## Confidence Level
High

## Rare Disease Indicators
- Affects fewer than 200,000 people in the US, which is the typical criteria for a rare disease in the US.
- Generally characterized by low prevalence, chronicity, and genetic origin, which are common features of rare diseases.",True
NCT05352672,Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is melanoma, which is not considered a rare disease. The brief summary indicates that the study is focused on treating melanoma skin cancer in both adolescent and adult participants. Melanoma is a relatively common type of skin cancer, with an estimated 100,000 new cases diagnosed in the United States each year, which is well above the threshold of 200,000 cases for a rare disease in the US.

## Confidence Level
High

## Rare Disease Indicators
None. The information provided does not indicate that this clinical trial is targeting a rare disease.",False
NCT05392114,A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE),"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The clinical trial is for the treatment of hereditary angioedema (HAE), which is a rare genetic disorder. According to the information provided, HAE affects fewer than 200,000 people in the United States, which meets the criteria for a rare disease in the US. Additionally, HAE is generally characterized by low prevalence, chronicity, and genetic origin, further supporting the classification as a rare disease.

## Confidence Level
High

## Rare Disease Indicators
- The condition, hereditary angioedema (HAE), affects fewer than 200,000 people in the United States, which is the accepted criterion for a rare disease in the US.
- HAE is a chronic, genetic condition, which are characteristics typical of rare diseases.",True
NCT05511220,Pivotal Response Intervention Minimal Responders Study,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is Autism Spectrum Disorder (ASD), which is not considered a rare disease. According to the information provided, ASD is characterized by impaired functional language, which is a common symptom of the disorder. The prevalence of ASD is estimated to be around 1 in 54 children in the United States, which is significantly higher than the criteria for a rare disease (fewer than 200,000 people in the US or 1 in 2,000 people in Europe).

## Confidence Level
High

## Rare Disease Indicators
None. The condition being studied, Autism Spectrum Disorder, does not meet the criteria for a rare disease.",False
NCT05989178,Prospective Recurrent Pregnancy Loss Registry,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The provided information indicates that the study is focused on Recurrent Pregnancy Loss (RPL), which is a condition affecting a significant number of women. The brief summary states that the program at the BC Women's Centre for Reproductive Health has provided specialized care to RPL patients for the past 15 years, suggesting that the condition is not considered a rare disease.

## Confidence Level
High

## Rare Disease Indicators
None. The prevalence of Recurrent Pregnancy Loss does not meet the criteria for a rare disease, which is defined as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.",False
NCT06161168,Bootle Blast: Understanding the Family Experience,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The conditions listed in the clinical trial, such as cerebral palsy, developmental coordination disorder, autism spectrum disorder, and stroke, are not considered rare diseases based on the provided criteria. The brief summary states that ""One in 60 children have a physical disability that can impact activities and participation,"" which suggests that the target population for this trial is not considered a rare disease.

## Confidence Level
High

## Rare Disease Indicators
None of the conditions listed in the trial meet the criteria for a rare disease, which is defined as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe, and is generally characterized by low prevalence, chronicity, and often genetic origin.",False
NCT04221932,"Implementation of CRRT KPI Reports to Standardize and Improve the Quality of CRRT Delivery in Alberta ""QUALITY CRRT""","## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on implementing a quality assurance and improvement program for the delivery of continuous renal replacement therapy (CRRT) in intensive care units (ICUs) in Alberta, Canada. The condition being studied, acute kidney failure, is not considered a rare disease. According to the information provided, acute kidney replacement therapy is used in 6-10% of patients admitted to ICUs, which suggests a relatively high prevalence. The trial is not aimed at treating a disease that affects fewer than 200,000 people in the United States or fewer than 1 in 2,000 people in Europe, which are the generally accepted criteria for a rare disease.

## Confidence Level
High

## Rare Disease Indicators
There are no specific indicators in the provided information that suggest this is a rare disease trial.",False
NCT05355701,A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The conditions listed in the clinical trial (melanoma, non-small-cell lung cancer, thyroid cancer, glioma) are not considered rare diseases based on the provided criteria. Melanoma and non-small-cell lung cancer are relatively common types of cancer, and thyroid cancer and glioma, while less common, do not meet the definition of a rare disease affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
There are no specific indicators in the provided information that this is a rare disease trial.",False
NCT04978727,"A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma","## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The clinical trial is targeting several types of pediatric brain tumors, including medulloblastoma, high-grade glioma, ependymoma, and diffuse intrinsic pontine glioma. These are rare and aggressive types of brain cancer that primarily affect children and young adults. According to the provided information, these conditions are generally characterized by low prevalence, chronicity, and often genetic origin, which aligns with the accepted criteria for rare diseases.

## Confidence Level
High

## Rare Disease Indicators
- Targets pediatric brain tumors, which are rare conditions
- Affected population is generally small, with fewer than 200,000 people in the US
- Conditions are characterized by low prevalence, chronicity, and genetic origin",True
NCT05230758,Effect of Metformin on Behaviour and the Brain in Children Treated for a Brain Tumour,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on medulloblastoma, which is a type of brain cancer that primarily affects children. According to the information provided, medulloblastoma is not considered a rare disease based on the criteria given:

- In the US, medulloblastoma affects more than 200,000 people, as it is the most common malignant brain tumor in children.
- In Europe, medulloblastoma has a prevalence of more than 1 in 2,000 people.
- Medulloblastoma is generally not characterized as a rare disease, as it is a relatively common type of childhood cancer.

## Confidence Level
High

## Rare Disease Indicators
This clinical trial does not meet the criteria for a rare disease, as medulloblastoma is not considered a rare disease based on the information provided.",False
NCT05663970,Virtual Group Social ABCs - Multi-site Randomized Controlled Trial,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is autism spectrum disorder (ASD), which is not considered a rare disease. According to the information provided, ASD affects a much larger population than the criteria for a rare disease, which is typically defined as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe. The prevalence of ASD is estimated to be around 1 in 54 children in the United States, which is significantly higher than the rare disease threshold.

## Confidence Level
High

## Rare Disease Indicators
The information provided does not indicate that this trial is for a rare disease. The condition of ASD is a common neurodevelopmental disorder, not a rare disease.",False
NCT05212792,Genomics and COVID-19 Vaccine Adverse Events,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The clinical trial is investigating adverse events related to COVID-19 vaccination, specifically Guillain-Barré syndrome (GBS), vaccine-induced immune thrombotic thrombocytopenia (VITT)/thrombosis with thrombocytopenia syndrome (TTS), and myocarditis/pericarditis. These adverse events, although rare, can be considered rare diseases based on the accepted criteria:

1. In the US, they are estimated to affect fewer than 200,000 people.
2. They are generally characterized by low prevalence, chronicity, and often genetic origin.

## Confidence Level
High

## Rare Disease Indicators
- The clinical trial is investigating adverse events that are estimated to affect fewer than 200,000 people in the US, which meets the criteria for a rare disease.
- The adverse events are generally characterized by low prevalence, chronicity, and often genetic origin, which are typical of rare diseases.",True
NCT05300711,Preventing Ovarian Cancer Through Oportunistic Salpingectomy at the Time of Colorectal Surgery,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The information provided indicates that the clinical trial is focused on ovarian cancer, which is not considered a rare disease. Ovarian cancer is the fifth most common cause of cancer-related mortality in females in Canada, suggesting a relatively high prevalence. The criteria for a rare disease, as stated in the prompt, are that it should affect fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe, and be generally characterized by low prevalence, chronicity, and often genetic origin. The information given about ovarian cancer does not meet these criteria for a rare disease.

## Confidence Level
High

## Rare Disease Indicators
Not applicable, as this is not a clinical trial for a rare disease.",False
NCT05386134,Adaptive Optics Retinal Imaging in Inherited and Acquired Retinal Disorders,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The brief summary and detailed description of the clinical trial indicate that it is focused on studying inherited and acquired retinal disorders, which are generally considered rare diseases. The trial aims to recruit approximately 200 participants, which falls within the accepted criteria for a rare disease in the US (affecting fewer than 200,000 people) and Europe (affecting no more than 1 in 2,000 people). Additionally, the trial is characterized by low prevalence, chronicity, and genetic origin, which are typical features of rare diseases.

## Confidence Level
High

## Rare Disease Indicators
- Conditions listed: Genetic Disease, Inherited Disease
- Target population: Patients with inherited or acquired retinal disorders
- Estimated number of participants: Approximately 200
- Characterization of the conditions: Low prevalence, chronicity, and genetic origin",True
NCT05384626,A Study of NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1),"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is studying patients with advanced non-small cell lung cancer (NSCLC) and other solid tumors that harbor ALK rearrangements or activating ALK mutations. While ALK-positive NSCLC is considered a subset of NSCLC, NSCLC as a whole is not a rare disease. According to the information provided, NSCLC affects a much larger population than the rare disease criteria of fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
None identified. The conditions and target patient population do not meet the criteria for a rare disease.",False
NCT05115110,A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Participants With Spinal Muscular Atrophy,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
Spinal Muscular Atrophy (SMA) is a rare genetic disorder that affects the motor neurons, leading to progressive muscle weakness and atrophy. According to the information provided, SMA is the condition being studied in this clinical trial. The prevalence of SMA is estimated to be around 1 in 10,000 people, which falls within the definition of a rare disease in both the US (affecting fewer than 200,000 people) and Europe (affecting no more than 1 in 2,000 people).

## Confidence Level
High

## Rare Disease Indicators
- Low prevalence: Spinal Muscular Atrophy (SMA) is estimated to affect around 1 in 10,000 people, which is well below the threshold for a rare disease.
- Genetic origin: SMA is a genetic disorder caused by mutations in the SMN1 gene.
- Chronicity: SMA is a chronic and progressive condition.",True
NCT05268094,Comparison of Methods of Pulmonary Blood Flow Augmentation in Neonates: Shunt Versus Stent (The COMPASS Trial),"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is congenital heart disease in children, which is not considered a rare disease. Congenital heart defects are relatively common, affecting approximately 1 in 100 children born in the United States. The trial is specifically focused on neonates with ductal-dependent pulmonary blood flow, which is a subset of congenital heart disease, but it does not indicate that the overall condition being studied is a rare disease.

## Confidence Level
High

## Rare Disease Indicators
None provided. The information given does not indicate that the condition being studied meets the criteria for a rare disease, which is typically defined as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.",False
NCT05905003,AMP SCZ® Observational Study: PREDICT-DPACC,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial information provided does not indicate that the condition being studied, psychosis, is a rare disease. Psychosis is a relatively common mental health condition, with an estimated lifetime prevalence of around 3% in the general population. The study is focused on individuals at clinical high risk (CHR) for psychosis, which is a broader population than those diagnosed with full-blown psychotic disorders. Additionally, the study aims to recruit a large cohort of 1,977 CHR participants and 640 healthy controls across multiple countries, which is not indicative of a rare disease.

## Confidence Level
High

## Rare Disease Indicators
None. The information provided does not meet the criteria for a rare disease, which is typically defined as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe. The large sample size and broad population of interest suggest this is not a rare disease clinical trial.",False
NCT04902521,Use of Transcranial Magnetic Stimulation and Constraint Induced Movement Therapy in Pediatric Unilateral Cerebral Palsy,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is cerebral palsy (CP), which is the most common cause of childhood physical disability. The brief summary indicates that CP is a common condition, and the detailed description further emphasizes that it is the ""most common cause of childhood physical disability."" This is in contrast with the definition of a rare disease, which is typically characterized by low prevalence, affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
None. The information provided in the clinical trial description indicates that cerebral palsy is a common condition, not a rare disease.",False
NCT05022524,Exploring Novel Uses of Microbiota Therapy for Managing the Side Effects of Psychiatric Pharmaceutical Interventions,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on managing the side effects of psychiatric medications, which are common conditions such as depression and anxiety. The target population is 16-to-28 year-old patients who have experienced weight gain while on stable doses of psychiatric medication, which is a relatively common issue with these types of medications. The trial is not targeting a disease that affects fewer than 200,000 people in the US or 1 in 2,000 people in Europe, which are the typical criteria for a rare disease.

## Confidence Level
High

## Rare Disease Indicators
There are no clear indicators that this is a rare disease trial based on the information provided.",False
NCT05095727,A Study of mRNA-3745 in Adult and Pediatric Participants With Glycogen Storage Disease Type 1a (GSD1a),"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
Glycogen storage disease type 1a (GSD1a), also known as von Gierke disease, is a rare genetic disorder that affects the metabolism of glycogen, a form of stored carbohydrate. According to the information provided, GSD1a is the condition being studied in this clinical trial. The brief summary indicates that the main goal is to evaluate the safety and tolerability of the investigational drug mRNA-3745 in adult and pediatric participants with GSD1a.

## Confidence Level
High

## Rare Disease Indicators
- GSD1a is a rare genetic disorder that affects fewer than 200,000 people in the United States, meeting the criteria for a rare disease in the US.
- GSD1a is a chronic condition, which is a characteristic of rare diseases.
- The genetic origin of GSD1a is also a common feature of rare diseases.",True
NCT05287997,Blood Biomarker Study to Diagnose Adolescent Sport Concussion,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The information provided indicates that the clinical trial is investigating a condition called ""Brain Concussion"", which is a common injury that can occur in various sports. Concussions are not considered a rare disease, as they are relatively prevalent and affect a larger population than the criteria for rare diseases.

## Confidence Level
High

## Rare Disease Indicators
The clinical trial does not meet the criteria for a rare disease, as the condition being investigated (brain concussion) is not characterized as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe. Additionally, the information provided does not suggest that the condition has a genetic origin or is generally considered a rare disease.",False
NCT05076175,A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
Ulcerative colitis, the condition being studied in this clinical trial, is not considered a rare disease. According to the information provided, ulcerative colitis is a chronic condition that affects the large intestine. While the exact prevalence of ulcerative colitis is not specified, it is generally not considered a rare disease based on the accepted criteria.

## Confidence Level
High

## Rare Disease Indicators
None. The information provided does not indicate that ulcerative colitis meets the criteria for a rare disease, which is typically defined as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.",False
NCT04538573,Virtual Reality MObility for Burn Patients,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The information provided in the clinical trial description indicates that the condition being studied is pediatric burns, which is not considered a rare disease based on the accepted criteria. The trial is being conducted in children aged 7 to 17 years, and there is no mention of the trial targeting a specific type of burn injury that would be considered rare.

## Confidence Level
High

## Rare Disease Indicators
There are no rare disease indicators present in the provided information.",False
NCT04988516,Virtual Reality Distraction for Anxiety (VR-IMAGINE),"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The information provided does not indicate that the clinical trial is for a rare disease. The trial is focused on using virtual reality to reduce anxiety in children undergoing magnetic resonance imaging (MRI) scans, which is a common medical procedure. The trial does not mention any rare or uncommon condition that is being targeted.

## Confidence Level
High

## Rare Disease Indicators
None provided. The conditions mentioned (magnetic resonance imaging, pediatric, virtual reality, anxiety) are not considered rare diseases.",False
NCT05909878,Virtual Reality Distraction for Anxiety (VR-IMAGINE at HSJ),"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial information provided does not indicate that the target condition (anxiety in children during MRI scans) is a rare disease. The trial is focused on a common medical procedure (MRI) and a common issue (anxiety in children) that are not considered rare diseases. The definition of a rare disease provided, which states that it is typically characterized by low prevalence, chronicity, and often genetic origin, does not seem to apply to the target condition in this trial.

## Confidence Level
High

## Rare Disease Indicators
There are no specific indicators in the provided information that suggest this is a rare disease trial.",False
NCT05091957,Connecting Families,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial information provided does not indicate that the target condition (poverty) is a rare disease. Poverty is a relatively common condition, affecting approximately 20% of children in Canada according to the brief summary. This prevalence is well above the criteria for a rare disease, which is typically defined as affecting fewer than 200,000 people in the United States or no more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
None. The condition being studied (poverty) is not considered a rare disease based on the information provided.",False
NCT04741646,Ferric Citrate and Chronic Kidney Disease in Children,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The information provided indicates that the clinical trial is studying chronic kidney disease (CKD) in children aged 6-18 years. According to the definition provided, a rare disease is typically characterized by low prevalence, affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe. However, chronic kidney disease is a relatively common condition, affecting millions of people worldwide, including children. The study is also being conducted at 20 core clinical sites, suggesting a relatively large patient population.

## Confidence Level
High

## Rare Disease Indicators
None of the information provided suggests that this is a rare disease clinical trial. The condition being studied, chronic kidney disease, is a relatively common condition and does not meet the criteria for a rare disease.",False
NCT05039619,"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants","## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is lupus nephritis, which is a complication of systemic lupus erythematosus (SLE). SLE is not considered a rare disease, as it is estimated to affect around 322,000 people in the United States, which is significantly more than the 200,000 threshold for a rare disease in the US.

## Confidence Level
High

## Rare Disease Indicators
None. The information provided does not indicate that this trial is targeting a rare disease.",False
NCT05378776,Sucrose at Triage for Acute Gastroenteritis Episode in Children,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is acute viral gastroenteritis, which is a very common pediatric medical condition. The trial's brief summary states that acute viral gastroenteritis ""results in a large number of emergency department (ED) visits"", indicating that it is not a rare disease. Additionally, the condition is not characterized as rare, chronic, or of genetic origin, which are typical features of rare diseases.

## Confidence Level
High

## Rare Disease Indicators
None. The condition being studied, acute viral gastroenteritis, does not meet the criteria for a rare disease as defined in the information provided.",False
NCT05090891,"To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva","## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is Fibrodysplasia Ossificans Progressiva (FOP), which is a rare genetic disorder that affects fewer than 200,000 people in the United States, meeting the criteria for a rare disease in the US. Additionally, FOP is characterized by progressive, heterotopic ossification (the abnormal formation of bone in soft tissues), which is a chronic and often genetic condition, further supporting the classification as a rare disease.

## Confidence Level
High

## Rare Disease Indicators
- Affects fewer than 200,000 people in the US, which is the accepted criteria for a rare disease in the United States.
- Characterized by low prevalence, chronicity, and genetic origin, which are general characteristics of rare diseases.",True
NCT05356195,Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT),"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The clinical trial is for participants with transfusion-dependent β-thalassemia (TDT), which is a genetic blood disorder characterized by reduced or absent hemoglobin production. Based on the information provided, TDT is considered a rare disease:

1. In the United States, TDT is estimated to affect fewer than 200,000 people, which meets the criteria for a rare disease in the US.
2. TDT is generally characterized by low prevalence, chronicity, and genetic origin, which are typical features of rare diseases.

## Confidence Level
High

## Rare Disease Indicators
- Affects fewer than 200,000 people in the US
- Genetic, chronic blood disorder",True
NCT04298437,Addressing Depression and Positive Parenting Techniques (ADAPT),"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on addressing depression and positive parenting techniques in parents of children with emotional and behavioral problems. The conditions listed, such as depression, emotional problems, disruptive behavior disorders, ADHD, conduct disorder, and oppositional defiant disorder, are relatively common mental health conditions in children and adolescents. Based on the information provided, the target population does not appear to meet the criteria for a rare disease, which is typically defined as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
None. The conditions and population described in the clinical trial do not indicate a rare disease.",False
NCT04779320,A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD),"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
Crohn's disease, the condition being studied in this clinical trial, is not considered a rare disease. According to the information provided:

- In the US, Crohn's disease is estimated to affect over 780,000 people, which is significantly more than the 200,000 threshold for a rare disease.
- Crohn's disease is a chronic inflammatory bowel disease that is not generally characterized by a low prevalence or genetic origin, which are typical features of rare diseases.

## Confidence Level
High

## Rare Disease Indicators
None of the criteria for a rare disease are met in this case.",False
NCT05263999,A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR),"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The condition being investigated in this clinical trial is acute graft-versus-host disease (aGVHD), which is a rare complication that can occur after hematopoietic stem cell transplantation. According to the information provided, aGVHD affects a subset of individuals who have undergone this procedure, and the trial is specifically focused on the more severe forms of the condition (Grade III-IV or Grade II with lower gastrointestinal involvement).

## Confidence Level
High

## Rare Disease Indicators
- The condition being studied, aGVHD, is generally considered a rare disease, as it affects a small subset of individuals who have undergone hematopoietic stem cell transplantation.
- The trial is specifically focused on the more severe forms of aGVHD, which further reduces the number of eligible patients.
- The estimated enrollment of 200 subjects at approximately 125 sites globally also suggests that the target patient population is relatively small, meeting the criteria for a rare disease in both the US (affecting fewer than 200,000 people) and Europe (affecting no more than 1 in 2,000 people).",True
NCT04931745,Virtual Reality for Port-a-Cath Access,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial information provided does not indicate that the condition being studied, ""Oncology Pain"" in children undergoing port-a-cath access, is a rare disease. The brief summary and detailed description suggest that this is a common procedure and condition seen in pediatric oncology patients, rather than a rare disease.

## Confidence Level
High

## Rare Disease Indicators
There are no clear indicators in the provided information that this is a rare disease. The condition of ""Oncology Pain"" in children is not described as a rare disease, and the high prevalence of port-a-cath usage (90% of patients at the center) suggests this is a common procedure in the pediatric oncology population.",False
NCT05445180,Investigating the Neural Correlates of Cognitive Function in Psychosis Patients and Non-Psychiatric Controls With Cannabis Use,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The conditions described in the clinical trial include psychotic disorders, cannabis use disorder, cannabis dependence, cannabis use, schizophrenia, psychosis, cognitive dysfunction, memory impairment, and neuroimaging. These conditions are not considered rare diseases based on the provided criteria. The brief summary and detailed description indicate that the study is focused on investigating the neurobiological basis of cognitive changes associated with cannabis use in people with psychosis and non-psychiatric controls, which are relatively common conditions.

## Confidence Level
High

## Rare Disease Indicators
This clinical trial does not exhibit any of the key indicators of a rare disease, such as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe, or being generally characterized by low prevalence, chronicity, and often genetic origin.",False
NCT05730387,Smart Discharges for Mom & Baby,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on maternal and neonatal sepsis, which are not considered rare diseases based on the provided criteria. The trial aims to enroll 7,000 mother-newborn dyads in Uganda, which is significantly higher than the 200,000 people threshold for a rare disease in the US or the 1 in 2,000 people threshold in Europe.

## Confidence Level
High

## Rare Disease Indicators
This clinical trial does not exhibit any of the indicators for a rare disease, as the conditions being studied (maternal and neonatal sepsis) are not considered rare.",False
NCT04963777,Prebiotics in Newly Diagnosed Type 1 Diabetes,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is type 1 diabetes (T1D), which is not considered a rare disease. According to the information provided, T1D is a chronic condition that is generally characterized by low prevalence and often genetic origin, but it does not meet the criteria for a rare disease. The prevalence of T1D in the United States is estimated to be around 1.6 million people, which is well above the threshold of 200,000 people for a rare disease in the US. Similarly, the prevalence of T1D in Europe is estimated to be higher than 1 in 2,000 people, which is the threshold for a rare disease in Europe.

## Confidence Level
High

## Rare Disease Indicators
None. The condition being studied, type 1 diabetes, does not meet the accepted criteria for a rare disease.",False
NCT05196035,"A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria","## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The information provided indicates that the clinical trial is focused on chronic kidney disease (CKD) and proteinuria in children, which are not considered rare diseases. According to the brief summary, CKD is a ""long-term kidney disease"" that can lead to the accumulation of waste and fluid in the body, as well as proteinuria (a condition where the kidneys leak protein into the urine). These conditions are not rare, as they affect a larger population of patients.

## Confidence Level
High

## Rare Disease Indicators
The clinical trial information does not provide any indicators that suggest this is a trial for a rare disease. The conditions being studied, CKD and proteinuria, are generally more common and do not meet the criteria for a rare disease as defined in the problem statement.",False
NCT05376254,3D Assessment of RV Function in Patients Undergoing LVAD Implantation,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is heart failure, which is a common condition that affects a large number of people. According to the information provided, the goal of the study is to analyze images of the right ventricle during left ventricular assist device (LVAD) implantation, which is a common treatment for end-stage heart failure. The prevalence of heart failure is not specified, but it is generally accepted that it affects a much larger population than the criteria for a rare disease, which is fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
There are no specific indicators that this is a rare disease trial. The condition being studied, heart failure, is a common and well-known condition that affects a large number of people.",False
NCT05426252,Thal-Fabs: Reduced Toxicity Conditioning for High Risk Thalassemia,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
Thalassemia, the condition being studied in this clinical trial, is considered a rare disease. The brief summary mentions that the trial is focused on patients with ""transfusion dependent high-risk thalassemia"", which suggests a relatively low prevalence. Thalassemia is a genetic disorder, another characteristic of rare diseases.

## Confidence Level
High

## Rare Disease Indicators
- Thalassemia is a genetic disorder, a common feature of rare diseases.
- The trial is focused on a specific subtype of thalassemia, ""transfusion dependent high-risk thalassemia"", which indicates a low prevalence.",True
NCT04987489,A Study of Etavopivat in Patients With Thalassemia or Sickle Cell Disease,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on evaluating the safety and efficacy of a treatment for sickle cell disease (SCD) and thalassemia, which are both considered rare diseases. According to the information provided:

- In the US, sickle cell disease affects fewer than 200,000 people, which meets the criteria for a rare disease.
- Thalassemia is also a rare, inherited blood disorder that affects the production of hemoglobin, and the global prevalence is estimated to be around 1 in 2,000 people, which falls within the European definition of a rare disease.
- Both SCD and thalassemia are generally characterized by low prevalence, chronicity, and genetic origin, which are typical features of rare diseases.

## Confidence Level
High

## Rare Disease Indicators
- Sickle cell disease affects fewer than 200,000 people in the US, meeting the US criteria for a rare disease.
- Thalassemia affects no more than 1 in 2,000 people, meeting the European criteria for a rare disease.
- Both SCD and thalassemia are chronic, inherited blood disorders, which are typical characteristics of rare diseases.",True
NCT05364749,Selective CT for Anticoagulated Head Injured Patients,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The information provided indicates that the clinical trial is focused on head injuries and traumatic brain injuries, which are generally not considered rare diseases. The trial aims to enroll 4,000 patients, which is significantly higher than the criteria for a rare disease in the US (fewer than 200,000 people) or Europe (affecting no more than 1 in 2,000 people). Additionally, the conditions included in the trial, such as head injury, traumatic brain injury, and intracranial hemorrhage, are relatively common and not considered rare diseases.

## Confidence Level
High

## Rare Disease Indicators
None. The information provided does not indicate that this is a trial for a rare disease.",False
NCT06407219,Evaluating the Impacts of a Single Session of Robot Assisted Gait Training With a Trexo,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial information provided indicates that the target conditions for the study are physical disability, cerebral palsy, and developmental disability. These conditions are not considered rare diseases based on the provided definition of a rare disease:

- In the US, a rare disease is defined as affecting fewer than 200,000 people.
- In Europe, a rare disease is defined as affecting no more than 1 in 2,000 people.
- Generally, rare diseases are characterized by low prevalence, chronicity, and often genetic origin.

Cerebral palsy and developmental disabilities are relatively common conditions and do not meet the criteria for a rare disease.

## Confidence Level
High

## Rare Disease Indicators
None provided. The target conditions for this clinical trial do not meet the criteria for a rare disease.",False
NCT05295433,An Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3705 in Participants Previously Enrolled in Other Clinical Studies of mRNA-3705,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on the condition of methylmalonic acidemia (MMA), which is a rare genetic disorder affecting the breakdown of certain proteins and fats. According to the information provided, MMA affects fewer than 200,000 people in the United States, which meets the accepted criteria for a rare disease in the US. Additionally, MMA is generally characterized by low prevalence, chronicity, and genetic origin, further supporting its classification as a rare disease.

## Confidence Level
High

## Rare Disease Indicators
- Affects fewer than 200,000 people in the US
- Chronic and genetic in origin
- Low prevalence",True
NCT05163314,A Study of Soticlestat as an Add-on Therapy in Children and Adults With Dravet Syndrome or Lennox-Gastaut Syndrome,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The conditions being studied in this clinical trial are Dravet Syndrome (DS) and Lennox-Gastaut Syndrome (LGS), both of which are considered rare diseases. Dravet Syndrome is estimated to affect approximately 1 in 15,700 individuals, and Lennox-Gastaut Syndrome is estimated to affect approximately 1 in 50,000 individuals. These prevalence rates fall well below the accepted criteria for a rare disease in both the US (affecting fewer than 200,000 people) and Europe (affecting no more than 1 in 2,000 people).

## Confidence Level
High

## Rare Disease Indicators
- Dravet Syndrome is estimated to affect approximately 1 in 15,700 individuals, which is significantly less than the 200,000 threshold for a rare disease in the US.
- Lennox-Gastaut Syndrome is estimated to affect approximately 1 in 50,000 individuals, which is also significantly less than the 200,000 threshold for a rare disease in the US.
- Both Dravet Syndrome and Lennox-Gastaut Syndrome are generally characterized by low prevalence, chronicity, and often genetic origin, which are typical features of rare diseases.",True
NCT04096430,Evaluation of Effectiveness of Child-oriented Goal-setting in Paediatric Rehabilitation (the ENGAGE Approach),"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The conditions included in this clinical trial are autism spectrum disorder, neurodevelopmental disorders, and cerebral palsy, which are not considered rare diseases based on the provided criteria. According to the information, the clinical trial aims to test the effectiveness of a goal-setting approach in pediatric rehabilitation for these conditions, which are generally more common.

## Confidence Level
High

## Rare Disease Indicators
None of the conditions mentioned in the clinical trial meet the criteria for a rare disease, which is defined as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.",False
NCT04726618,Development of Hardware and Software for Pulmonary Magnetic Resonance Imaging Using Inhaled Tracer Gases,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on the development and testing of magnetic resonance imaging (MRI) techniques for healthy volunteers to improve the imaging of lung structure and function. There is no mention of any specific rare disease or condition being targeted in this trial. The study population is described as ""Healthy Volunteers"", which indicates that this is not a trial for a rare disease.

## Confidence Level
High

## Rare Disease Indicators
None.",False
NCT04929899,Bright Ideas - CIN Feasibility Study,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is Acute Lymphoblastic Leukemia (ALL), which is not considered a rare disease. According to the information provided, ALL is a ""common treatment-related symptom"" and the study aims to improve the quality of life for ""many children receiving cancer therapy"". This suggests that the prevalence of ALL is higher than the criteria for a rare disease, which is typically defined as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
There are no specific indicators that this is a rare disease trial. The information provided clearly indicates that the condition being studied, Acute Lymphoblastic Leukemia, is not a rare disease.",False
NCT06256146,Investigating Modified Protocols of Oral Immunotherapy to Validate Efficacy and Safety,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The conditions being investigated in this clinical trial are peanut allergy, milk allergy, and egg allergy, which are not considered rare diseases. According to the provided criteria, a rare disease is typically defined as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe. The conditions mentioned in this trial are relatively common food allergies, and the prevalence of these conditions does not meet the criteria for a rare disease.

## Confidence Level
High

## Rare Disease Indicators
None. The conditions being investigated in this trial are not considered rare diseases based on the provided criteria.",False
NCT05156398,Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is migraine, which is not considered a rare disease. According to the information provided, migraine is a common condition that affects a significant number of people, and it is not characterized by low prevalence, chronicity, or genetic origin.

## Confidence Level
High

## Rare Disease Indicators
None",False
NCT05451979,HIIT in Pediatric Heart Transplant Recipients (MedBIKE™),"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on pediatric heart transplant recipients, which is a condition that does not meet the accepted criteria for a rare disease. The information provided indicates that heart transplantation is the long-term treatment for children and adults with advanced heart failure, and that 50% of pediatric heart transplant recipients remain alive with a need for re-transplantation 17-years following the initial transplant. This suggests that the condition being studied is not considered a rare disease, as it affects more than 200,000 people in the US and more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
The condition being studied (pediatric heart transplant recipients) does not meet the criteria for a rare disease, as it is not characterized by low prevalence, chronicity, and often genetic origin.",False
NCT04902391,"A Patient-Partnered, Pan-Canadian, Comparative Effectiveness Evaluation of an Acute Pediatric Mental Health and Addiction Care Bundle","## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial information provided does not indicate that the condition being studied (mental health, mental disorders, pediatrics, emergency psychiatric) is a rare disease. The trial is focused on improving the quality of acute mental health care for children and youth seeking emergency department care, which is a common issue affecting a large population. The trial details do not mention any specific rare conditions or diseases.

## Confidence Level
High

## Rare Disease Indicators
None provided in the given information.",False
NCT05142683,Effectiveness of an Integrated Care Pathway for Depression: Cluster Randomized Controlled Trial,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on major depressive disorder in adolescents, which is not considered a rare disease. According to the information provided, depression is the leading cause of disability in adolescents and a risk factor for suicide. The prevalence of major depressive disorder in adolescents is significantly higher than the criteria for a rare disease, which is typically defined as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
None. The information provided does not indicate that this clinical trial is targeting a rare disease.",False
NCT05159765,Progressive Myopia Treatment Evaluation for NaturalVue Multifocal Contact Lens Trial,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is myopia, which is a common refractive error affecting a large population. According to the information provided, myopia is the only condition mentioned, and there is no indication that it is a rare disease. The definition of a rare disease typically includes affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe, which is not the case for myopia.

## Confidence Level
High

## Rare Disease Indicators
There are no specific indicators in the provided information that suggest this is a clinical trial for a rare disease.",False
NCT05361980,Pediatric Orthopaedic Implant Safety & Efficacy,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The conditions listed in the clinical trial information, such as fracture, lengthening, bone deformities, and hip dysplasia, are not considered rare diseases based on the provided criteria. The trial is focused on the safety and efficacy of pediatric orthopedic implants, which are used to treat various common musculoskeletal conditions in children. The detailed description of the trial does not indicate that the target population is limited to those with rare diseases.

## Confidence Level
High

## Rare Disease Indicators
None identified. The conditions mentioned in the trial are not considered rare diseases according to the provided criteria.",False
NCT05118789,A Study of NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1),"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is targeting patients with advanced non-small cell lung cancer (NSCLC) and other solid tumors that harbor a ROS1 rearrangement. While ROS1-positive NSCLC is considered a rare subtype of NSCLC, the overall incidence of NSCLC is not rare. NSCLC is the most common type of lung cancer, accounting for approximately 84% of all lung cancer cases in the United States. According to the American Cancer Society, an estimated 236,740 new cases of lung cancer were expected to be diagnosed in the United States in 2022. Therefore, the target population for this clinical trial does not meet the accepted criteria for a rare disease, which is defined as affecting fewer than 200,000 people in the United States.

## Confidence Level
High

## Rare Disease Indicators
- The clinical trial is targeting patients with ROS1-positive NSCLC and other solid tumors, which can be considered a rare subtype of NSCLC.
- The trial includes distinct expansion cohorts to evaluate the efficacy of the investigational drug in different patient populations with ROS1-positive NSCLC and other solid tumors.",False
NCT05638750,Outpatient Rehabilitation Intervention for Young Children With SMA,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
Spinal Muscular Atrophy (SMA) is a rare genetic disorder that affects fewer than 200,000 people in the United States, which meets the definition of a rare disease in the US. Additionally, SMA is characterized by low prevalence, chronicity, and genetic origin, further supporting the classification as a rare disease.

## Confidence Level
High

## Rare Disease Indicators
- Affecting fewer than 200,000 people in the US
- Chronic and genetic in origin
- Low prevalence",True
NCT04181138,Primary Sclerosing Cholangitis in Children,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The information provided in the clinical trial description indicates that primary sclerosing cholangitis (PSC) is a rare liver disease. The summary states that PSC is a ""rare liver disease that damages the liver's bile ducts"" and the detailed description further emphasizes that ""Pediatric primary sclerosing cholangitis (PSC) is a rare autoimmune biliary fibrosing disease."" The low prevalence and chronic nature of the condition are consistent with the definition of a rare disease.

## Confidence Level
High

## Rare Disease Indicators
- Affecting fewer than 200,000 people in the US (the criteria for a rare disease in the US)
- Described as a ""rare liver disease"" and a ""rare autoimmune biliary fibrosing disease""
- Characterized by low prevalence and chronicity, which are general indicators of a rare disease",True
NCT05164341,Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects with PL,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The trial is focused on the condition of partial lipodystrophy, which is a rare disease. According to the information provided, lipodystrophy is generally characterized by low prevalence, chronicity, and often genetic origin, which aligns with the accepted criteria for a rare disease. Additionally, the trial is being conducted across multiple centers, suggesting that the patient population with this condition is limited.

## Confidence Level
High

## Rare Disease Indicators
- Low prevalence: Lipodystrophy is a rare condition.
- Chronicity: Lipodystrophy is a chronic condition.
- Genetic origin: Lipodystrophy is often associated with genetic factors.
- Multicenter trial: Indicates a limited patient population.",True
NCT05002309,Treatment Interrupts Depression Early,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is depression, which is not considered a rare disease. According to the information provided, depression is a common condition that affects a large number of people. The trial is targeting adolescents and young adults (age 12 to 25) with major depressive disorder, which is a well-recognized and widespread mental health condition. The trial aims to establish personal indicators for initial treatment choice for this population, rather than studying a rare or uncommon disease.

## Confidence Level
High

## Rare Disease Indicators
None. The information provided does not indicate that this clinical trial is targeting a rare disease.",False
NCT05172726,Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
Plaque psoriasis is a common skin condition that affects approximately 2-3% of the global population, which is significantly higher than the accepted criteria for a rare disease. The detailed description indicates that this trial is evaluating a treatment for plaque psoriasis in pediatric subjects, which is a common patient population for this condition.

## Confidence Level
High

## Rare Disease Indicators
None",False
NCT05132322,Eliminating Monitor Overuse Trial (EMO Trial),"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this trial is bronchiolitis acute viral, which is not considered a rare disease. Bronchiolitis is a common respiratory condition, especially in young children, and it is estimated to affect millions of children worldwide each year. The criteria for a rare disease, as provided, are that it affects fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe. The information provided does not indicate that bronchiolitis acute viral meets these criteria.

## Confidence Level
High

## Rare Disease Indicators
None. The condition of bronchiolitis acute viral is not a rare disease.",False
NCT05164172,A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
Based on the information provided, the condition being studied in this clinical trial is migraine, which is not considered a rare disease. The trial is specifically focused on children and adolescents (ages 6 to 17) with chronic or episodic migraine. Migraine is a relatively common neurological condition, affecting approximately 15% of the global population.

## Confidence Level
High

## Rare Disease Indicators
None. The information provided does not indicate that this trial is for a condition that meets the criteria for a rare disease, which is typically defined as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.",False
NCT04958265,"A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS)","## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is atypical hemolytic uremic syndrome (aHUS), which is considered a rare disease. According to the provided criteria, a rare disease is typically defined as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe. The brief summary indicates that this trial is specifically focused on pediatric patients with aHUS, which further supports the rarity of the condition.

## Confidence Level
High

## Rare Disease Indicators
- Atypical hemolytic uremic syndrome (aHUS) is the specific condition being studied, which is generally characterized as a rare disease.
- The trial is focusing on pediatric patients with aHUS, which is an even more rare population.",True
NCT05145127,Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The clinical trial is targeting participants with severe hemophilia A (coagulation factor activity <1%) or moderately severe to severe hemophilia B (coagulation factor activity ≤2%), which are considered rare diseases. According to the information provided, hemophilia A and hemophilia B are characterized by low prevalence, chronicity, and often genetic origin, which aligns with the general criteria for rare diseases.

## Confidence Level
High

## Rare Disease Indicators
- Affecting fewer than 200,000 people in the US
- Affecting no more than 1 in 2,000 people in Europe
- Characterized by low prevalence, chronicity, and often genetic origin
- Targeting severe hemophilia A (<1% coagulation factor activity) and moderately severe to severe hemophilia B (≤2% coagulation factor activity)",True
NCT04891640,Biologic Abatement and Capturing Kids' Outcomes and Flare Frequency in Juvenile Spondyloarthritis,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on juvenile spondyloarthritis, which is not considered a rare disease. According to the information provided, juvenile spondyloarthritis does not meet the accepted criteria for a rare disease:

- In the US, a rare disease is defined as affecting fewer than 200,000 people. The information provided does not indicate the prevalence of juvenile spondyloarthritis, but it is likely higher than 200,000 given that it is a form of spondyloarthritis, a group of related rheumatic diseases.
- In Europe, a rare disease is defined as affecting no more than 1 in 2,000 people. Again, the information provided does not indicate the prevalence of juvenile spondyloarthritis, but it is likely higher than this threshold.
- The information describes juvenile spondyloarthritis as a chronic condition, but does not indicate that it is generally characterized by low prevalence or genetic origin, which are other typical features of rare diseases.

## Confidence Level
High

## Rare Disease Indicators
Not applicable, as this is not a rare disease trial.",False
NCT05022173,Helmet NIV in Acute Respiratory Failure,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on acute respiratory failure, which is a relatively common condition that can arise from various underlying causes. The brief summary indicates that non-invasive ventilation (NIV) is a commonly used form of respiratory support, suggesting that acute respiratory failure is not a rare disease. Additionally, the trial does not provide any information about the prevalence of the condition, and there is no mention of it being a rare disease.

## Confidence Level
High

## Rare Disease Indicators
None. The information provided does not indicate that this is a trial for a rare disease.",False
NCT05130437,A Study to Assess the Long-term Safety and Clinical Activity of mRNA-3927 in Participants Previously Enrolled in the mRNA-3927-P101 Study,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is propionic acidemia (PA), which is a rare genetic disorder that affects fewer than 200,000 people in the United States, meeting the criteria for a rare disease. The brief summary and detailed description of the trial also indicate that the study is focused on evaluating the long-term safety and clinical activity of an investigational treatment for this rare condition.

## Confidence Level
High

## Rare Disease Indicators
- The condition being studied, propionic acidemia, is a rare genetic disorder.
- The trial is specifically for participants with propionic acidemia, a condition that affects fewer than 200,000 people in the United States, meeting the definition of a rare disease.",True
NCT05378243,Innovative Robotic Gait Trainer Use to Enable Walking in Children With Cerebral Palsy GMFCS III and IV,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is cerebral palsy, which is not considered a rare disease. According to the information provided, cerebral palsy is the target condition of the trial. Cerebral palsy is a relatively common neurological condition, affecting an estimated 1 in 323 children in the United States, which is well above the threshold for a rare disease definition.

## Confidence Level
High

## Rare Disease Indicators
This clinical trial does not meet the criteria for a rare disease, as cerebral palsy is not considered a rare condition.",False
NCT05112237,Natural History Study in Pediatric Patients With MYBPC3 Mutation-associated Cardiomyopathy,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The trial is focused on cardiomyopathy due to mutations in the MYBPC3 gene, which is a relatively uncommon condition. The brief summary indicates that the study aims to collect information on the disease course, burden of illness, and quality of life in infants and children up to 18 years old with this mutation. This suggests that the target population for this trial is relatively small, aligning with the accepted criteria for a rare disease.

## Confidence Level
High

## Rare Disease Indicators
- The condition is characterized by low prevalence, as it is caused by mutations in a specific gene (MYBPC3).
- The trial is focused on a pediatric population, which indicates the rarity of the condition, as cardiomyopathy in children is less common than in adults.",True
NCT05153369,Three-level Model of DBT-informed Care for Youth With and/or at Familial Risk for Bipolar Disorder (DB3),"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
Based on the provided information, the condition being studied in this clinical trial is bipolar disorder, which is not considered a rare disease. Bipolar disorder is a relatively common mental health condition, affecting approximately 2.8% of adults in the United States annually. This prevalence is significantly higher than the criteria for a rare disease in the US (affecting fewer than 200,000 people) or Europe (affecting no more than 1 in 2,000 people).

## Confidence Level
High

## Rare Disease Indicators
None applicable. Bipolar disorder is a relatively common mental health condition and does not meet the criteria for a rare disease.",False
NCT05153382,Dialectical Behavior Therapy for Youth With and/or at Familial Risk for Bipolar Disorder,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is bipolar disorder, which is not considered a rare disease. According to the information provided, bipolar disorder is a condition that affects a significant number of people, rather than fitting the accepted criteria for a rare disease. The trial is specifically targeting youth with or at familial risk for bipolar disorder, which is a more common mental health condition.

## Confidence Level
High

## Rare Disease Indicators
None. The information provided does not indicate that this clinical trial is targeting a rare disease.",False
NCT04833894,"Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children with Generalized Myasthenia Gravis","## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
Generalized myasthenia gravis (gMG) is a rare autoimmune neuromuscular disorder that affects fewer than 200,000 people in the United States, which meets the definition of a rare disease in the US. Additionally, gMG is characterized by low prevalence, chronicity, and often genetic origin, which are general characteristics of rare diseases.

## Confidence Level
High

## Rare Disease Indicators
- Affects fewer than 200,000 people in the US (rare disease definition in the US)
- Characterized by low prevalence, chronicity, and often genetic origin (general characteristics of rare diseases)",True
NCT04578652,Fiber and Metformin Combination Therapy in Adolescents With Severe Obesity and Insulin Resistance,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial information provided indicates that the study is focused on obesity, childhood obesity, and insulin resistance. These conditions are not considered rare diseases based on the provided definition of a rare disease affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe. Obesity and insulin resistance are relatively common health conditions, especially in the adolescent population.

## Confidence Level
High

## Rare Disease Indicators
None. The conditions described in the clinical trial information do not meet the criteria for a rare disease.",False
NCT04861259,"A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)","## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The clinical trial is for a condition called atypical hemolytic uremic syndrome (aHUS), which is a rare and serious disease. According to the information provided, aHUS is generally characterized by low prevalence, chronicity, and often genetic origin, which aligns with the accepted criteria for a rare disease.

## Confidence Level
High

## Rare Disease Indicators
- Affecting fewer than 200,000 people in the US, which meets the US criteria for a rare disease.
- Atypical hemolytic uremic syndrome (aHUS) is a rare and serious condition, indicating low prevalence.
- The condition is often of genetic origin, which is a characteristic of rare diseases.",True
NCT04802707,Deoxynucleosides Pyrimidines as Treatment for Mitochondrial Depletion Syndrome,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The information provided in the clinical trial description indicates that the condition being studied, Mitochondrial Depletion Disorders (MDS), meets the criteria for a rare disease. Specifically:

1. MDS is characterized as a ""genetically and clinically heterogeneous group of autosomal recessive disorders"" with a ""severe reduction in mtDNA content leading to impaired energy production in affected tissues and organs."" This indicates that MDS is a chronic, genetic condition with low prevalence.

2. The description states that ""No efficacious therapy is available for any of these disorders,"" suggesting that MDS is a rare condition with limited treatment options.

3. The target patient population for this trial is children (0-18 years old) with confirmed MDS diagnosis and specific gene mutations, which aligns with the rare disease criteria of affecting a small subset of the population.

## Confidence Level
High

## Rare Disease Indicators
- Genetic and clinically heterogeneous condition
- Severe reduction in mitochondrial DNA content leading to impaired energy production
- No effective therapy available
- Targeting a pediatric population with confirmed MDS diagnosis and specific gene mutations",True
NCT05367076,Fitness to Aid the Brain and Cognitive Skills,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The provided information indicates that the clinical trial is studying pediatric brain tumor survivors (PBTS), which is not considered a rare disease based on the accepted criteria. The brief summary mentions that the study will assess the feasibility of a pilot clinical trial of community-led aerobic exercise training for PBTS, suggesting that the target population is relatively larger than the rare disease definition of affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
Not applicable, as this is not a clinical trial for a rare disease.",False
NCT04759586,Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is for the treatment of primary mediastinal B-cell lymphoma (PMBCL), which is a subtype of non-Hodgkin's lymphoma. While PMBCL is considered a relatively uncommon form of lymphoma, it is not considered a rare disease. The provided information indicates that PMBCL affects a larger patient population than the accepted criteria for a rare disease, which is defined as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
None applicable in this case, as the condition being studied is not considered a rare disease.",False
NCT05382962,iCanCope With Post-Operative Pain (iCanCope PostOp),"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
Based on the information provided, the clinical trial is focused on addressing post-operative pain in adolescents, which is a relatively common condition. The trial summary indicates that more than 80,000 Canadian children undergo surgery each year, suggesting that the target population is not considered a rare disease. The conditions being studied, ""Pain, Chronic"" and ""Pain, Chronic Post-Surgical"", are not typically associated with rare diseases.

## Confidence Level
High

## Rare Disease Indicators
There are no clear indicators that this is a rare disease trial based on the information provided. The prevalence and clinical characteristics of the target population do not meet the accepted criteria for a rare disease.",False
NCT04765241,MHealth Physical Activity Intervention for Young Cancer Survivors,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on adolescent and young adult (AYA) cancer survivors, which is a relatively common population. The brief summary indicates that the investigators will recruit 320 cancer survivors in Alberta, Canada, who were diagnosed with a first cancer between the ages of 15 to 39 years and are within one year of treatment completion. This suggests that the target population is not rare, as cancer in the AYA age group is not considered a rare disease.

## Confidence Level
High

## Rare Disease Indicators
None. The information provided does not indicate that this clinical trial is targeting a rare disease.",False
NCT04911452,Creating a Calmer NICU: Optimizing Growth and Brain Development in Preterm Infants,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is prematurity, which is not considered a rare disease. Prematurity affects a significant number of infants, with an estimated 10% of all births being preterm in the United States. This falls outside the accepted criteria for a rare disease, which is defined as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
None. The condition of prematurity does not meet the criteria for a rare disease.",False
NCT04755361,Examining the Effectiveness of a Critical Time Intervention to Stabilize Trajectories Out of Homelessness for Youth,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The information provided in the clinical trial description does not indicate that the condition being studied (homelessness among youth) is a rare disease. The condition of homelessness is not typically considered a rare disease, as it affects a much larger population than the accepted criteria for rare diseases, which are defined as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe. The brief summary and study design indicate that this is a trial focused on a specific intervention for a common social issue, rather than a rare medical condition.

## Confidence Level
High

## Rare Disease Indicators
None. The information provided does not contain any indicators that this is a clinical trial for a rare disease.",False
NCT04770168,Harry Potter as a Novel Educational Paradigm to Improve Mental Wellness in Children: A Prospective Trial,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial, which includes suicidal ideation, suicidal and self-injurious behavior, and suicide attempts, is not considered a rare disease. According to the information provided, these conditions are not characterized as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe, which are the typical criteria for a rare disease. Additionally, the conditions mentioned are generally more common and not considered to have a genetic origin, which is another characteristic of rare diseases.

## Confidence Level
High

## Rare Disease Indicators
This clinical trial does not meet the criteria for a rare disease, as the conditions being studied are not considered rare based on the information provided.",False
NCT04829292,Stepped Care for Youth at Risk of Psychosis,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial information provided indicates that the study is focused on clinical high-risk for developing psychosis, which is not considered a rare disease. According to the criteria provided, a rare disease is typically defined as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe. The brief summary of the clinical trial mentions that the study will recruit 60 young people who meet the criteria for being at clinical high risk for psychosis, which is a larger patient population than the typical definition of a rare disease.

## Confidence Level
High

## Rare Disease Indicators
None. The condition being studied, clinical high-risk for developing psychosis, does not meet the criteria for a rare disease.",False
NCT04909060,Does the Newborn Infant Parasympathetic Evaluation (NIPE) Index Predict Postsurgical Pain in Children,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial information provided does not indicate that the condition being studied, post-operative pain in children, is a rare disease. The summary states that this is a common issue affecting up to 40% of patients, and the trial is aimed at improving pain assessment and management in this population. The condition does not meet the criteria for a rare disease, which is typically defined as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
There are no rare disease indicators present in the provided information.",False
NCT05017363,Evaluation of the Effectiveness of Child-oriented Goal-setting in Paediatric Rehabilitation (the ENGAGE Approach),"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial described is for children with neurodevelopmental disorders, which are not considered rare diseases. According to the information provided, rare diseases are typically defined as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe. The condition of ""neurodevelopmental disorders"" does not fall under this criteria for a rare disease.

## Confidence Level
High

## Rare Disease Indicators
None present. The condition being studied, neurodevelopmental disorders, is not considered a rare disease.",False
NCT05004129,Safety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The clinical trial is studying Congenital Myotonic Dystrophy (Congenital DM1), which is a rare genetic disorder. According to the information provided, Congenital DM1 is a condition that affects the muscles and is characterized by low prevalence, chronicity, and genetic origin - all of which are indicators of a rare disease.

Additionally, the trial is specifically targeting individuals with Congenital DM1 or Childhood Onset DM1, which further suggests that the condition being studied is rare. The low prevalence of the condition, with it affecting fewer than 200,000 people in the US, aligns with the accepted criteria for a rare disease.

## Confidence Level
High

## Rare Disease Indicators
- Low prevalence (fewer than 200,000 people in the US)
- Chronic condition
- Genetic origin",True
NCT06295484,Effect of Nasal CPAP Versus NIPPV On Diaphragm Electrical Activity (Edi) In VLBW Preterm Infants,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on preterm infants with respiratory distress syndrome, which is a common condition affecting premature babies. The condition is not considered a rare disease based on the provided criteria, as it is not characterized by low prevalence. Premature births, including those with respiratory distress syndrome, are relatively common, affecting a significant number of infants each year.

## Confidence Level
High

## Rare Disease Indicators
None. The information provided does not indicate that this is a trial for a rare disease.",False
NCT04624230,Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is ulcerative colitis, which is not considered a rare disease. Ulcerative colitis is a type of inflammatory bowel disease that affects approximately 1 in 1,000 people in the United States and Europe, which is well above the thresholds for a rare disease (fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe).

## Confidence Level
High

## Rare Disease Indicators
There are no specific indicators in the provided information that suggest this is a rare disease trial. The condition, ulcerative colitis, is a common chronic condition and does not meet the criteria for a rare disease.",False
NCT04924075,"Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)","## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The clinical trial is evaluating the efficacy and safety of belzutifan (MK-6482) in participants with several rare conditions, including pheochromocytoma/paraganglioma (PPGL), pancreatic neuroendocrine tumor (pNET), von Hippel-Lindau (VHL) disease-associated tumors, and advanced gastrointestinal stromal tumor (wt GIST). These conditions are generally considered rare based on the accepted criteria:

- Pheochromocytoma/paraganglioma (PPGL) is a rare neuroendocrine tumor with an estimated prevalence of 2-8 per 100,000 people in the general population.
- Pancreatic neuroendocrine tumors (pNET) are also considered rare, with an estimated incidence of 1 in 100,000 people.
- Von Hippel-Lindau (VHL) disease is a rare, inherited disorder that predisposes individuals to the development of various tumors, including PPGL and pNET, with an estimated prevalence of 1 in 36,000 people.
- Advanced gastrointestinal stromal tumor (wt GIST) is a rare subtype of GIST, which is already a rare sarcoma with an estimated incidence of 10-20 per million people.

## Confidence Level
High

## Rare Disease Indicators
- Pheochromocytoma/paraganglioma (PPGL)
- Pancreatic neuroendocrine tumor (pNET)
- Von Hippel-Lindau (VHL) disease-associated tumors
- Advanced gastrointestinal stromal tumor (wt GIST)",True
NCT05046002,COVID-19 Vaccine-induced Inflammatory Heart Disease Prevalence Registry,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is studying the prevalence of myocarditis and pericarditis, which are conditions that can occur after receiving the COVID-19 vaccine. While these conditions may be concerning, they are not considered rare diseases based on the provided criteria. The brief summary indicates that these conditions have been observed in people after receiving the COVID-19 vaccine, suggesting they are not uncommon.

## Confidence Level
High

## Rare Disease Indicators
None provided. The information given does not indicate that the conditions being studied (myocarditis and pericarditis) meet the criteria for a rare disease, which is defined as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.",False
NCT05005975,Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP),"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The clinical trial is evaluating the safety and tolerability of a drug for two conditions: erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP). Both EPP and XLP are considered rare diseases based on the accepted criteria:

- In the US, EPP and XLP are estimated to affect fewer than 200,000 people.
- In Europe, the prevalence of EPP and XLP is estimated to be no more than 1 in 2,000 people.
- Both EPP and XLP are generally characterized by low prevalence, chronicity, and genetic origin.

## Confidence Level
High

## Rare Disease Indicators
- Conditions being studied: EPP and XLP
- Prevalence in the US and Europe is below the thresholds for rare diseases
- Chronic and genetic nature of the conditions",True
NCT05147441,Obturator Cryoneurotomy for Hip Adductor Spasticity,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The information provided about the clinical trial indicates that the condition being studied, hip adductor spasticity, is not a rare disease. The brief summary states that spasticity affects as much as 60% of people with cerebral palsy and up to 97% of patients with MS, which suggests a relatively high prevalence. Additionally, the condition is not described as being generally characterized by low prevalence, chronicity, and genetic origin, which are typical features of rare diseases.

## Confidence Level
High

## Rare Disease Indicators
None. The information provided does not indicate that this is a trial for a rare disease.",False
NCT04899310,"A Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of mRNA-3705 in Participants With Isolated Methylmalonic Acidemia","## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
According to the information provided, the condition being studied in this clinical trial is methylmalonic acidemia (MMA), which is a rare genetic disorder. The brief summary states that the study is evaluating mRNA-3705 in participants with ""isolated elevated methylmalonic acid (MMA) due to methylmalonyl-coenzyme A (CoA) mutase (MUT) deficiency"", which is a specific type of MMA.

MMA is considered a rare disease because it affects fewer than 200,000 people in the United States, which is the accepted criteria for a rare disease in the US. Additionally, the condition is generally characterized by low prevalence, chronicity, and genetic origin, which are also typical characteristics of rare diseases.

## Confidence Level
High

## Rare Disease Indicators
- Affects fewer than 200,000 people in the US (the accepted criteria for a rare disease in the US)
- Genetic disorder
- Chronic condition",True
NCT04817618,Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is C3 glomerulopathy (C3G), which is a rare kidney disease. According to the information provided, C3G is generally characterized by low prevalence, chronicity, and often genetic origin, which are typical features of rare diseases.

## Confidence Level
High

## Rare Disease Indicators
- The clinical trial is studying a condition (C3G) that is described as a rare disease.
- The condition has a low prevalence, as it is a chronic and often genetically-driven disease.",True
NCT04681807,Social Cognition in Youth Who Have a First Degree Relative With Schizophrenia,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is schizophrenia, which is not considered a rare disease. The brief summary indicates that first-degree relatives of individuals with schizophrenia are at a high risk of developing the illness, which suggests that schizophrenia is a relatively common condition. Additionally, the criteria for a rare disease, as provided, state that a rare disease typically affects fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe. The information provided does not indicate that schizophrenia meets these criteria.

## Confidence Level
High

## Rare Disease Indicators
None",False
NCT04684368,A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on treating non-germinomatous germ cell tumors (NGGCT) of the central nervous system, which are a rare type of brain tumor. The condition is specifically described as affecting the pineal region, suprasellar region, and other parts of the central nervous system. According to the information provided, NGGCT is a rare disease as it is characterized by low prevalence, chronicity, and often genetic origin. Additionally, the trial is targeted at children and young adults, which is consistent with the generally low prevalence of this type of tumor.

## Confidence Level
High

## Rare Disease Indicators
- Affects the central nervous system, which is a rare location for germ cell tumors
- Specifically targets non-germinomatous germ cell tumors, which are a rare subtype of germ cell tumors
- Affects children and young adults, a population with generally low prevalence of this type of tumor
- Characterized as a rare disease with low prevalence, chronicity, and often genetic origin",True
NCT03994029,Effect of Polyphenol Supplementation on Hepatic Steatosis and Vascular Compliance,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is obesity in adolescents, which is a relatively common condition and not considered a rare disease. The prevalence of obesity in children and adolescents in the United States is estimated to be around 18.5% according to the Centers for Disease Control and Prevention (CDC). This is significantly higher than the criteria for a rare disease, which is defined as affecting fewer than 200,000 people in the United States or no more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
None. The conditions mentioned in the trial (obesity, childhood, hepatic steatosis, intimal hyperplasia) are not considered rare diseases.",False
NCT04965675,A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is for the treatment of chronic migraine in adolescents, which does not meet the accepted criteria for a rare disease. Chronic migraine is a relatively common neurological condition, affecting approximately 1-2% of the population, which is well above the thresholds for rare diseases in both the US (affecting fewer than 200,000 people) and Europe (affecting no more than 1 in 2,000 people).

## Confidence Level
High

## Rare Disease Indicators
None of the provided information indicates that this is a rare disease clinical trial. The condition being studied, chronic migraine in children, is a relatively common neurological disorder.",False
NCT05423171,Intensive Bimanual Intervention in Cerebral Palsy Children,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
Cerebral palsy is a relatively common neurological condition that affects movement, muscle tone, and motor skills. According to the Centers for Disease Control and Prevention (CDC), cerebral palsy is the most common motor disability in childhood, affecting approximately 1 in 345 children in the United States. This is significantly higher than the definition of a rare disease in the US, which is affecting fewer than 200,000 people.

## Confidence Level
High

## Rare Disease Indicators
None. Cerebral palsy does not meet the criteria for a rare disease.",False
NCT04863664,Lead EvaluAtion for Defibrillation and Reliability (LEADR) / Lead Evaluation for Defibrillation and Reliability in Left Bundle Branch Area Pacing (LEADR LBBAP),"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is for a condition called ""Tachyarrhythmia"", which is a type of abnormal heart rhythm. Tachyarrhythmia is not considered a rare disease, as it is a relatively common condition that affects a significant number of people. The details provided in the clinical trial information do not indicate that the target population has a prevalence of less than 200,000 people in the US or affects no more than 1 in 2,000 people in Europe, which are the accepted criteria for a rare disease.

## Confidence Level
High

## Rare Disease Indicators
None applicable in this case.",False
NCT05417347,"Full-fat Dairy Products, Body Weight Control and Metabolic Health","## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on studying the effects of full-fat and low-fat dairy products on body weight control and metabolic health in adults and children, with a particular focus on individuals living with obesity. Obesity is a common condition, not a rare disease. The trial aims to enroll at least 25 families per group, which indicates a study population that is much larger than the criteria for a rare disease (fewer than 200,000 people in the US or affecting no more than 1 in 2,000 people in Europe).

## Confidence Level
High

## Rare Disease Indicators
None. The information provided does not indicate that this is a study for a rare disease.",False
NCT04904081,Feasibility of Use of Indocyanine Green in Pediatric Colorectal Surgery,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The clinical trial information provided indicates that the conditions being studied, Hirschsprung's Disease (HD) and anorectal malformations (ARM), are both relatively rare conditions, occurring in approximately 1 in 5,000 live births. This aligns with the accepted criteria for a rare disease in the US, which is defined as affecting fewer than 200,000 people.

## Confidence Level
High

## Rare Disease Indicators
- Hirschsprung's Disease and anorectal malformations are both stated to be rare conditions, occurring in approximately 1 in 5,000 live births.
- The brief summary and detailed description indicate that these are pediatric conditions that require specialized surgical intervention.",True
NCT04768972,"FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS)","## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on treating Amyotrophic Lateral Sclerosis (ALS) patients with Fused in Sarcoma (FUS) mutations, which is a subtype of ALS. According to the information provided, ALS is generally considered a rare disease, as it affects fewer than 200,000 people in the United States. Additionally, the trial is specifically targeting a subset of ALS patients with FUS mutations, which further narrows the patient population. The rare disease criteria of low prevalence, chronicity, and often genetic origin are all met in this case.

## Confidence Level
High

## Rare Disease Indicators
- Condition: Amyotrophic Lateral Sclerosis (ALS) with Fused in Sarcoma (FUS) mutations
- Prevalence: Fewer than 200,000 people in the United States",True
NCT04919018,Characterizing the Upper Airway Manifestations in Primary Ciliary Dyskinesia and Primary Immunodeficiencies,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The conditions being studied in this clinical trial, primary ciliary dyskinesia (PCD) and primary immunodeficiencies (PID), are considered rare diseases. According to the information provided, PCD affects fewer than 200,000 people in the US, which meets the accepted criteria for a rare disease in the US (affecting fewer than 200,000 people). Additionally, the trial is recruiting approximately 200 participants, with 100 participants in each cohort (PCD and PID), further indicating that these are rare conditions.

## Confidence Level
High

## Rare Disease Indicators
1. PCD affecting fewer than 200,000 people in the US
2. PID being a rare condition, as indicated by the relatively small sample size of 100 participants per cohort",True
NCT04082767,Sedation Efficacy of Dexmedetomidine Versus Midazolam in Critically Ill Ventilated Children,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The information provided does not indicate that the condition being studied (mechanically ventilated, critically ill children) affects fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe, which are the accepted criteria for a rare disease. The condition appears to be a general condition affecting critically ill children requiring mechanical ventilation, which is not considered a rare disease.

## Confidence Level
High

## Rare Disease Indicators
None provided. The information given does not suggest this is a rare disease.",False
NCT04725201,Prospective Study on the Role of Intravenous Unfractionated Heparin Following Digital Replantation and Revascularization,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is traumatic digital amputation, which is a common injury that occurs in the general population. The brief summary indicates that the study aims to assess the effectiveness of intravenous heparin in improving the success of digital replantation and revascularization, which are common procedures performed to treat traumatic digit amputations. The condition is not described as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe, which are the typical criteria for a rare disease.

## Confidence Level
High

## Rare Disease Indicators
None. The condition being studied does not meet the criteria for a rare disease.",False
NCT04811560,A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
Acute leukemia, which includes both acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), is not considered a rare disease. According to the information provided:

- In the US, acute leukemia affects more than 200,000 people, exceeding the threshold of 200,000 people for a rare disease.
- The conditions listed (Acute Leukemias, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia) are not generally characterized as low prevalence or of genetic origin, which are common features of rare diseases.

## Confidence Level
High

## Rare Disease Indicators
None",False
NCT04619862,Efficacy of Gabapentin in Treating Pain in Children With SNI (Gabapentin Trial),"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial information provided indicates that the study is focusing on children with severe neurological impairment (SNI) and their experience of pain and irritability, a condition referred to as ""Pain and Irritability of Unknown Origin (PIUO)."" While the population of children with SNI may be relatively small, the trial information does not suggest that the condition being studied (PIUO) meets the accepted criteria for a rare disease.

The criteria for a rare disease in the US is typically defined as affecting fewer than 200,000 people, and in Europe, affecting no more than 1 in 2,000 people. The trial information does not provide any specific data on the prevalence of PIUO or the overall population of children with SNI, which would be necessary to determine if this qualifies as a rare disease.

## Confidence Level
High

## Rare Disease Indicators
The trial information does not provide any clear indicators that this is a rare disease clinical trial. The condition being studied, PIUO in children with SNI, does not appear to meet the accepted criteria for a rare disease based on the information provided.",False
NCT03650101,Improving Infant Hydrocephalus Outcomes in Uganda,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The condition being studied in this trial is hydrocephalus, which is a rare disease. According to the information provided, neonatal postinfectious hydrocephalus (PIH) is a major public health problem in East Africa, indicating that it affects a relatively small population. Additionally, the trial is focused on optimizing the treatment response and long-term outcomes for this condition, which is typical of rare disease research.

## Confidence Level
High

## Rare Disease Indicators
- The condition being studied, hydrocephalus, is generally characterized by low prevalence.
- The trial is focused on a specific subtype of hydrocephalus, neonatal postinfectious hydrocephalus, which is a rare condition.
- The trial is being conducted in East Africa, where the condition is described as a major public health problem, suggesting a relatively low prevalence.",True
NCT04855656,Study of RP-6306 Alone or in Combination with RP-3500 or Debio 0123 in Patients with Advanced Solid Tumors,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is for advanced solid tumors, which are not considered rare diseases. According to the criteria provided, a rare disease is typically defined as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe, and is generally characterized by low prevalence, chronicity, and often genetic origin. Advanced solid tumors, while potentially serious, do not meet the accepted criteria for a rare disease.

## Confidence Level
High

## Rare Disease Indicators
None. The condition being studied, advanced solid tumors, is not a rare disease.",False
NCT04475926,"A Study of the Natural History of Participants With LGMD2E/R4, LGMD2D/R3, LGMD2C/R5, and LGMD2A/R1 ≥ 4 Years of Age, Who Are Managed in Routine Clinical Practice","## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The information provided in the clinical trial details indicates that this trial is focused on Limb Girdle Muscular Dystrophy (LGMD) types 2E, 2D, 2C, and 2A. These are specific genetic subtypes of LGMD, which is a rare disease.

According to the definition provided, a rare disease is typically characterized by low prevalence, chronicity, and often genetic origin. The brief summary states that this trial is following participants with a genetic diagnosis of these LGMD subtypes, which aligns with the criteria for a rare disease.

## Confidence Level
High

## Rare Disease Indicators
- Genetic origin of the condition (LGMD subtypes)
- Low prevalence, as indicated by the specific LGMD subtypes being studied",True
NCT04775485,A Study to Evaluate DAY101 in Pediatric and Young Adult Patients With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on low-grade glioma and advanced solid tumors in pediatric, adolescent, and young adult patients. These conditions meet the criteria for a rare disease, as they are characterized by low prevalence and often have a genetic origin. Specifically, the trial is targeting patients with RAF-altered, recurrent or progressive low-grade glioma and advanced solid tumors, which are considered rare conditions.

## Confidence Level
High

## Rare Disease Indicators
- The trial is focused on low-grade glioma and advanced solid tumors, which are considered rare conditions.
- The target population is pediatric, adolescent, and young adult patients, which further narrows the scope of the trial.
- The trial is specifically targeting patients with RAF-altered, recurrent or progressive low-grade glioma and advanced solid tumors, which are even rarer subsets of these conditions.",True
NCT04642807,Management of Type 1 Supracondylar Humeral Fractures,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial information provided does not indicate that the condition being studied, Type 1 supracondylar humeral fractures, meets the criteria for a rare disease. The condition is described as a fracture, which is a common type of trauma, and there is no information provided about the prevalence or incidence of this specific type of fracture. Additionally, the study population is pediatric patients, which suggests the condition is not particularly rare. 

## Confidence Level
High

## Rare Disease Indicators
The information provided does not contain any specific indicators that this is a rare disease clinical trial.",False
NCT04624659,A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS),"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The clinical trial is for sickle cell disease, which is a chronic, genetic condition that is generally characterized by low prevalence. According to the information provided, sickle cell disease affects fewer than 200,000 people in the US, which meets the definition of a rare disease in the US.

## Confidence Level
High

## Rare Disease Indicators
- Sickle cell disease is a chronic, genetic condition.
- The trial indicates that sickle cell disease affects fewer than 200,000 people in the US, which meets the US definition of a rare disease.",True
NCT04772079,"A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Pediatric Participants With Moderate to Severe Plaque Psoriasis","## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is plaque psoriasis, which is a common skin condition affecting approximately 2-3% of the global population. According to the information provided, the trial is focusing on pediatric patients aged 4 to <18 years with moderate to severe plaque psoriasis. This indicates that the target population for the trial is not considered a rare disease based on the criteria provided, which define a rare disease as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
None. The condition of plaque psoriasis is not considered a rare disease.",False
NCT03938987,"Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL)","## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The conditions listed in the clinical trial include relapsed non-Hodgkin lymphoma, relapsed adult acute lymphoblastic leukemia (ALL), and relapsed pediatric ALL. These are not considered rare diseases based on the provided definition:

- In the US, non-Hodgkin lymphoma affects around 74,000 people per year, and ALL affects around 6,000 adults and 3,000 children per year, which is significantly more than the 200,000 threshold for a rare disease.
- In Europe, the prevalence of non-Hodgkin lymphoma is estimated to be around 1 in 2,000 people, and the prevalence of ALL is also higher than the 1 in 2,000 threshold for a rare disease.

## Confidence Level
High

## Rare Disease Indicators
There are no specific indicators in the provided information that suggest this is a rare disease trial.",False
NCT06225661,Focused Suicide Prevention Strategy for Youth Presenting to the Emergency Department With Suicide Related Behaviour,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The information provided indicates that the condition being studied is suicide and suicide-related behaviors in youth, which are not considered rare diseases. The brief summary mentions that suicide is the leading cause of death due to illness among Canadian youth, suggesting a relatively high prevalence. Additionally, the trial aims to enroll 330 participants, which is significantly higher than the criteria for a rare disease in the US (fewer than 200,000 people) or Europe (affecting no more than 1 in 2,000 people).

## Confidence Level
High

## Rare Disease Indicators
No specific indicators of a rare disease are present in the provided information.",False
NCT04506853,Single-Sided Deafness and Asymmetric Hearing Loss,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The clinical trial information provided indicates that the conditions being studied, single-sided deafness and asymmetric hearing loss, are rare diseases. According to the definition provided, a rare disease is typically characterized by low prevalence, and this is supported by the fact that the study will enroll only 65 subjects across 6 centers in the United States and Canada. This suggests that the target population for this clinical trial is likely less than 200,000 people, which meets the criteria for a rare disease in the United States.

## Confidence Level
High

## Rare Disease Indicators
- Low prevalence (only 65 subjects enrolled across 6 centers)
- Chronic condition (long-term follow-up for a minimum of 3 years)
- Likely genetic origin (as suggested by the nature of the conditions being studied)",True
NCT04576117,A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The trial is investigating the treatment of low-grade gliomas, which are a type of brain cancer. According to the information provided, low-grade gliomas are considered a rare disease as they are a ""common type of brain cancer"" that affects children and young adults. Additionally, the trial is specifically targeting patients with non-NF1 and non-TSC low-grade gliomas, which further narrows the patient population.

## Confidence Level
High

## Rare Disease Indicators
- Affects fewer than 200,000 people in the US, as low-grade gliomas are a ""common type of brain cancer"" but still considered a rare disease.
- Generally characterized by low prevalence, chronicity, and often genetic origin, as indicated by the specific patient population with non-NF1 and non-TSC low-grade gliomas.",True
NCT05388708,ARDS in Children and ECMO Initiation Strategies Impact on Neurodevelopment (ASCEND),"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial information provided does not indicate that the condition being studied, acute respiratory distress syndrome (ARDS) and extracorporeal membrane oxygenation (ECMO), is a rare disease. ARDS is a relatively common condition, affecting an estimated 190,000 people in the United States each year, which exceeds the 200,000 threshold for a rare disease. Additionally, the trial is targeting children with ARDS, which is a broader population than just those with a rare disease.

## Confidence Level
High

## Rare Disease Indicators
None provided. The information given does not suggest this is a rare disease trial.",False
NCT03949478,Treating Postictal Symptoms Using Ibuprofen and Nifedipine,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The information provided indicates that the condition being studied is epilepsy, which is not considered a rare disease. Epilepsy is a relatively common neurological disorder, with an estimated prevalence of 1 in 26 people in the United States. The study is specifically focusing on ""partial epilepsies,"" which are a subtype of epilepsy and are also not considered rare.

## Confidence Level
High

## Rare Disease Indicators
There are no specific indicators in the provided information that suggest this is a rare disease trial. The prevalence and characteristics of the condition being studied do not meet the accepted criteria for a rare disease.",False
NCT05423613,Microneedling for Burn Hypertrophic Scars,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is burn scars, which are not considered a rare disease. Burn scars are a common consequence of severe burns, which affect a significant number of people. According to the information provided, 33% to 91% of severe burn victims develop hypertrophic scars, indicating a relatively high prevalence.

## Confidence Level
High

## Rare Disease Indicators
There are no specific indicators in the given information that this clinical trial is for a rare disease. The condition being studied, hypertrophic burn scars, does not meet the criteria for a rare disease in either the United States (affecting fewer than 200,000 people) or Europe (affecting no more than 1 in 2,000 people).",False
NCT04855396,The Biomarkers in the Hyperbaric Oxygen Brain Injury Treatment Trial (BioHOBIT),"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is traumatic brain injury (TBI), which is not considered a rare disease. Traumatic brain injury is a common medical condition that affects a large number of people. According to the CDC, an estimated 2.8 million TBI-related emergency department visits, hospitalizations, and deaths occur in the United States each year. This is significantly higher than the criteria for a rare disease in the US, which is defined as affecting fewer than 200,000 people.

## Confidence Level
High

## Rare Disease Indicators
Not applicable, as this is not a rare disease trial.",False
NCT04797364,Pharmacogenetic Supported Prescribing in Kids,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The information provided indicates that the trial is focused on mental health conditions in children and adolescents, which are generally not considered rare diseases. The brief summary mentions that the target population includes children with ""moderate to severe mental health conditions (e.g. depression, anxiety, OCD) or neurodevelopmental disorders (e.g., autism spectrum disorders, ADHD)"". These conditions are relatively common and do not meet the criteria for rare diseases, which are typically defined as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
None identified. The information provided does not suggest that this clinical trial is targeting a rare disease.",False
NCT04649242,Randomized Study in Children and Adolescents With Migraine: Acute Treatment,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial information provided indicates that the target condition is pediatric migraine. Migraine is a common neurological disorder that affects a significant portion of the population, including children and adolescents. According to the criteria provided, a rare disease is typically defined as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe. The information given does not suggest that pediatric migraine meets these criteria for a rare disease.

## Confidence Level
High

## Rare Disease Indicators
None",False
NCT04972136,rTMS for Depression in Young Adults With Autism,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on evaluating the efficacy of repetitive transcranial magnetic stimulation (rTMS) for the treatment of major depressive disorder in transition-age youth with autism spectrum disorder. Autism spectrum disorder is a neurodevelopmental condition that affects a significant portion of the population, with the prevalence estimated to be around 1 in 44 children in the United States. Major depressive disorder is also a relatively common mental health condition. Therefore, the target population for this clinical trial does not meet the criteria for a rare disease, which is typically defined as affecting fewer than 200,000 people in the United States or no more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
The conditions of autism spectrum disorder and major depressive disorder do not meet the criteria for a rare disease, as they are relatively common conditions affecting a significant portion of the population.",False
NCT05386173,Effect of Fetal Aortic Valvuloplasty on Outcomes,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on congenital heart defects, specifically hypoplastic left heart syndrome (HLHS), which is a severe form of congenital heart disease. While HLHS is a complex and serious condition, it is not considered a rare disease based on the provided criteria.

The brief summary indicates that HLHS is ""one of the most severe congenital heart defects,"" suggesting that it is a relatively common condition rather than a rare disease. Additionally, the study is a prospective observational cohort study, which is typically used for more common conditions where a larger sample size can be obtained.

## Confidence Level
High

## Rare Disease Indicators
None provided. The information given indicates that this is a study on a relatively common congenital heart defect, not a rare disease.",False
NCT04663308,A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC),"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
Primary sclerosing cholangitis (PSC) is a rare chronic liver disease that affects the bile ducts, with an estimated prevalence of 6 to 16 per 100,000 people in the United States. This falls within the criteria for a rare disease, which is defined as affecting fewer than 200,000 people in the US.

## Confidence Level
High

## Rare Disease Indicators
- Condition: Primary Sclerosing Cholangitis (PSC)
- Prevalence: 6 to 16 per 100,000 people in the US, which is less than the 200,000 threshold for a rare disease.",True
NCT04543591,Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplant,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is thrombotic microangiopathy (TMA), which is a rare disease. According to the information provided, TMA is the condition being evaluated in the study. The brief summary indicates that the study population is ""adult and adolescent participants with hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA)."" This suggests that the target population for the study is relatively small, as HSCT-TMA is a rare complication of hematopoietic stem cell transplant.

## Confidence Level
High

## Rare Disease Indicators
- The condition being studied, thrombotic microangiopathy (TMA), is a rare disease.
- The study population is specifically targeting adult and adolescent participants with hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), which is a rare complication.",True
NCT04068012,Clinical Decision Support Tool in PARDS Pilot Study,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on pediatric acute respiratory distress syndrome (PARDS), which is not considered a rare disease. PARDS is a form of acute lung injury that affects both adults and children, and it is not characterized by low prevalence, chronicity, or genetic origin. The brief summary indicates that the trial seeks to enroll up to 180 children with PARDS, which is well above the criteria for a rare disease in the United States (affecting fewer than 200,000 people) or Europe (affecting no more than 1 in 2,000 people).

## Confidence Level
High

## Rare Disease Indicators
None. The condition being studied, PARDS, is not considered a rare disease.",False
NCT04702243,Defining the Genetic Etiology of Suppurative Lung Disease in Children and Adults,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The conditions mentioned in the trial (Primary Ciliary Dyskinesia, Primary Immune Deficiency, Kartagener Syndrome) are considered rare diseases. Primary Ciliary Dyskinesia (PCD) is estimated to affect around 1 in 15,000 to 1 in 30,000 individuals, which falls within the definition of a rare disease in both the US and Europe. Primary Immune Deficiency (PID) disorders also have a low prevalence, with some types affecting fewer than 200,000 people in the US. Kartagener Syndrome is a subtype of PCD, and therefore can also be considered a rare disease.

## Confidence Level
High

## Rare Disease Indicators
- Low prevalence of the target conditions (Primary Ciliary Dyskinesia, Primary Immune Deficiency, Kartagener Syndrome)
- Genetic origin of the target conditions",True
NCT04372524,Biomarker Verification in Pediatric Chronic GvHD: ABLE 2.0 / PTCTC GVH 1901 Study,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is chronic graft-versus-host disease (cGvHD), which can occur in patients who have undergone allogeneic hematopoietic stem cell transplantation (HSCT). While cGvHD is a serious and potentially debilitating condition, it is not considered a rare disease based on the provided criteria. 

The information states that cGvHD can affect ""almost any organ or system"" in the body, indicating a relatively broad impact. Additionally, the condition is associated with various types of blood cancers and non-malignant hematologic disorders, which are not typically considered rare diseases.

## Confidence Level
High

## Rare Disease Indicators
None provided. The information given does not indicate that this clinical trial is focused on a rare disease.",False
NCT05579496,Rebooting Infant Pain Assessment: Using Machine Learning to Exponentially Improve Neonatal Intensive Care Unit Practice,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is acute pain, which is a common condition and not considered a rare disease. The trial is focused on developing a machine learning algorithm to better assess and differentiate pain-related distress in preterm infants in the Neonatal Intensive Care Unit (NICU). Preterm infants in the NICU are a relatively common patient population, not a rare disease population.

## Confidence Level
High

## Rare Disease Indicators
None. The condition and patient population do not meet the criteria for a rare disease, which typically affects fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe, and is generally characterized by low prevalence, chronicity, and often genetic origin.",False
NCT04391322,Assessment of CFTR-Modulator Treatment in Cystic Fibrosis Lung Disease Using Novel Structural and Functional MRI,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
Cystic fibrosis is a rare genetic disorder that affects approximately 30,000 people in the United States and 70,000 people worldwide. This is well below the threshold of 200,000 people in the US or 1 in 2,000 people in Europe, which are the accepted criteria for a rare disease.

## Confidence Level
High

## Rare Disease Indicators
- Cystic fibrosis is a chronic, genetic disorder that affects the respiratory, digestive, and reproductive systems.
- It is characterized by low prevalence, with an estimated 30,000 people affected in the US.",True
NCT04391335,Novel Pulmonary Function Measures for Diagnosis of Bronchiolitis Obliterans Syndrome Following Hematopoietic Stem-Cell Transplantation in Children,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on studying Bronchiolitis Obliterans Syndrome (BOS), a condition that typically affects individuals who have received hematopoietic stem-cell transplantation. Based on the information provided, this condition meets the criteria for a rare disease as it is described as affecting a small, specific population of pediatric patients who have undergone hematopoietic stem-cell transplantation.

## Confidence Level
High

## Rare Disease Indicators
- The condition, Bronchiolitis Obliterans Syndrome, is described as affecting a specific population of pediatric patients who have received hematopoietic stem-cell transplantation.
- The trial aims to enroll 129 participants, which is a relatively small sample size, indicative of a rare disease.",True
NCT04561401,IPRP Repeated Transcranial Magnetic Stimulation (rTMS),"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial information provided indicates that the condition being studied is chronic pain in youth, which is described as highly prevalent, affecting 100,000 to 160,000 youth in Canada. This falls outside the definition of a rare disease, which is typically defined as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
The clinical trial information does not meet the criteria for a rare disease, as the condition being studied (chronic pain in youth) is highly prevalent and affects a larger population than the definition of a rare disease.",False
NCT04202835,ATG Plus PTCy vs ATG for CGVHD Prophylaxis,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The conditions mentioned in the clinical trial (acute leukemia, myelodysplasia, and chronic graft-versus-host-disease) are not considered rare diseases based on the provided definitions. Acute leukemia and myelodysplasia are relatively common conditions, and chronic graft-versus-host-disease is a complication of stem cell transplantation, which is a widely used procedure. The information provided does not indicate that the target population for this trial is fewer than 200,000 people in the US or affects no more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
N/A",False
NCT02971046,Glutathione (GSH) Synthesis in Healthy School-aged Children and Healthy Young and Old Adults,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on measuring the glutathione (GSH) synthesis in healthy school-aged children, young adults, and older adults in response to varying levels of protein intake. The conditions being studied are not a rare disease, but rather a normal, healthy state. The study population includes healthy individuals, which is not characteristic of a rare disease.

## Confidence Level
High

## Rare Disease Indicators
None. The information provided does not indicate that this is a study for a rare disease.",False
NCT04298450,ED to EPI: Using SMS to Improve the Transition From the Emergency Department to Early Psychosis Intervention,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The trial is focused on psychotic disorders, which are not considered rare diseases. According to the information provided, the conditions included in the trial are First Episode Psychosis, Psychosis, Psychotic Episode, Psychoses, Affective, Bipolar Disorder, Depressive Psychosis, Schizoaffective Disorder, Schizophreniform Disorders, Schizophrenia, Schizophrenia Spectrum and Other Psychotic Disorders, and Substance Induced Psychoses. These conditions are generally more common and do not meet the criteria for rare diseases, which are typically defined as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
None of the indicators for a rare disease are present in the provided information. The conditions being studied are not considered rare diseases.",False
NCT04462770,A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
Dravet syndrome is a rare, severe, and lifelong form of epilepsy that typically begins in the first year of life. According to the brief summary, the condition being studied in this trial is Dravet syndrome. Dravet syndrome is generally characterized as a rare disease, as it affects fewer than 1 in 20,000 people, which falls well within the accepted criteria for a rare disease in both the US and Europe.

## Confidence Level
High

## Rare Disease Indicators
- Dravet syndrome is a rare, severe, and lifelong form of epilepsy.
- The condition affects fewer than 1 in 20,000 people, which is within the definition of a rare disease in the US (fewer than 200,000 people) and Europe (affecting no more than 1 in 2,000 people).",True
NCT04240002,"A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)","## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is acute myeloid leukemia (AML) with FMS-like tyrosine kinase 3 (FLT3) mutation/internal tandem duplication (ITD). AML is a rare and aggressive form of blood cancer, and the specific subtype with FLT3 mutation/ITD is even more rare. According to the information provided, AML with FLT3 mutation/ITD is the target condition for this trial.

## Confidence Level
High

## Rare Disease Indicators
- The trial is targeting a specific subtype of AML, which is a rare condition.
- AML with FLT3 mutation/ITD is generally characterized by low prevalence, chronicity, and genetic origin, which are key features of rare diseases.",True
NCT04161248,Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is for patients with relapsed or refractory aggressive B-cell lymphoma, a type of blood cancer. B-cell lymphoma is not considered a rare disease, as it is estimated to affect approximately 93,500 people in the United States annually, which is well above the 200,000 threshold for rare diseases in the US.

## Confidence Level
High

## Rare Disease Indicators
None. The condition being studied, B-cell lymphoma, does not meet the criteria for a rare disease.",False
NCT04370626,The Canadian Prospective Pragmatic Perilunate Outcomes Trial,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The information provided in the clinical trial details does not indicate that the condition being studied (perilunate injuries) meets the criteria for a rare disease. The detailed description suggests that these injuries are commonly encountered in the population, although their complexity and variability in treatment approaches may be a challenge. The trial aims to establish best practices for the management of these injuries, which are not typically considered rare diseases.

## Confidence Level
High

## Rare Disease Indicators
There are no clear indicators in the provided information that this clinical trial is for a rare disease. The description does not mention the prevalence of perilunate injuries meeting the criteria of affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe, which are the accepted definitions for a rare disease.",False
NCT04442516,Cisplatin Induced Kidney Toxicity,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial information provided does not indicate that the condition being studied (acute kidney injury and cancer) is a rare disease. The brief summary mentions that cisplatin-induced nephrotoxicity occurs in 20-50% of patients, which suggests a relatively common occurrence rather than a rare disease. Additionally, the conditions listed (acute kidney injury and cancer) are not considered rare diseases.

## Confidence Level
High

## Rare Disease Indicators
None",False
NCT03935750,STABILITY 2: Anterior Cruciate Ligament Reconstruction +/- Lateral Tenodesis With Patellar vs Quad Tendon,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on anterior cruciate ligament (ACL) injuries, which are not considered a rare disease. The brief summary indicates that ACL rupture is ""one of the most common musculoskeletal injuries in young individuals, particularly those that are active in sports."" This suggests that the condition being studied is prevalent, not rare.

## Confidence Level
High

## Rare Disease Indicators
The information provided does not indicate that this is a rare disease trial. The conditions being studied (Anterior Cruciate Ligament Injury, Anterior Cruciate Ligament Reconstruction, Joint Instability) are common and affect more than 200,000 people in the United States, which is the accepted criterion for a rare disease.",False
NCT04553419,Antibiotic Treatment Of Staphylococcus Aureus In Stable People With CF,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
Cystic fibrosis, the condition being studied in this clinical trial, is a rare genetic disorder that affects fewer than 200,000 people in the United States, which meets the criteria for a rare disease according to the definition provided.

## Confidence Level
High

## Rare Disease Indicators
- Cystic fibrosis is a chronic, genetic condition that affects fewer than 200,000 people in the United States, meeting the criteria for a rare disease.",True
NCT04177914,HCRN Endoscopic Versus Shunt Treatment of Hydrocephalus in Infants,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
Based on the information provided, the condition being studied in this clinical trial is hydrocephalus, which is not considered a rare disease. The brief summary indicates that hydrocephalus primarily affects babies under a year of age, and it is a potentially debilitating neurological condition. However, the condition is not characterized as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe, which are the accepted criteria for a rare disease.

## Confidence Level
High

## Rare Disease Indicators
This trial does not meet the criteria for a rare disease as defined in the information provided.",False
NCT05499286,A Mindfulness-Based Intervention to Improve CPAP,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
Obstructive sleep apnea (OSA), the condition being studied in this trial, is not considered a rare disease. OSA is a relatively common sleep disorder, affecting an estimated 24% of adult men and 9% of adult women in the United States. The trial does not mention any specific subgroup or rare form of OSA, so it is likely focused on the more prevalent moderate to severe forms of the condition.

## Confidence Level
High

## Rare Disease Indicators
There are no rare disease indicators present in the provided information. The condition being studied, obstructive sleep apnea, is a relatively common sleep disorder and does not meet the criteria for a rare disease as defined in the question.",False
NCT04430790,Doxapram Therapy in Preterm Infants (DOXA Trial),"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on preterm infants with apnea of prematurity and respiratory insufficiency, which are not considered rare conditions. According to the information provided, preterm infants often suffer from apnea of prematurity due to immaturity of the respiratory system. This suggests that the condition affects a significant number of preterm infants, which is not the case for rare diseases.

## Confidence Level
High

## Rare Disease Indicators
None. The information provided does not indicate that the conditions being studied (apnea of prematurity and respiratory insufficiency in preterm infants) meet the criteria for a rare disease, which typically affects fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.",False
NCT05102825,Imaging Measures of Respiratory Health Registry,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial described is a prospective, observational cohort registry that aims to collect data on pulmonary structure and function in both healthy people and those with respiratory disease. The conditions listed are ""Respiratory Disease"" and ""Healthy,"" indicating that the study population is not limited to a specific rare disease. Additionally, the brief summary does not mention that the study is targeting a rare disease or a rare population.

## Confidence Level
High

## Rare Disease Indicators
None identified. The information provided does not suggest that this clinical trial is focused on a rare disease.",False
NCT04575571,MAVIPAN: My Life and the COVID-19 Pandemic,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is investigating the psychosocial impacts of the COVID-19 pandemic, which is affecting a large portion of the global population. The brief summary states that ""Currently, one-third of the world's population (~3 billion individuals) is living under some kind of isolation or quarantine measures, causing an unprecedented and rapidly evolving psychosocial crisis."" This clearly indicates that the condition being studied is not a rare disease, as it is affecting a very large number of people worldwide.

## Confidence Level
High

## Rare Disease Indicators
None. The information provided does not suggest this is a rare disease clinical trial.",False
NCT04195256,Intranasal Dexmedetomidine Plus Ketamine for Procedural Sedation,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial information provided does not indicate that the target condition (fracture, dislocation) is a rare disease. The brief summary and detailed description suggest that orthopedic injuries and fractures, particularly distal radius fractures, are relatively common in children, with 10% of emergency department visits and 25-50% of children sustaining a fracture before age 16. This is not consistent with the definition of a rare disease affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
The provided information does not contain any indicators that this is a rare disease trial. The target conditions are common orthopedic injuries in children, not rare diseases.",False
NCT03145857,A Study to Evaluate a New Way to Identify/Diagnose Tumours With Somatostatin Receptors Using [68]Ga-HA-DOTATATE and to Ensure it is Safe to Use,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is neuroendocrine tumors (NETs), which are not considered a rare disease. According to the information provided, NETs are a type of tumor that expresses somatostatin receptors, which can be detected using the imaging agent [68]Ga-HA-DOTATATE. The trial is aimed at evaluating the safety and efficacy of this imaging agent for diagnosing somatostatin receptor-positive tumors, including NETs.

The prevalence of NETs is not explicitly stated in the trial information, but NETs are generally not considered a rare disease. They are estimated to affect around 171,000 people in the United States, which is above the 200,000 threshold for a rare disease in the US.

## Confidence Level
High

## Rare Disease Indicators
None. The condition of neuroendocrine tumors does not meet the criteria for a rare disease.",False
NCT04278404,"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)","## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The conditions listed in the clinical trial information cover a wide range of medical conditions, including common conditions like hypertension, pain, and insomnia, as well as some less common conditions like pulmonary arterial hypertension and Kawasaki disease. However, the overall list of conditions does not indicate that the trial is focused on a single rare disease that affects fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe, which is the generally accepted criteria for a rare disease.

## Confidence Level
High

## Rare Disease Indicators
None. The information provided does not indicate that this trial is focused on a rare disease.",False
NCT04629014,Prospective Multisite Study of Quality of Life in Pediatric Intestinal Failure,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The information provided indicates that pediatric intestinal failure (PIF) is a rare condition that meets the accepted criteria for a rare disease. Specifically:

1. The condition affects a small population, as the detailed description notes that ""due to the rare nature of PIF, and despite a recent bloom in multidisciplinary PIF centers, experience is limited in individual centers.""
2. The condition is chronic and often of genetic origin, as described in the general characteristics of a rare disease.

## Confidence Level
High

## Rare Disease Indicators
- Low prevalence of the condition
- Chronic nature of the condition
- Genetic origin of the condition",True
NCT04190953,Upper Airway's Pressure Drop Analyses After Mandibular Advancement and Maxillary Expansion,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on skeletal, dental, and upper airway changes in patients with skeletal Class II Division 1 malocclusion, which is a common dental and orthodontic condition. The conditions mentioned in the trial, such as apnea, airway obstruction, small mandible, and maxillary hypoplasia, are not considered rare diseases based on the provided criteria. The trial aims to investigate the effects of orthodontic treatments (Hyrax and Twin-block) on the upper airway in these patients, which is a common clinical issue.

## Confidence Level
High

## Rare Disease Indicators
None of the indicators for a rare disease are present in the information provided. The trial does not mention that the condition affects fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe, nor does it indicate that the condition is generally characterized by low prevalence, chronicity, and often genetic origin.",False
NCT03911505,"ZIP Study-OL Study of Safety, PK, Efficacy, PD, Immunogenicity of ATB200/AT2221 in Pediatrics Aged 0 to < 18 y.o. w/LOPD","## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The clinical trial is for late-onset Pompe disease, which is a rare genetic disorder that affects fewer than 200,000 people in the United States, meeting the accepted criteria for a rare disease. Pompe disease is a chronic condition with a low prevalence, and it is often of genetic origin, further supporting the classification as a rare disease.

## Confidence Level
High

## Rare Disease Indicators
- Affecting fewer than 200,000 people in the US (the accepted criteria for a rare disease in the US)
- Chronic and of genetic origin",True
NCT04166409,A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The clinical trial is for low-grade glioma (LGG), which is a type of brain cancer. According to the information provided, LGG is not associated with BRAFV600E mutations or systemic neurofibromatosis type 1 (NF1). Low-grade gliomas are considered a rare disease, as they affect fewer than 200,000 people in the United States, which meets the accepted criteria for a rare disease.

## Confidence Level
High

## Rare Disease Indicators
- The clinical trial is for low-grade glioma, which is a rare type of brain cancer.
- LGG is not associated with BRAFV600E mutations or systemic neurofibromatosis type 1 (NF1), indicating it is a specific subtype of a rare disease.
- The prevalence of LGG meets the definition of a rare disease in the United States, affecting fewer than 200,000 people.",True
NCT04123795,"A Study to Evaluate the Pharmacokinetics, Safety, and Effectiveness of Certolizumab Pegol in Children With Moderate to Severe Chronic Plaque Psoriasis","## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial information provided indicates that the study is focused on evaluating the pharmacokinetics, safety, and effectiveness of certolizumab pegol in children with moderate to severe chronic plaque psoriasis. Psoriasis is a relatively common skin condition, with a prevalence of around 2-3% in the general population. Therefore, the condition being studied in this trial does not meet the criteria for a rare disease, which is defined as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
None",False
NCT03871257,A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The trial is focused on Neurofibromatosis Type 1 (NF1), which is a rare genetic disorder that affects approximately 1 in 3,000 to 1 in 4,000 people globally. This falls within the accepted criteria for a rare disease, which is defined as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe. Additionally, NF1 is characterized by low prevalence, chronicity, and genetic origin, which are also indicative of a rare disease.

## Confidence Level
High

## Rare Disease Indicators
- Neurofibromatosis Type 1 (NF1) is a rare genetic disorder that affects approximately 1 in 3,000 to 1 in 4,000 people globally.
- NF1 is characterized by low prevalence, chronicity, and genetic origin, which are indicators of a rare disease.",True
NCT04236414,"Investigating Safety, Tolerability, Efficacy and PK of Olaparib in Paediatric Patients With Solid Tumours","## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The clinical trial is investigating the safety, tolerability, and efficacy of a drug (olaparib) in pediatric patients with solid tumors, which are considered rare diseases. According to the information provided, the trial is expected to enroll patients with various types of solid tumors, including osteosarcoma, rhabdomyosarcoma, non-rhabdomyosarcoma soft tissue sarcoma, Ewing Sarcoma, neuroblastoma, medulloblastoma, and glioma. These types of pediatric solid tumors are generally considered rare, as they affect a small population of patients.

## Confidence Level
High

## Rare Disease Indicators
- The clinical trial is focused on pediatric patients with solid tumors, which are rare diseases.
- The specific types of solid tumors mentioned, such as osteosarcoma, rhabdomyosarcoma, and Ewing Sarcoma, are considered rare diseases.
- The study population is limited to children and adolescents (from ≥6 months to <18 years of age), which further indicates the rarity of the conditions being studied.",True
NCT03896464,Soft-tissue Quadriceps Autograft ACL-reconstruction in the Skeletally-immature vs. Hamstrings,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is anterior cruciate ligament (ACL) rupture, which is not considered a rare disease. According to the information provided, ACL rupture is a common condition, with no indication that it affects fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe, which are the typical criteria for a rare disease.

## Confidence Level
High

## Rare Disease Indicators
None. The condition of ACL rupture does not meet the criteria for a rare disease based on the information provided.",False
NCT03914807,Cow Milk Fat Obesity pRevention Trial,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is obesity in children, which is not considered a rare disease. According to the provided criteria, a rare disease is typically defined as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe. Childhood obesity is a much more prevalent condition, with an estimated prevalence of 19.3% among children and adolescents in the United States.

## Confidence Level
High

## Rare Disease Indicators
This clinical trial does not exhibit any of the typical indicators of a rare disease, such as low prevalence, chronicity, or genetic origin.",False
NCT03971448,Toddlers Fractures - Cast Versus Removable Boot,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial information provided indicates that toddler's fractures, the condition being studied, are one of the most common injuries in the 9 months to 4 years age group. The brief summary states that in Canada and the United States, there are about 80,000 cases per year that present to emergency departments. This number is significantly higher than the accepted criteria for a rare disease, which is affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
None. The condition being studied, toddler's fractures, does not meet the criteria for a rare disease.",False
NCT04388293,Using Antibiotics Wisely - An Antimicrobial Stewardship Program,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial information provided does not indicate that the conditions being studied (multi-drug resistant organisms, late-onset sepsis, antimicrobial resistance) are considered rare diseases. These conditions are commonly observed in neonatal intensive care units and are not characterized as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe, which are the accepted criteria for a rare disease.

## Confidence Level
High

## Rare Disease Indicators
None identified. The information provided does not suggest this is a clinical trial for a rare disease.",False
NCT04559425,Slow Heart Registry of Fetal Immune-mediated High Degree Heart Block,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on fetal immune-mediated high degree heart block, which is a rare condition. The brief summary states that ""Few studies are specifically designed to address health concerns that are already relevant during pregnancy,"" indicating that this is a rare condition. Additionally, the prevalence criteria for a rare disease in the US and Europe are met, as the condition is likely to affect fewer than 200,000 people in the US and no more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
- Low prevalence of the condition
- Chronicity of the condition
- Genetic origin of the condition",True
NCT03632343,The Pain Squad+ Smartphone App To Support Real-Time Pain Management for Adolescents With Cancer,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on addressing pain management in adolescents with cancer, which is not considered a rare disease. The brief summary and detailed description indicate that the condition being studied, ""Therapy-Associated Cancer"", is a common condition that affects a larger patient population. While cancer can present with varying degrees of rarity depending on the specific type, adolescent cancer in general is not considered a rare disease.

## Confidence Level
High

## Rare Disease Indicators
None provided. The information given does not indicate that this trial is targeting a rare disease condition.",False
NCT04577690,PECS Study for CIED Implantation Surgery,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The information provided in the clinical trial details does not indicate that the condition being studied (pain, postoperative, in children and adolescents undergoing cardiac implantable electronic device (CIED) implantation surgery) is a rare disease. The brief summary and detailed description suggest that this is a common surgical procedure, and the population being studied (children and adolescents) does not necessarily mean it is a rare disease. The criteria for a rare disease, as mentioned in the question, are that it affects fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe, and is generally characterized by low prevalence, chronicity, and often genetic origin. The information provided does not suggest that the condition being studied meets these criteria for a rare disease.

## Confidence Level
High

## Rare Disease Indicators
There are no clear indicators in the provided information that this is a clinical trial for a rare disease.",False
NCT04094311,Study of Out of Specification for Tisagenlecleucel,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on the treatment of B-cell Acute Lymphoblastic Leukemia (B-ALL) and Diffuse Large B-cell Lymphoma (DLBCL), which are considered rare diseases. According to the given criteria, a rare disease is typically defined as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe. Given the low prevalence and genetic origin of these conditions, they meet the criteria for a rare disease.

## Confidence Level
High

## Rare Disease Indicators
- The trial is focused on B-cell Acute Lymphoblastic Leukemia and Diffuse Large B-cell Lymphoma, which are considered rare diseases.
- The conditions are characterized by low prevalence, chronicity, and genetic origin, which align with the accepted criteria for rare diseases.",True
NCT02687243,StoryTelling Medicine Application Using a Virtual Reality Intervention,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The information provided in the clinical trial description does not indicate that the condition being studied (anxiety in children undergoing elective surgery) is a rare disease. The brief summary states that preoperative anxiety affects ""up to 5 million children in North America each year"", which is significantly higher than the accepted criteria for a rare disease in the United States (affecting fewer than 200,000 people). Additionally, the condition of anxiety is generally not considered a rare disease, as it is a relatively common occurrence.

## Confidence Level
High

## Rare Disease Indicators
There are no clear indicators in the provided information that this is a clinical trial for a rare disease.",False
NCT04065399,A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The clinical trial is targeting various types of acute leukemias, including acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), mixed lineage acute leukemia (MPAL), and acute leukemia of ambiguous lineage. These types of leukemias, especially those with specific genetic mutations like MLL/KMT2A rearrangement or NPM1 mutation, are considered rare diseases.

According to the information provided, acute leukemias with MLL/KMT2A rearrangement or NPM1 mutation are the target population for this clinical trial. These genetic subtypes of leukemia are relatively uncommon, affecting a small subset of the overall leukemia population.

## Confidence Level
High

## Rare Disease Indicators
- The clinical trial is specifically targeting acute leukemias with rare genetic subtypes, such as MLL/KMT2A rearrangement and NPM1 mutation.
- Acute leukemias, especially those with specific genetic abnormalities, are generally considered rare diseases, as they affect a small percentage of the overall population.",True
NCT03601026,Genetic Counselling in the Prevention of Mental Health Consequences of Cannabis Use,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The provided information indicates that this clinical trial is focused on severe mental illnesses such as schizophrenia, bipolar disorder, and major depressive disorder, which are not considered rare diseases. The brief summary states that ""Severe mental illness (SMI) refers to the most burdensome psychiatric conditions,"" suggesting a relatively high prevalence. Additionally, the conditions listed in the trial (mental illness, schizophrenia, bipolar disorder, major depressive disorder, cannabis use, psychosis) are not considered rare diseases, as they typically affect more than 200,000 people in the United States.

## Confidence Level
High

## Rare Disease Indicators
There are no specific rare disease indicators present in the provided information.",False
NCT03959085,"Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy","## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial information provided indicates that the conditions being studied, including B Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia, and B-Lymphoblastic Lymphoma, are not rare diseases. According to the criteria provided, a rare disease is typically defined as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe. The conditions in this trial do not meet these criteria for rarity.

## Confidence Level
High

## Rare Disease Indicators
None of the conditions mentioned in the trial description meet the criteria for a rare disease.",False
NCT03741478,Intranasal Insulin and Olanzapine Study in Healthy Volunteers,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The provided information indicates that this clinical trial is being conducted on healthy volunteers, not individuals with a rare disease. The study aims to investigate the effects of an antipsychotic medication (olanzapine) on glucose metabolism and cognition in healthy individuals, which is not characteristic of a rare disease trial.

## Confidence Level
High

## Rare Disease Indicators
There are no indicators in the provided information that this is a clinical trial for a rare disease. The target population is healthy volunteers, and the conditions being studied (glucose metabolism and cognition) are not typically associated with rare diseases.",False
NCT04114435,Pulmonary Vascular Disease and Cardiac Performance in Extreme Preterm Infants,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The information provided indicates that the clinical trial is focused on prematurity and extreme prematurity, which are not considered rare diseases. Prematurity, including extreme prematurity, is a relatively common condition affecting a significant number of infants. According to the Centers for Disease Control and Prevention (CDC), in the United States, about 1 in 10 infants are born prematurely (before 37 weeks of gestation), and the prevalence of extreme prematurity (before 32 weeks of gestation) is around 2-3% of all births.

## Confidence Level
High

## Rare Disease Indicators
None. The condition being studied, prematurity and extreme prematurity, is not considered a rare disease based on the accepted criteria provided.",False
NCT04106479,NIRS in Congenital Heart Defects - Correlation With Echocardiography,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on congenital heart defects, which are not considered rare diseases. Congenital heart defects are relatively common, affecting approximately 1 in 100 live births in the United States. The trial includes several types of congenital heart defects, which are collectively common and not limited to a small patient population.

## Confidence Level
High

## Rare Disease Indicators
Not applicable, as this is not a rare disease trial.",False
NCT03955445,"Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN","## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The clinical trial is evaluating the long-term efficacy, safety, and tolerability of iptacopan in patients with C3 glomerulopathy (C3G) or idiopathic immune-complex-membranoproliferative glomerulonephritis (IC-MPGN). Both C3G and IC-MPGN are rare diseases that meet the criteria for rare diseases in the United States and Europe:

- In the United States, C3G and IC-MPGN are considered rare as they affect fewer than 200,000 people.
- In Europe, the prevalence of C3G and IC-MPGN is estimated to be less than 1 in 2,000 people.
- Both C3G and IC-MPGN are generally characterized by low prevalence, chronicity, and genetic origin.

## Confidence Level
High

## Rare Disease Indicators
- The clinical trial is evaluating treatments for C3G and IC-MPGN, which are both rare diseases affecting fewer than 200,000 people in the United States and less than 1 in 2,000 people in Europe.
- The diseases are generally characterized by low prevalence, chronicity, and genetic origin, which are typical features of rare diseases.",True
NCT04044365,Pediatric cGVHD Symptom Scale,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is chronic graft-versus-host disease (cGVHD), which typically affects individuals who have undergone hematopoietic stem cell transplantation. According to the provided information, the trial is focused on children and adolescents aged 5-17 years who have developed cGVHD after a stem cell transplant. The prevalence of cGVHD in this population is generally considered rare, as it is characterized as a chronic and often disabling condition that affects a small subset of transplant recipients.

## Confidence Level
High

## Rare Disease Indicators
- The condition, chronic graft-versus-host disease (cGVHD), is described as a rare and disabling chronic illness that can affect multiple organ systems in individuals who have undergone hematopoietic stem cell transplantation.
- The clinical trial is specifically targeting children and adolescents aged 5-17 years, which further indicates the rarity of the condition in this population.
- The trial aims to develop a patient-reported outcome measure for cGVHD symptoms in the pediatric population, which suggests the lack of available tools specifically designed for this rare patient group.",True
NCT03595267,"Kidney Check: Diabetes, Blood Pressure & Kidney Health Checks & Care in Indigenous Communities.","## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The information provided in the clinical trial description indicates that the conditions being studied, namely chronic kidney disease, diabetes, and hypertension, are not considered rare diseases. The brief summary states that these conditions disproportionately affect indigenous populations in Canada, particularly those living in rural and remote areas, suggesting a larger patient population. Additionally, the goal of the study is to develop a platform for early diagnosis and treatment of these conditions, which is not typical for rare disease trials.

## Confidence Level
High

## Rare Disease Indicators
The information provided does not indicate any specific rare disease criteria. The conditions being studied, while affecting certain populations more severely, are not considered rare diseases based on the provided definitions.",False
NCT04792606,Long-Term Outcomes of Hip Interventions for Children With Cerebral Palsy,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is cerebral palsy (CP), which is not considered a rare disease. According to the information provided, cerebral palsy is a common condition that affects the motor function and development of children. The trial is specifically focused on children with severe (non-ambulant) cerebral palsy, which is a subset of the overall cerebral palsy population.

## Confidence Level
High

## Rare Disease Indicators
None. The prevalence of cerebral palsy is not provided, but it is generally recognized as a relatively common neurological condition, not a rare disease.",False
NCT03988764,Monogenic Diabetes Misdiagnosed as Type 1,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on studying the misdiagnosis of monogenic diabetes, which includes conditions such as Neonatal Diabetes, Maturity-onset Diabetes in the Young (MODY), Wolfram Syndrome, and Wolcott-Rallison Syndrome. These monogenic forms of diabetes are considered rare diseases, as they affect a small subset of the population.

The trial aims to determine the frequency of monogenic diabetes misdiagnosed as type 1 diabetes, which is a key characteristic of rare diseases. Additionally, the trial is seeking to discover novel genes whose mutations cause monogenic diabetes, further indicating the focus on rare genetic conditions.

## Confidence Level
High

## Rare Disease Indicators
- The clinical trial is focused on studying monogenic forms of diabetes, which are generally characterized by low prevalence and genetic origin.
- The target population is individuals diagnosed with type 1 diabetes under the age of 25, which aligns with the rarity of the conditions being investigated.
- The trial aims to identify novel genetic mutations causing monogenic diabetes, a key characteristic of rare diseases.",True
NCT04994756,Stroke Thrombectomy and Aneurysm Registry,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The conditions listed in the trial, such as stroke, thromboses, intracranial aneurysm, and brain injuries, are relatively common and affect a large population. The brief summary indicates that this is an international multi-center registry that collects information and outcomes for patients undergoing operations to treat these conditions, which suggests they are not rare diseases.

## Confidence Level
High

## Rare Disease Indicators
None. The information provided does not indicate that this trial is for a rare disease as defined by the criteria.",False
NCT03819062,Sacral Neuromodulation as Treatment for Chronic Constipation,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
Chronic constipation is a relatively common condition, affecting around 15-20% of the general population. The trial description does not provide any information about the prevalence of the specific condition being studied (severe chronic refractory constipation), but it is reasonable to assume that it is also not a rare condition, as it is a subset of the broader chronic constipation population.

## Confidence Level
High

## Rare Disease Indicators
None provided. The trial description does not indicate that the condition being studied meets the criteria for a rare disease (affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe).",False
NCT03825575,Sacral Neuromodulation as Treatment for Fecal Incontinence,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is fecal incontinence, which is not considered a rare disease. Fecal incontinence affects a significant portion of the population, with an estimated prevalence of 7% to 15% in adults. This is well above the criteria for a rare disease, which is defined as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
None. The condition of fecal incontinence does not meet the criteria for a rare disease.",False
NCT04072978,Anterior Chamber Versus Scleral Fixated Intraocular Lens: Long-term Vision and Safety Outcomes,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial information provided does not indicate that the conditions being studied (corneal endothelial cell loss and secondary intraocular lens) are rare diseases. These conditions are not characterized as having a low prevalence, and there is no information provided about their genetic origin or chronicity. The trial is focused on comparing the long-term vision outcomes and safety of different types of intraocular lenses, which is a common medical intervention.

## Confidence Level
High

## Rare Disease Indicators
There are no specific rare disease indicators present in the provided information.",False
NCT03911492,Canadian-American Spinal Cord Perfusion Pressure and Biomarker Study,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
Based on the information provided, the conditions being studied in this clinical trial, which include acute spinal cord injury, acute spinal paralysis, spinal cord injuries, and spinal fractures, are not considered rare diseases. These conditions are relatively common and affect a larger population than the criteria for a rare disease (fewer than 200,000 people in the US or affecting no more than 1 in 2,000 people in Europe).

## Confidence Level
High

## Rare Disease Indicators
None applicable in this case, as the conditions being studied are not considered rare diseases.",False
NCT03754114,"Brain Oxygen Optimization in Severe TBI, Phase 3","## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is traumatic brain injury (TBI), which is not considered a rare disease. According to the information provided, TBI is a common condition that can affect a large number of people. The clinical trial is aimed at determining the comparative effectiveness of two different monitoring and treatment strategies for managing severe TBI, which is a significant public health issue.

## Confidence Level
High

## Rare Disease Indicators
None of the indicators for a rare disease are present in this clinical trial:
- The condition, TBI, is not affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.
- The condition is not characterized by low prevalence, chronicity, and often genetic origin.",False
NCT03687359,Observational Evaluation of Atopic Dermatitis in Pediatric Patients,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
Atopic dermatitis, also known as eczema, is a common skin condition that affects a large number of people, especially children. According to the provided information, the study is focused on pediatric patients with moderate to severe atopic dermatitis whose disease is not adequately controlled with topical therapies. This suggests that the condition being studied is not a rare disease, as it is a prevalent condition affecting a significant portion of the population.

## Confidence Level
High

## Rare Disease Indicators
There are no rare disease indicators present in the provided information. The study is focused on a common and well-known condition that does not meet the criteria for a rare disease, which is typically defined as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.",False
NCT04035811,Prospective Clinical Assessment Study in Children with Achondroplasia (ACH),"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on studying Achondroplasia, which is a rare genetic disorder that affects the growth of bones and cartilage. According to the provided information, Achondroplasia is characterized as a rare disease based on the criteria:

- In the US, it is estimated to affect fewer than 200,000 people.
- In Europe, it is estimated to affect no more than 1 in 2,000 people.
- It is a chronic, genetic condition with low prevalence.

The clinical trial is specifically targeting children with Achondroplasia, further confirming that it is a rare disease population.

## Confidence Level
High

## Rare Disease Indicators
- Affects fewer than 200,000 people in the US
- Affects no more than 1 in 2,000 people in Europe
- Chronic, genetic condition with low prevalence",True
NCT03474029,"Assessment of the Safety, Tolerability, and Effectiveness of Rifapentine Given Daily for LTBI","## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on the treatment of latent tuberculosis infection (LTBI), which is not considered a rare disease. Tuberculosis, including its latent form, is a common infectious disease that affects a significant portion of the global population. According to the World Health Organization, in 2021, an estimated 10 million people developed tuberculosis, and 1.6 million people died from the disease.

The information provided does not indicate that the target population for this trial is limited to fewer than 200,000 people in the United States or affecting no more than 1 in 2,000 people in Europe, which are the typical criteria for a rare disease. Additionally, the trial is being conducted in low, medium, and high tuberculosis incidence settings, suggesting a broader target population rather than a rare disease.

## Confidence Level
High

## Rare Disease Indicators
There are no specific indicators in the provided information that suggest this is a rare disease trial.",False
NCT03615053,Personalized Medicine for Canadians With Hemophilia,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on the treatment of hemophilia A and hemophilia B, which are rare genetic disorders that affect the blood's ability to clot. According to the information provided, hemophilia is generally characterized by low prevalence, chronicity, and genetic origin, which are consistent with the criteria for a rare disease.

## Confidence Level
High

## Rare Disease Indicators
- Hemophilia A and hemophilia B are rare genetic disorders that affect fewer than 200,000 people in the United States, meeting the criteria for a rare disease in the US.
- The study aims to evaluate the impact of implementing personalized treatment regimens for hemophilia patients, which is a hallmark of rare disease management.",True
NCT03836040,Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The information provided indicates that the clinical trial is for the treatment of migraine, which is a relatively common condition. Migraine is estimated to affect around 15% of the global population, or around 1 in 7 people. This is significantly higher than the criteria for a rare disease, which is defined as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
None",False
NCT03862950,A Trial of Metformin in Individuals With Fragile X Syndrome (Met),"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
Fragile X syndrome (FXS) is a rare genetic disorder that affects approximately 1 in 4,000 males and 1 in 8,000 females in the United States, which is well below the threshold of 200,000 people for a rare disease in the US. Additionally, FXS is generally characterized by low prevalence, chronicity, and genetic origin, which aligns with the accepted criteria for a rare disease.

## Confidence Level
High

## Rare Disease Indicators
- Affects fewer than 200,000 people in the US
- Genetic origin
- Chronic condition",True
NCT03645928,Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on treating solid tumors, such as metastatic melanoma, squamous cell carcinoma of the head and neck, and non-small cell lung cancer. These types of cancers are not considered rare diseases based on the accepted criteria. According to the information provided, these conditions are not affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe, which are the typical definitions for a rare disease.

## Confidence Level
High

## Rare Disease Indicators
None. The conditions being studied in this clinical trial are not rare diseases.",False
NCT04735952,Improving P. Aeruginosa Detection With Breath-based Diagnostics (IMPACT-Breath),"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is cystic fibrosis (CF), which is a relatively common genetic disorder. According to the information provided, the study aims to enroll 300 patients with CF from 5 clinical sites in the USA. 

The generally accepted criteria for a rare disease in the US is affecting fewer than 200,000 people. However, the prevalence of cystic fibrosis in the US is estimated to be around 30,000 people, which is significantly higher than the rare disease threshold.

## Confidence Level
High

## Rare Disease Indicators
None. Cystic fibrosis does not meet the criteria for a rare disease in the US.",False
NCT03813407,An Open-label Study to Assess Safety and Efficacy of SZC in Paediatric Patients With Hyperkalaemia,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial information provided indicates that the condition being studied is hyperkalaemia, which is not considered a rare disease. The trial is aiming to enroll a total of approximately 140 participants, which exceeds the criteria for a rare disease in the United States (affecting fewer than 200,000 people) and Europe (affecting no more than 1 in 2,000 people).

## Confidence Level
High

## Rare Disease Indicators
None of the criteria for a rare disease are met in this case.",False
NCT03286569,Study the Effect of Upper Expansion Appliances on Lower Jaw Forward Projection/Growth,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is studying the effects of upper jaw expansion appliances on forward growth of the lower jaw in young children with overbite. This condition is not considered a rare disease, as it is a common orthodontic issue affecting a significant portion of the population. The brief summary and detailed description indicate that the target population is young children aged 9-11, which suggests a higher prevalence compared to the rare disease criteria of affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
None of the provided information indicates that this is a rare disease. The condition being studied, overbite, is a common orthodontic issue and does not meet the criteria for a rare disease.",False
NCT03401398,Stress Hydrocortisone in Pediatric Septic Shock,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is septic shock, which is a life-threatening complication of a severe infection. According to the detailed description, sepsis represents the most common cause of childhood mortality worldwide, and in the United States alone, 200 cases of pediatric sepsis are diagnosed each day. This indicates that septic shock is not a rare condition, as it affects a significant number of people.

## Confidence Level
High

## Rare Disease Indicators
This clinical trial does not meet the criteria for a rare disease, as the condition being studied (septic shock) is not considered a rare disease.",False
NCT03929614,Development and Validation of the MOBI Questionnaire,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial information provided indicates that the condition being studied is idiopathic scoliosis, which is a common spinal deformity in adolescents. The brief summary states that scoliosis is a ""common spinal deformity in adolescents,"" which does not meet the criteria for a rare disease. According to the information provided, a rare disease is typically defined as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe, and is generally characterized by low prevalence, chronicity, and often genetic origin. The information on idiopathic scoliosis does not suggest that it meets these criteria for a rare disease.

## Confidence Level
High

## Rare Disease Indicators
None",False
NCT04142307,Biofeedback in Idiopathic Infantile Nystagmus Syndrome,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The information provided indicates that the condition being studied, Idiopathic Infantile Nystagmus Syndrome (IIN), is not considered a rare disease based on the accepted criteria. Specifically:

- In the US, a rare disease is defined as affecting fewer than 200,000 people. The clinical trial information does not provide the exact prevalence of IIN, but it is described as the ""most common among infantile nystagmus cases,"" suggesting it is more prevalent than a rare disease.
- In Europe, a rare disease is defined as affecting no more than 1 in 2,000 people. Again, the information does not provide the exact prevalence, but the description of IIN as a common condition among infantile nystagmus cases implies it is likely more prevalent than the European rare disease threshold.
- The condition is also described as ""generally characterized by low prevalence, chronicity, and often genetic origin,"" which does not align with the provided criteria for a rare disease.

## Confidence Level
High

## Rare Disease Indicators
This clinical trial does not appear to have any indicators of a rare disease based on the information provided.",False
NCT03672877,Randomized Controlled Trial of Early Intensive Leg Exercise to Improve Walking in Children With Diplegia,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition described in the clinical trial, spastic diplegia and periventricular leukomalacia, is not considered a rare disease based on the provided criteria. Cerebral palsy, which includes spastic diplegia, is estimated to affect 1 in 323 children in the United States, which is significantly higher than the 200,000 people threshold for a rare disease in the US. Additionally, the detailed description indicates that the condition is a common complication of prematurity, further suggesting that it is not a rare disease.

## Confidence Level
High

## Rare Disease Indicators
The condition described in the clinical trial does not meet the criteria for a rare disease, as it affects more than 200,000 people in the US and more than 1 in 2,000 people in Europe.",False
NCT03506867,A Healthy People Initiative: Building the Socio-Economic Capital of Low Income Population At-Risk for HIV and Hepatitis-C,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial described in the information provided focuses on conditions such as nicotine dependence and substance use disorders, which are not considered rare diseases. The brief summary indicates that the study population is the ""low income population at-risk for HIV and Hepatitis-C"", which suggests a relatively larger population size compared to the criteria for rare diseases.

## Confidence Level
High

## Rare Disease Indicators
The conditions mentioned in the trial (nicotine dependence, substance use disorders) do not meet the criteria for rare diseases, which are typically defined as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe, and are often characterized by low prevalence, chronicity, and genetic origin.",False
NCT03953014,Pharmacogenetics of Antidepressant-Induced Disinhibition,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on studying the adverse effects of selective serotonin reuptake inhibitors (SSRIs) in children with major depressive disorder, anxiety disorders, and obsessive-compulsive disorder. These are relatively common mental health conditions that affect a significant proportion of the population, particularly in children and adolescents. The brief summary states that 10-20% of children treated with SSRIs experience behavioral disinhibition, which suggests that the target population is not a rare disease.

## Confidence Level
High

## Rare Disease Indicators
The conditions mentioned in the trial (major depressive disorder, anxiety disorders, and obsessive-compulsive disorder) do not meet the criteria for a rare disease, as they are relatively common and affect more than 200,000 people in the United States.",False
NCT05685745,Multisite Inventory of Neonatal-Perinatal Interventions (MINI) Minimum Dataset,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The conditions listed in the clinical trial, such as ""Infant, Extremely Premature"", ""Premature Birth"", and ""Neonatal Intensive Care"", are not considered rare diseases. These conditions are relatively common and affect a significant number of people, particularly newborns and infants. Additionally, the goal of the study is to collect observational data on a broad range of neonatal and perinatal interventions, which suggests a larger patient population.

## Confidence Level
High

## Rare Disease Indicators
There are no clear indicators in the provided information that this clinical trial is for a rare disease. The conditions and the goal of the study are not consistent with the accepted criteria for a rare disease.",False
NCT03427736,Anesthetics and Analgesics in Children,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial described is focused on characterizing the pharmacokinetic and safety profile of commonly used anesthetics and analgesics in children and adolescents. These drugs are not used to treat a rare disease, but rather are widely used in various medical settings. The conditions mentioned, ""Anesthesia"" and ""Pain"", are not considered rare diseases.

## Confidence Level
High

## Rare Disease Indicators
There are no clear indicators that this is a trial for a rare disease. The target population (children and adolescents) and the conditions being studied (anesthesia and pain) are not characteristic of rare diseases.",False
NCT03567473,Bronchiolitis in Infants Placebo Versus Epinephrine and Dexamethasone Study,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is bronchiolitis, which is a common respiratory illness that affects infants and young children. According to the information provided, bronchiolitis is not a rare disease as it does not meet the criteria for a rare disease in either the US or Europe. The condition is generally characterized by a high prevalence, rather than low prevalence, and it is not typically considered a chronic or genetic condition.

## Confidence Level
High

## Rare Disease Indicators
None identified. The condition of bronchiolitis does not meet the accepted criteria for a rare disease.",False
NCT03666377,Chewing Gum on Postoperative Ileus in Children,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial information provided does not indicate that the condition being studied, postoperative ileus, is a rare disease. Postoperative ileus is a common complication following abdominal surgery, which can affect a significant number of patients. The trial is focused on evaluating the impact of chewing gum on postoperative ileus in children, not on a rare disease.

## Confidence Level
High

## Rare Disease Indicators
There are no clear indicators in the provided information that this is a rare disease trial. The condition being studied, postoperative ileus, is a common complication and not a rare disease as defined by the criteria provided (affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe).",False
NCT03598244,Volitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The clinical trial is investigating the treatment of primary central nervous system (CNS) tumors, which are generally considered rare diseases. Specifically, the trial is enrolling patients with recurrent or refractory medulloblastoma, high-grade glioma, diffuse intrinsic pontine glioma, and CNS tumors harboring MET aberrations. These types of CNS tumors are typically characterized by low prevalence, chronicity, and often genetic origin, which aligns with the accepted criteria for rare diseases.

## Confidence Level
High

## Rare Disease Indicators
- The trial is investigating the treatment of primary CNS tumors, which are generally considered rare diseases.
- The specific conditions included in the trial (recurrent or refractory medulloblastoma, high-grade glioma, diffuse intrinsic pontine glioma, and CNS tumors with MET aberrations) are all rare and often genetically driven.
- The trial is being conducted to determine the maximum tolerated dose and define the toxicities of the investigational drug, savolitinib, in this patient population, which is typical of rare disease trials.",True
NCT03827694,Non-Invasive Diagnosis of Pediatric Pulmonary Invasive Mold Infections,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The conditions listed in the clinical trial information, ""Pulmonary Invasive Fungal Infections"" and ""Pulmonary Invasive Aspergillosis,"" are considered rare diseases. According to the criteria provided, a rare disease is typically defined as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe, and is often characterized by low prevalence, chronicity, and genetic origin. The brief summary of the clinical trial indicates that it is targeting a population of children at high-risk for pulmonary invasive fungal infections, which aligns with the criteria for a rare disease.

## Confidence Level
High

## Rare Disease Indicators
- Conditions: Pulmonary Invasive Fungal Infections, Pulmonary Invasive Aspergillosis
- Low prevalence of the target conditions
- Chronic and often genetic origin of the target conditions
- Targeting a specific high-risk population (pediatric patients)",True
NCT03619551,Conditioning SCID Infants Diagnosed Early,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on studying a condition called Severe Combined Immunodeficiency (SCID), which is a group of rare, life-threatening inherited disorders that result in a severely compromised immune system. According to the information provided, SCID typically affects fewer than 200,000 people in the US, which meets the criteria for a rare disease in the US (affecting fewer than 200,000 people). Additionally, SCID is generally characterized by low prevalence, chronicity, and genetic origin, which are common features of rare diseases.

## Confidence Level
High

## Rare Disease Indicators
- Affects fewer than 200,000 people in the US
- Chronic and life-threatening condition
- Genetic origin",True
NCT05501587,Measures of Respiratory Health Registry,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on studying respiratory diseases, including cystic fibrosis (CF) and non-CF respiratory diseases. Cystic fibrosis is a genetic disorder that affects approximately 30,000 people in the United States, which is more than the 200,000 threshold for a rare disease in the US. Additionally, the trial aims to establish a normal range of small airways function in healthy children, indicating that the targeted population is not exclusively those with rare respiratory diseases.

## Confidence Level
High

## Rare Disease Indicators
Although cystic fibrosis is a chronic and often genetic condition, the overall scope of the trial is not limited to rare respiratory diseases, as it includes both healthy children and those with non-CF respiratory diseases. Therefore, this trial does not meet the criteria for a rare disease clinical study.",False
NCT03453710,Remplissage Versus Latarjet Coracoid Transfer for Recurrent Shoulder Instability,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is shoulder dislocation, which is a relatively common musculoskeletal injury and not considered a rare disease. The brief summary and detailed description indicate that the study is focused on comparing different surgical treatment options for recurrent anterior glenohumeral instability with subcritical bone loss, which is a specific subgroup of shoulder dislocation patients. However, the overall prevalence of shoulder dislocation does not meet the criteria for a rare disease, which is typically defined as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
None",False
NCT03677102,Fluids in Septic Shock (FISSH),"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is sepsis and septic shock, which are not considered rare diseases. Sepsis is a leading cause of death worldwide, with an estimated incidence of 48.9 million cases and 11 million deaths globally in 2017. In the United States, the incidence of sepsis is estimated to be around 1.7 million cases per year, which far exceeds the criteria for a rare disease (affecting fewer than 200,000 people).

## Confidence Level
High

## Rare Disease Indicators
There are no indicators in the provided information that this clinical trial is for a rare disease. The condition being studied, sepsis and septic shock, is a common and widespread condition that affects a large number of people.",False
NCT02991469,A Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (SKYPS),"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on Systemic Juvenile Idiopathic Arthritis (sJIA), which is a rare form of juvenile idiopathic arthritis. According to the information provided, sJIA is a condition that affects children and adolescents aged 1 to 17 years. Juvenile idiopathic arthritis, in general, is considered a rare disease as it affects fewer than 200,000 people in the United States, which meets the criteria for a rare disease as defined in the United States.

## Confidence Level
High

## Rare Disease Indicators
- Affects fewer than 200,000 people in the United States
- Targeted patient population is children and adolescents aged 1 to 17 years, which is a specific and relatively small subset of the overall population",True
NCT04110041,Effects of Aerobic Exercise Intensity on Clinical & Neural Outcomes in Depressed Youth,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial information provided indicates that the condition being studied is depression, which is not considered a rare disease. According to the given criteria, a rare disease is typically defined as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe. The trial details mention that major depressive disorder (MDD) is estimated to affect 4.4% of the global population, or over 300 million individuals, which is significantly higher than the criteria for a rare disease.

## Confidence Level
High

## Rare Disease Indicators
None. The condition being studied, depression, is not considered a rare disease.",False
NCT02407028,Hyperbaric Oxygen Brain Injury Treatment Trial,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial information provided indicates that the condition being studied is Traumatic Brain Injury (TBI), which is not considered a rare disease. According to the given criteria, a rare disease is typically defined as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe. TBI is a relatively common condition, with an estimated 1.5 million new cases in the US each year.

## Confidence Level
High

## Rare Disease Indicators
None. The information provided does not indicate that this clinical trial is targeting a rare disease.",False
NCT04117841,SCFE Longitudinal International Prospective Registry,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied, Slipped Capital Femoral Epiphysis (SCFE), is described as the ""most common disorder of the adolescent hip,"" indicating that it is not a rare disease. The information provided does not specify the exact prevalence of SCFE, but the description suggests that it is a relatively common condition, rather than a rare one.

## Confidence Level
High

## Rare Disease Indicators
None provided. The information given does not indicate that SCFE meets the criteria for a rare disease, which is typically defined as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe, and is generally characterized by low prevalence, chronicity, and often genetic origin.",False
NCT03587272,Minimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell Disease,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on treating sickle cell disease, which is a rare genetic disorder. According to the information provided, sickle cell disease affects fewer than 200,000 people in the United States, which meets the criteria for a rare disease in the US (affecting fewer than 200,000 people). Additionally, sickle cell disease is generally characterized by low prevalence, chronicity, and genetic origin, which are typical features of rare diseases.

## Confidence Level
High

## Rare Disease Indicators
- The clinical trial is focused on sickle cell disease, which affects fewer than 200,000 people in the US.
- Sickle cell disease is a chronic, genetic disorder, which are common characteristics of rare diseases.",True
NCT03481010,Periacetabular Osteotomy With and Without Arthroscopic Management of Central Compartment Pathology,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is hip dysplasia, which is a developmental abnormality of the hip socket that can lead to painful arthritis at a young age. According to the information provided, hip dysplasia is not considered a rare disease based on the accepted definitions:

- In the US, rare diseases are defined as those affecting fewer than 200,000 people. The clinical trial information does not provide an estimate of the prevalence of hip dysplasia, but it is likely higher than this threshold.
- In Europe, rare diseases are defined as those affecting no more than 1 in 2,000 people. Again, the information provided does not give a specific prevalence for hip dysplasia, but it is likely higher than this threshold.

Additionally, the condition is described as a ""developmental abnormality"" and is not characterized as being generally rare, chronic, and of genetic origin, which are typically associated with rare diseases.

## Confidence Level
High

## Rare Disease Indicators
None applicable. The condition being studied, hip dysplasia, does not meet the criteria for a rare disease.",False
NCT03363373,Naxitamab for High-Risk Neuroblastoma Patients with Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone And/or Bone Marrow,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
Neuroblastoma, the condition being studied in this clinical trial, is a rare type of cancer that primarily affects children. According to the National Cancer Institute, neuroblastoma accounts for about 6% of all childhood cancers, and the estimated annual incidence is 10.54 cases per million children under the age of 15 in the United States. This falls well within the criteria for a rare disease in the US, where it affects fewer than 200,000 people.

## Confidence Level
High

## Rare Disease Indicators
- Neuroblastoma is a rare type of cancer, primarily affecting children.
- The estimated annual incidence of neuroblastoma is 10.54 cases per million children under the age of 15 in the United States, which is below the threshold of 200,000 people for a rare disease in the US.",True
NCT03004547,Sodium Deposition in Soft Tissues of Patients with Kidney Disease,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is investigating the association between sodium deposition in soft tissues and uremic symptoms in patients with chronic kidney disease (CKD) and heart failure. CKD is a common chronic condition, with an estimated prevalence of 14% in the United States and 11.8% in Europe. While the specific complication being studied (sodium deposition in soft tissues) may not be as well-known, the underlying condition (CKD) is not considered a rare disease based on the provided criteria.

## Confidence Level
High

## Rare Disease Indicators
None. The information provided does not indicate that this trial is targeting a rare disease.",False
NCT03339128,Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is irritable bowel syndrome (IBS), which is a common gastrointestinal disorder. IBS is estimated to affect around 10-15% of the global population, which is significantly higher than the thresholds for a rare disease (fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe).

## Confidence Level
High

## Rare Disease Indicators
None. The information provided does not indicate that this clinical trial is targeting a rare disease.",False
NCT03118986,RCT of Olanzapine for Control of CIV in Children Receiving Highly Emetogenic Chemotherapy,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is for the treatment of chemotherapy-induced vomiting (CIV) in children receiving highly emetogenic chemotherapy, including those receiving hematopoietic stem cell transplant (HSCT) conditioning. The conditions listed (vomiting in infants and/or children, nausea, hematopoietic system--cancer, oncology) are not considered rare diseases based on the provided criteria. Chemotherapy-induced nausea and vomiting are common and well-recognized side effects of cancer treatment, especially in children receiving highly emetogenic chemotherapy.

## Confidence Level
High

## Rare Disease Indicators
None. The conditions described in the clinical trial are not considered rare diseases according to the provided definition.",False
NCT03400371,Biology of Juvenile Myoclonic Epilepsy,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is Juvenile Myoclonic Epilepsy (JME), which is a type of Genetic Generalized Epilepsy (GGE). According to the detailed description, GGE affects around 40% of epilepsy patients, and JME is the most common type of GGE. While the exact prevalence of JME is not provided, the description indicates that it is a relatively uncommon form of epilepsy, affecting a subset of the overall epilepsy population. Additionally, the trial is specifically focused on finding the genetic causes of JME, which suggests that it is a rare and complex condition.

## Confidence Level
High

## Rare Disease Indicators
- The condition being studied, Juvenile Myoclonic Epilepsy, is described as a relatively uncommon form of epilepsy, affecting a subset of the overall epilepsy population.
- The trial is specifically focused on finding the genetic causes of JME, indicating that it is a rare and complex condition.",True
NCT03214354,Nonmyeloablative Stem Cell Transplant in Children with Sickle Cell Disease and a Major ABO-Incompatible Matched Sibling Donor,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
Sickle cell disease, the condition being studied in this clinical trial, is considered a rare disease. The provided information states that sickle cell disease is ""a debilitating chronic blood disorder with multi-system end-organ damage that leads to morbidity and early mortality."" Additionally, the condition is characterized as ""a rare disease"" in the detailed description.

## Confidence Level
High

## Rare Disease Indicators
- Sickle cell disease is a chronic, genetic blood disorder that affects fewer than 200,000 people in the United States, meeting the criteria for a rare disease in the US.
- Sickle cell disease is also characterized as a rare disease with low prevalence, chronicity, and genetic origin, which are general indicators of a rare disease.",True
NCT03031210,Twice Daily Treatment With Amoxicillin for Non-severe Community Acquired Pneumonia.,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on the treatment of community-acquired pneumonia, which is a common condition and not considered a rare disease. The detailed description indicates that the study is targeting a patient population of children between 3 months and 18 years of age, which is a relatively large population. Additionally, the sample size of the trial is 685 participants per arm, which is much larger than the typical sample size for a rare disease trial.

## Confidence Level
High

## Rare Disease Indicators
None. The information provided does not indicate that this clinical trial is targeting a rare disease.",False
NCT03376438,Prospective Observational Cohort Study of Fetal Atrial Flutter & Supraventricular Tachycardia,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The clinical trial is studying fetal atrial flutter (AF) and supraventricular tachycardia (SVT), which are considered rare conditions. According to the information provided, fetal SVA, including AF and other forms of SVT, is the most common cause of intended in-utero fetal therapy, suggesting that the target population for this trial is relatively small. Additionally, the trial aims to address a knowledge gap in the management of these rare fetal arrhythmias, further indicating that they are not commonly encountered conditions.

## Confidence Level
High

## Rare Disease Indicators
- The conditions being studied, fetal atrial flutter and supraventricular tachycardia, are described as the most common cause of intended in-utero fetal therapy, suggesting a relatively low prevalence.
- The trial is focused on addressing a knowledge gap in the management of these rare fetal arrhythmias, indicating that they are not commonly encountered conditions.",True
NCT05022940,Functional Evolution of Traumatic Brain Injured Adults During Rehabilitation and Social Participation,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is traumatic brain injury (TBI), which is not considered a rare disease. According to the information provided, TBI is a widespread condition that affects a large number of people, rather than a rare disease that affects fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
None of the indicators for a rare disease are present in this clinical trial. The information provided does not suggest that TBI is a rare, chronic condition with a genetic origin, and the number of people affected by TBI is significantly higher than the threshold for a rare disease.",False
NCT03073967,Trial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Subjects,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The trial is focused on treating acyclovir-resistant mucocutaneous HSV infections in immunocompromised subjects. This suggests that the target population is likely to be relatively small, as acyclovir resistance and immunocompromised status are both uncommon conditions. Additionally, the trial is using a novel investigational drug, pritelivir, which indicates that the condition being studied is not commonly treated.

## Confidence Level
High

## Rare Disease Indicators
- Targeting a specific subpopulation of HSV-infected individuals (those with acyclovir resistance and immunocompromised status)
- Investigating a novel investigational drug (pritelivir) for a specific condition",True
NCT02936024,One Stage vs. Two Stage Gubernaculum Sparing Laparoscopic Orchidopexy (GSLO),"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is cryptorchidism, or undescended testis, which is a relatively common congenital anomaly in male infants. According to the provided information, undescended testis is the ""most common congenital anomaly of the genitalia in boys"". This suggests that the condition is not considered a rare disease, as it does not meet the criteria of affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
The information provided does not indicate that cryptorchidism is a rare disease. The condition is described as the ""most common congenital anomaly of the genitalia in boys"", which suggests it has a relatively high prevalence.",False
NCT03093116,"A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements","## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on advanced solid tumors harboring specific genetic alterations (ALK, ROS1, or NTRK1-3 rearrangements). These genetic alterations are not limited to a rare disease, as they can be found in various types of solid tumors, including more common cancer types like lung cancer and certain sarcomas. The detailed description of the trial indicates that the study will enroll patients across multiple expansion cohorts, suggesting a broader patient population.

## Confidence Level
High

## Rare Disease Indicators
The information provided does not indicate that this trial is focused on a rare disease. The conditions described (locally advanced and metastatic solid tumors) are not inherently rare, and the genetic alterations of interest are not exclusive to rare diseases.",False
NCT02603848,Ibuprofen Compared to Morphine as a Pediatric Postoperative Pain Management Tool Following Inguinal Surgery,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on evaluating the effectiveness of ibuprofen compared to morphine as a postoperative pain management tool in children undergoing inguinal surgery. Inguinal surgery, which includes hernia/hydrocele repair and orchidopexy, is a relatively common procedure in pediatric populations. The prevalence of inguinal hernia in children is estimated to be around 1-5% in full-term infants and up to 30% in premature infants, which does not meet the criteria for a rare disease (affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe).

## Confidence Level
High

## Rare Disease Indicators
This clinical trial does not meet the accepted criteria for a rare disease, as the condition being studied (inguinal surgery in children) is not considered a rare disease.",False
NCT02818192,Improving Renal Complications in Adolescents With Type 2 Diabetes Through REsearch Cohort Study (National iCARE Study),"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on type 2 diabetes in adolescents, which is not considered a rare disease. According to the provided criteria, a rare disease is typically defined as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe. Type 2 diabetes, while a serious condition, is not a rare disease as it affects a much larger population.

## Confidence Level
High

## Rare Disease Indicators
None. The conditions mentioned in the trial (type 2 diabetes, proteinuria, stress, nephropathy) are not considered rare diseases.",False
NCT02855476,HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
Huntington's disease, the condition being studied in this clinical trial, is considered a rare disease. According to the information provided, Huntington's disease is ""generally characterized by low prevalence, chronicity, and often genetic origin"", which aligns with the accepted criteria for a rare disease. Additionally, the brief summary indicates that the trial aims to enroll at least 2500 research participants, which suggests that the overall patient population with Huntington's disease is likely fewer than 200,000 people, the threshold for a rare disease in the United States.

## Confidence Level
High

## Rare Disease Indicators
- Huntington's disease is a chronic, genetic condition
- The trial aims to enroll at least 2500 research participants, suggesting a patient population fewer than 200,000 people in the United States.",True
NCT03004326,Clinical Transcriptomics in Systemic Vasculitis (CUTIS),"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The conditions listed in the clinical trial include several forms of vasculitis, which are generally considered rare diseases. According to the information provided, vasculitis is characterized by low prevalence, chronicity, and often genetic origin, which align with the accepted criteria for a rare disease.

## Confidence Level
High

## Rare Disease Indicators
- The conditions listed, including Cryoglobulinemic Vasculitis, Eosinophilic Granulomatosis With Polyangiitis (EGPA), Granulomatosis With Polyangiitis (GPA), Microscopic Polyangiitis (MPA), and Polyarteritis Nodosa (PAN), are all considered rare diseases.
- The clinical trial is a multi-center observational study, which is typical for rare disease research due to the need to gather data from a widely distributed patient population.",True
NCT02932150,Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is chronic hepatitis B (CHB), which is not considered a rare disease. According to the provided criteria, a rare disease typically affects fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe. However, CHB is a relatively common condition, with an estimated global prevalence of around 257 million people according to the World Health Organization.

## Confidence Level
High

## Rare Disease Indicators
There are no clear indicators that this is a rare disease trial based on the information provided. The condition, chronic hepatitis B, is a relatively common disease and does not meet the criteria for a rare disease.",False
NCT02512887,Caudal vs Local Anesthesia in Hypospadias,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
Hypospadias, the condition being studied in this clinical trial, is not considered a rare disease. According to the information provided, hypospadias is ""one of the most common congenital malformations of the genitalia in boys"". The prevalence of hypospadias is not explicitly stated, but it is described as a common condition, not a rare one.

## Confidence Level
High

## Rare Disease Indicators
There are no rare disease indicators present in the provided information. The condition being studied, hypospadias, is explicitly described as a common congenital malformation, not a rare disease.",False
NCT02808533,Topiramate and Schizophrenia: Effects on Weight and Psychopathology,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is schizophrenia and schizoaffective disorder, which are not considered rare diseases. Schizophrenia is a chronic mental illness that affects approximately 0.3-0.7% of the global population, which is significantly higher than the criteria for a rare disease in the US (affecting fewer than 200,000 people) or Europe (affecting no more than 1 in 2,000 people).

## Confidence Level
High

## Rare Disease Indicators
None. The prevalence of schizophrenia and schizoaffective disorder is well above the thresholds for a rare disease.",False
NCT02708134,Quality of Pediatric Resuscitation in a Multicenter Collaborative,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is cardiac arrest and cardiopulmonary arrest, which are not considered rare diseases. Cardiac arrest is a relatively common medical emergency, affecting around 350,000 to 400,000 people in the United States each year, which is significantly higher than the 200,000 people threshold for a rare disease as defined in the US. Additionally, the detailed description indicates that this is a major public health problem, further suggesting that it is not a rare condition.

## Confidence Level
High

## Rare Disease Indicators
None identified. The condition being studied does not meet the criteria for a rare disease.",False
NCT05429411,Nonsilicone Gel Sheet for Burn Hypertrophic Scars,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on the treatment of hypertrophic scars, which is a common condition that can occur after a burn injury. The brief summary indicates that the condition is being studied in ""adult burn survivors"", which suggests a relatively large patient population. Additionally, the trial is being conducted at multiple study sites, further indicating that the condition is not considered a rare disease.

## Confidence Level
High

## Rare Disease Indicators
None. The information provided does not indicate that this is a rare disease trial.",False
NCT02679144,Neuroblastoma Maintenance Therapy Trial,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
Neuroblastoma is a type of cancer that typically affects children and is considered a rare disease. According to the information provided, neuroblastoma affects fewer than 200,000 people in the United States, which meets the criteria for a rare disease in the US. Additionally, neuroblastoma is generally characterized by low prevalence, chronicity, and often genetic origin, which are typical characteristics of rare diseases.

## Confidence Level
High

## Rare Disease Indicators
- Neuroblastoma is a cancer that affects fewer than 200,000 people in the US, meeting the US definition of a rare disease.
- Neuroblastoma is characterized by low prevalence, chronicity, and often genetic origin, which are typical characteristics of rare diseases.",True
NCT02811523,In Vivo Lung Perfusion for Pulmonary Metastases of Sarcoma,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is investigating a treatment for pulmonary metastases of bone and soft tissue sarcomas. Sarcomas, while not extremely common, are not considered rare diseases. The brief summary indicates that sarcoma with lung metastases is a significant clinical problem, suggesting that the target population for this trial is likely larger than the rare disease criteria of affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
None. The information provided does not indicate that this trial is targeting a rare disease.",False
NCT02391324,Effectiveness of Robotic Gait Training and Physical Therapy for Children and Youth With Cerebral Palsy,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on cerebral palsy, which is not considered a rare disease. According to the information provided, cerebral palsy affects 2.0-2.5 in 1000 children, which is significantly higher than the accepted criteria for a rare disease in the US (fewer than 200,000 people) or Europe (affecting no more than 1 in 2,000 people).

## Confidence Level
High

## Rare Disease Indicators
This clinical trial does not meet the criteria for a rare disease, as cerebral palsy is a relatively common condition affecting a significant number of children.",False
NCT02657837,Measures of Respiratory Health (MRH),"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is investigating lung function in patients with various respiratory conditions, including cystic fibrosis, asthma, sickle cell anemia, and bronchiolitis obliterans. While some of these conditions may be considered rare, the trial is not specifically focused on a single rare disease. The conditions listed in the trial are relatively common, and the prevalence of these diseases does not meet the criteria for a rare disease as defined in the United States (affecting fewer than 200,000 people) or Europe (affecting no more than 1 in 2,000 people).

## Confidence Level
High

## Rare Disease Indicators
None of the conditions listed in the trial are considered rare diseases based on the provided criteria.",False
NCT02445222,CAR-T Long Term Follow Up (LTFU) Study,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The information provided in the clinical trial details does not indicate that the condition being studied is a rare disease. The trial is focused on long-term safety and efficacy monitoring of patients who have received CAR-T cell therapy, which is a type of cancer treatment. Cancer, in general, is not considered a rare disease. The trial is also not limited to a specific type of cancer or condition, but rather includes patients from ""eligible clinical trials or managed access programs"" who have received CAR-T therapy.

## Confidence Level
High

## Rare Disease Indicators
None provided. The information given does not mention any specific rare disease criteria, such as the prevalence of the condition being less than 200,000 people in the US or affecting no more than 1 in 2,000 people in Europe.",False
NCT02436707,Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The information provided indicates that the clinical trial is for the treatment of lymphoma, which is not considered a rare disease. Lymphoma is a type of cancer that affects the lymphatic system, and it is relatively common, with an estimated 81,560 new cases expected in the United States in 2023, according to the American Cancer Society.

## Confidence Level
High

## Rare Disease Indicators
None of the provided information suggests that this is a rare disease trial. The condition, lymphoma, is a common type of cancer and does not meet the criteria for a rare disease as defined in the question.",False
NCT02740868,Xenon-129 and Inert Fluorinated Gas Lung Magnetic Resonance Imaging: Study of Healthy Volunteers and Participants With Pulmonary Disease,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is studying two conditions, cystic fibrosis (CF) and asthma, which are not considered rare diseases. CF affects approximately 30,000 people in the United States, which is significantly higher than the 200,000 threshold for a rare disease. Asthma is also a common respiratory condition, affecting millions of people worldwide. The study is also including healthy volunteers as a control group, further indicating that this is not a trial focused on a rare disease.

## Confidence Level
High

## Rare Disease Indicators
The study does not meet the criteria for a rare disease clinical trial, as the conditions being studied (cystic fibrosis and asthma) are not considered rare diseases.",False
NCT05528471,Fructose and Liver Diseases in Youth: Help Them FLY,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial information provided indicates that the condition being studied is non-alcoholic fatty liver disease (NAFLD), which is not considered a rare disease. NAFLD is estimated to occur in 10-20% of obese children and adults, which is significantly higher than the criteria for a rare disease in the United States (affecting fewer than 200,000 people) or Europe (affecting no more than 1 in 2,000 people). Additionally, the trial is focused on the impact of dietary fructose on NAFLD, rather than investigating a treatment for a rare disease.

## Confidence Level
High

## Rare Disease Indicators
The provided information does not contain any indicators that this is a clinical trial for a rare disease.",False
NCT02193841,Simple Bone Cysts in Kids,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
Based on the information provided, the condition being studied in this clinical trial, simple bone cysts (SBCs), does not meet the criteria for a rare disease. The brief summary indicates that SBCs are ""the commonest bone lesion in children"", suggesting that the condition affects a larger population than the rare disease threshold. Additionally, the detailed description mentions that SBCs are ""the commonest bone lesion in children"", further reinforcing that this is not a rare disease.

## Confidence Level
High

## Rare Disease Indicators
None apparent. The information provided indicates that simple bone cysts are a common condition in children, not a rare disease.",False
NCT04622462,Early Prediction of Oral Cancer by S100A7 Immunohistochemistry Signature-based Assessment,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on studying oral neoplasms, which are not considered a rare disease. Oral cancer, the condition being studied, is a relatively common type of cancer, with an estimated 53,000 new cases diagnosed in the United States in 2022. This is significantly higher than the 200,000 people affected threshold for a rare disease in the United States.

## Confidence Level
High

## Rare Disease Indicators
None. The information provided does not indicate that this clinical trial is targeting a rare disease.",False
NCT02249923,Pediatric Pulmonary Hypertension Network (PPHNet) Informatics Registry,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on investigating pulmonary hypertension (PH) in children, which meets the criteria for a rare disease. According to the information provided:

1. Pulmonary hypertension is characterized as a syndrome with low prevalence, chronicity, and often genetic origin, which are general characteristics of rare diseases.
2. The trial's detailed description indicates that limited data is available on the etiologies, clinical course, and prognosis of pediatric pulmonary hypertension, suggesting it is a condition with low prevalence.
3. The trial aims to determine the incidence and natural history of the various etiologies of pediatric PH, further confirming the rarity of this condition.

## Confidence Level
High

## Rare Disease Indicators
- Low prevalence of pediatric pulmonary hypertension
- Chronic and often genetic nature of the condition
- Limited data available on the etiologies, clinical course, and prognosis of pediatric pulmonary hypertension",True
NCT02081768,90Yttrium Colloid for the Treatment of Cystic Sellar/Parasellar Tumors,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The provided information indicates that patients who are symptomatic from cystic lesions of the pituitary and surrounding areas (sellar/parasellar region) are rare. The brief summary states that ""Patients who are symptomatic from these tumours are rare."" This suggests that the condition being studied in this trial, cystic tumors of the sellar/parasellar region, meets the criteria for a rare disease, as it affects a small population of people.

## Confidence Level
High

## Rare Disease Indicators
- The brief summary explicitly states that patients who are symptomatic from these tumors are rare.
- The condition being studied, cystic tumors of the sellar/parasellar region, is a specific and uncommon type of tumor.",True
NCT02098252,Treatment of Brain AVMs (TOBAS) Study,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The information provided in the clinical trial details suggests that the condition being studied, brain arteriovenous malformations (AVMs), is not considered a rare disease. The detailed description indicates that the annual incidence of symptomatic AVM discovery is approximately 1.1 per 100,000 population. This is significantly higher than the criteria for a rare disease in the US (affecting fewer than 200,000 people) and Europe (affecting no more than 1 in 2,000 people).

## Confidence Level
High

## Rare Disease Indicators
While brain AVMs are relatively uncommon, they do not meet the accepted criteria for a rare disease based on the information provided in the clinical trial details.",False
NCT02434003,Prospective Multicenter Evaluation of a New Predictive Model for the Progression of Adolescent Idiopathic Scoliosis,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
Based on the information provided, the condition being studied in this clinical trial is adolescent idiopathic scoliosis (AIS), which has a prevalence of 1-3% affecting primarily young adolescent females. This falls outside the criteria for a rare disease, which is typically defined as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
Not applicable, as this is not a rare disease trial.",False
NCT02903680,RCT of IV Dexamethasone to Prevent Relapse in the Treatment of Migraine in a Paediatric ED,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on the treatment of migraine in pediatric patients, which is not considered a rare disease. According to the information provided, migraine is a common condition, with the trial being conducted in a large tertiary care pediatric hospital with approximately 70,000 annual visits. The study population, children aged 8 to 17 years with a diagnosis of acute migraine, does not meet the criteria for a rare disease, which is typically defined as affecting fewer than 200,000 people in the United States or no more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
None of the provided information suggests this is a rare disease trial. The condition being studied, migraine, is a common neurological disorder.",False
NCT01876771,A Trial to Assess the Safety and Effectiveness of Lutetium-177 Octreotate Therapy in Neuroendocrine Tumours,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The clinical trial information provided indicates that the condition being studied, neuroendocrine tumors (NETs), are considered a rare disease. The brief summary states that ""Neuroendocrine tumours (NETs) are rare, slow growing, and diagnosis is often delayed with advanced metastases at presentation."" This aligns with the accepted criteria for a rare disease, which includes low prevalence, chronicity, and often genetic origin.

## Confidence Level
High

## Rare Disease Indicators
- The brief summary states that NETs are ""rare, slow growing"" conditions.
- The condition, carcinoma (neuroendocrine), is generally characterized as a rare disease.",True
NCT01980147,Skills for Wellness,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The conditions targeted in this clinical trial, namely schizophrenia, bipolar disorder, and major depression, are not considered rare diseases. These mental health conditions are relatively common and affect a significant number of people. 

According to the provided criteria, a rare disease is typically defined as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe. The brief summary indicates that these conditions are ""severe mental illness"" that ""typically develops at a young age and can cause life-long disability,"" suggesting they are not rare.

## Confidence Level
High

## Rare Disease Indicators
There are no clear indicators in the provided information that this is a rare disease clinical trial. The conditions targeted are relatively common mental health disorders.",False
NCT02308917,The Canadian Children Inflammatory Bowel Disease Network (CIDsCaNN),"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The information provided indicates that the clinical trial is focused on inflammatory bowel diseases (IBD), including Crohn's disease and ulcerative colitis. These conditions are not considered rare diseases based on the given criteria:

- In the US, IBD is estimated to affect over 3 million people, which is significantly more than the 200,000 threshold for rare diseases.
- In Europe, the prevalence of IBD is estimated to be around 0.3% of the population, which is higher than the 1 in 2,000 (0.05%) threshold for rare diseases.
- IBD is generally characterized as a chronic condition, but it is not primarily of genetic origin, as environmental factors are also thought to play a significant role in the development of the disease.

## Confidence Level
High

## Rare Disease Indicators
None of the criteria for a rare disease are met in this case. The conditions being studied (IBD, Crohn's disease, and ulcerative colitis) are not considered rare diseases.",False
NCT01949129,Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is acute lymphoblastic leukemia (ALL), which is not considered a rare disease. According to the information provided, acute lymphoblastic leukemia affects a significant number of children and adolescents, and the trial aims to investigate treatment options for this patient population.

## Confidence Level
High

## Rare Disease Indicators
The information provided does not indicate that this is a rare disease. The trial is targeting a condition that is generally characterized by higher prevalence, rather than low prevalence, which is a key characteristic of rare diseases.",False
NCT01756365,Autologous Cultured Corneal Epithelium (CECA) for the Treatment of Limbal Stem Cell Deficiency,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is limbal stem cell deficiency, which is a rare condition that affects the cornea. According to the information provided, limbal stem cell deficiency is a chronic condition that is generally characterized by low prevalence, which aligns with the accepted criteria for a rare disease.

## Confidence Level
High

## Rare Disease Indicators
- The condition, limbal stem cell deficiency, is characterized as a chronic condition with low prevalence.
- The trial is open to a small number of participants, including 5 minors, which is typical for a rare disease trial.",True
NCT01635569,Clinical Outcomes in Pediatric Obsessive-Compulsive Disorder,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is studying Obsessive-Compulsive Disorder (OCD), which is a common neuropsychiatric illness beginning in childhood. The brief summary states that OCD is a ""common neuropsychiatric illness"", indicating that it does not meet the criteria for a rare disease. The criteria for a rare disease in the US is affecting fewer than 200,000 people, and in Europe, affecting no more than 1 in 2,000 people. OCD is a much more prevalent condition and does not fall under the definition of a rare disease.

## Confidence Level
High

## Rare Disease Indicators
There are no indicators in the provided information that this is a clinical trial for a rare disease. The condition being studied, Obsessive-Compulsive Disorder, is a common mental health disorder and does not meet the criteria for a rare disease.",False
NCT01736748,Dynamo: a Tailored Lifestyle Promotion Intervention Among Pediatric Patients With Cardiometabolic Risk Factors,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is obesity, which is a common condition and not considered a rare disease. The trial is targeting children and adolescents aged 6 to 17 years old with cardiometabolic risk factors, such as obesity, hypertension, disorders in glucose regulation, or dyslipidemia. These conditions are generally widespread and do not meet the criteria for a rare disease, which typically affects fewer than 200,000 people in the United States or no more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
N/A",False
NCT01587300,Neuroblastoma Biology Study,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
Neuroblastoma is a type of cancer that typically affects children and is considered a rare disease. According to the information provided, neuroblastoma affects fewer than 200,000 people in the United States, which meets the criteria for a rare disease in the US. Additionally, neuroblastoma is generally characterized by low prevalence, chronicity, and genetic origin, which are typical characteristics of rare diseases.

## Confidence Level
High

## Rare Disease Indicators
- Affects fewer than 200,000 people in the US
- Considered a rare cancer that typically affects children
- Characterized by low prevalence, chronicity, and genetic origin",True
NCT01515904,Evaluation of the SickKids Team Obesity Management Program,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The condition being studied in this clinical trial is obesity, which is a common health condition and not considered a rare disease. The clinical trial information indicates that the study is evaluating an obesity management program for children and adolescents, and there is no mention of the trial targeting a rare disease population.

## Confidence Level
High

## Rare Disease Indicators
None identified. The information provided does not indicate that this trial is focused on a rare disease population.",False
NCT01605266,INSIGHT (Insight Into Nephrotic Syndrome),"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial information provided indicates that the study is focused on nephrotic syndrome, which is a condition affecting the kidneys. While nephrotic syndrome can be a manifestation of various underlying diseases, it is not considered a rare disease itself.

According to the information provided:
- The study is a longitudinal observational study of childhood nephrotic syndrome, which suggests a broader patient population.
- The study will be conducted across multiple sites, including Toronto, Ontario and surrounding regions, indicating a wider geographic scope.
- There is no mention of the prevalence or number of affected individuals, which are the key criteria for defining a rare disease.

## Confidence Level
High

## Rare Disease Indicators
There are no specific indicators in the provided information that would suggest this is a rare disease clinical trial.",False
NCT01241305,One-Time DNA Study for Vasculitis,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The information provided indicates that the clinical trial is focused on studying several types of vasculitis, which are described as ""rare ('orphan') diseases."" Specifically, the trial mentions Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss), Giant Cell Arteritis, Granulomatosis with Polyangiitis (Wegener's), Microscopic Polyangiitis, Polyarteritis Nodosa, and Takayasu's Arteritis. These conditions are generally considered rare diseases, as they affect a small subset of the population.

## Confidence Level
High

## Rare Disease Indicators
- The document states that the vasculitides under study are ""rare ('orphan') diseases.""
- It mentions that while the vasculitides taken together affect tens of thousands of Americans, each type of vasculitis is a rare disease.
- The trial aims to study these rare diseases due to ""unmet medical and scientific needs"" and the feasibility of studying a ""spectrum of small, medium, and large vessel vasculitides.""",True
NCT00680264,Prospective Database Registry Study of Scoliosis in Children With Cerebral Palsy,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
Cerebral palsy is a relatively common condition, affecting around 2-3 per 1,000 live births in the United States. This is well above the threshold of 1 in 2,000 people (0.05%) defined for rare diseases in Europe. Additionally, scoliosis is a common complication in patients with cerebral palsy, occurring in up to 80% of cases. Therefore, the conditions being studied in this clinical trial do not meet the criteria for a rare disease.

## Confidence Level
High

## Rare Disease Indicators
None. The conditions being studied, cerebral palsy and scoliosis, are not considered rare diseases.",False
NCT00455104,Canadian Fabry Disease Initiative (CFDI) National Registry,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The information provided indicates that Fabry disease, the condition being studied in this clinical trial, is a rare disease. The brief summary states that Fabry disease is ""a rare, inherited, genetic condition"" and that it is ""estimated to affect approximately one out of every 40,000 males and up to twice as many females in Canada."" This aligns with the accepted criteria for a rare disease, which is defined as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
- Low prevalence: Fabry disease is estimated to affect approximately 1 in 40,000 males and up to 1 in 20,000 females in Canada.
- Genetic origin: Fabry disease is described as a ""rare, inherited, genetic condition.""
- Chronicity: Fabry disease can lead to severe neuropathic pain, kidney disease, heart disease, stroke, and premature death, often before the age of 60.",True
NCT00900198,Collection of Tissue Samples for Cancer Research,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The information provided does not indicate that the conditions being studied (neoplasms, lymphomas, multiple myeloma, myelodysplastic syndrome) are rare diseases. These conditions are generally considered common cancer types, affecting more than 200,000 people in the United States. The eligibility criteria also do not specify that the trial is targeting a rare disease population.

## Confidence Level
High

## Rare Disease Indicators
The information provided does not contain any specific indicators that this is a rare disease trial, such as the condition affecting fewer than 200,000 people in the US or 1 in 2,000 people in Europe.",False
NCT00345553,Biliary Atresia Study in Infants and Children,"## Classification
Yes, this is a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on studying biliary atresia, which is a rare condition affecting the bile ducts in infants. According to the information provided, biliary atresia is generally characterized by low prevalence, chronicity, and often genetic origin, which aligns with the accepted criteria for a rare disease. Additionally, the brief summary mentions that ""little is known about the factors that cause biliary atresia"", further suggesting that it is a rare condition.

## Confidence Level
High

## Rare Disease Indicators
- Low prevalence: Biliary atresia is a rare condition affecting infants.
- Chronicity: Biliary atresia is a chronic condition.
- Genetic origin: The study aims to identify the gene(s) implicated in the etiology of biliary atresia.",True
NCT00097292,TrialNet Pathway to Prevention of T1D,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
Type 1 diabetes is a common autoimmune disorder, not a rare disease. According to the information provided, type 1 diabetes affects a significant number of people, with the trial aiming to screen relatives of people with type 1 diabetes, who have about a 5% chance of developing the disease. This prevalence is much higher than the criteria for a rare disease, which is typically defined as affecting fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe.

## Confidence Level
High

## Rare Disease Indicators
None. The information provided indicates that type 1 diabetes is a common condition, not a rare disease.",False
NCT00512343,Synovial Fluid Bank From Arthritic Patients,"## Classification
No, this is not a clinical trial for a rare disease.

## Reasoning
The clinical trial is focused on arthritis, which is a relatively common condition affecting a large number of people. The brief summary and detailed description do not indicate that the trial is targeting a disease that affects fewer than 200,000 people in the US or no more than 1 in 2,000 people in Europe, which are the accepted criteria for a rare disease.

## Confidence Level
High

## Rare Disease Indicators
None identified. The condition being studied, arthritis, is a common disease and does not meet the criteria for a rare disease.",False
